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Abstract 
 
Rhinovirus-induced asthma exacerbations are a major cause of morbidity and mortality in 
patients. Experimental clinical infection studies indicate rhinovirus augments type 2 
inflammation in asthma. Additionally, asthmatic lung cells have impaired type I interferon 
production in response to rhinovirus stimulation. Evidence suggests co-regulation of type I 
interferon signalling and type 2 immunity exists; therefore, we hypothesised that type I 
interferon deficiency in asthma leads to the reduced regulation of type 2 immunity, resulting 
in exacerbation of allergen-induced type 2 inflammation during rhinovirus infection.  
 
To investigate the role of type I interferon signalling, type I interferon receptor (IFNAR1) 
knockout mice, an anti-IFNAR1 blocking antibody and recombinant interferon-β therapy 
were used in mouse models of rhinovirus-induced airways disease. Impaired IFNAR1 
signalling resulted in enhanced eosinophilic inflammation in response to allergen challenge 
and rhinovirus infection, which was associated with increased CCL24 and Th2 chemokines 
CCL17 and CCL22. Recombinant interferon-β treatment had limited effects on responses to 
the combination of allergen and rhinovirus, but suppressed allergen-induced CCL17. In 
THP1-derived macrophages, interferon-β co-treatment and pre-treatment suppressed IL-4 
and TNFα-induced Th2 chemokine production. Microarray analysis was performed on these 
cells to help identify the regulatory mechanism of type I interferon on Th2 chemokine 
expression.  Interferon-β pre-treatment significantly upregulated PTPN6 (encoding SHP1, a 
phosphatase that regulates STAT6 activity) expression compared with IL-4 and TNFα-
stimulated cells. Western blot analysis did not identify differences in STAT6 phosphorylation 
following interferon-β treatment, or differences in SHP1 protein levels.  
 
These findings support a role for type I interferon in the negative regulation of type 2 
inflammation in both the presence and absence of rhinovirus; however, this mechanism has 
yet to be identified. Impaired interferon responses in asthma may contribute to enhanced 
type 2 immunity that is considered pathological in allergic airways inflammation and virus-
induced asthma exacerbations.  
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RPMI Roswell Park Memorial Institute  
RSV Respiratory syncitial virus 
RV Rhinovirus 
SEM Standard error of the mean  
SIGN Scottish Intercollegiate Guidelines Network 
siRNA Small interfering RNA  
SLAP Src-like adaptor protein  
SOV  Sodium orthovanadate  
SSC Side scatter 
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SSG Sodium stibogluconate  
STAT Signal transducer activator of transcription 
TARC Thymus and activated-regulated chemokines /CCL17 
TBK1 TANK binding protein 1 
TBS Tris-buffered saline 
TCID50 50% Tissue-culture infective dose 
TCR T cell receptor 
Th T helper 
TLR Toll-like receptor  
TMB Tetramethylbenzidine 
TNFα Tumour necrosis factor α 
TRAF Tumour necrosis factor receptor associated factor  
Treg T regulatory 
TRIF  Toll/IL-1R homologous region-domain-containing adapter-inducing IFNβ 
TRIM Tripartite motif-containing 
TSLP Thymic stromal lymphopoeitin 
TWEEN-20  Polyethylene glycol sorbitan monolaurate 
UNG Uracil-DNA glycosylase 
UV Ultra-violet  
VP Viral proteins 
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Chapter 1: Introduction   
 
1.1. Asthma  
Asthma is a lung disease characterised by airflow limitation resulting in respiratory 
symptoms including wheeze, shortness of breath, chest tightness and cough. Airway 
pathology in asthma is often associated with chronic airways inflammation and airways 
hyperresponsiveness (AHR) to bronchoconstrictive stimuli, contributing to airways 
obstruction. Episodes of progressive worsening and loss of control of asthma symptoms, 
accompanied by reduced expiratory airflow are described as asthma exacerbations. Asthma 
exacerbations are considered to constitute the greatest burden associated with asthma, on 
both patients and healthcare resources. Understanding the pathogenesis of asthma 
exacerbations may provide insights into the treatment gap in asthma and provide 
opportunities to reduce their incidence and burden (GINA, 2016). 
 
It is estimated that 242 million people are currently diagnosed with asthma worldwide (Global 
burden of disease study, 2015). The incentive for new therapeutic approaches lies not only 
with reducing the burden of disease on patients, but also the high socioeconomic costs 
associated with asthma. The direct annual healthcare costs associated with asthma are 
reported to be €19.5 billion in Europe (ERS, 2013) and approximately $50 billion in the U.S 
(Barnett and Nurmagambetov, 2011). Asthma exacerbations account for up to 50% of 
asthma-related healthcare expenditures (Weiss and Sullivan, 2001, Bahadori et al., 2009). 
Moreover, the cost of managing a patient who has suffered an exacerbation is reported to 
cost over three times more than routine asthma management in the UK (Hoskins et al., 
2000).  
 
1.2. Asthma diagnosis  
An initial asthma assessment can be made based on a history of respiratory symptoms that 
are considered typical of asthma (wheeze, cough, chest tightness, shortness of breath). 
Additional information regarding triggering of the patient’s symptoms by cold viruses, 
exercise and allergen exposure among others can also support the initial diagnosis of 
asthma. A definitive diagnosis of asthma is made upon confirmation of variable expiratory 
airflow limitation, which describes the increased magnitude of variation in lung function over 
time observed specifically in asthma. Airflow limitation can be assessed by a ratio of forced 
expiratory volume in one second (FEV1) to forced vital capacity (FVC), whereby a reduced 
ratio is considered indicative of airflow obstruction, hence limited airflow. The variability in 
airflow limitation is then characterised by changes to FEV1, which can be revealed by its 
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increase upon bronchodilator administration or decrease following bronchial provocation. 
Greater than a 12% change in FEV1 from baseline is considered consistent with asthma 
(GINA, 2016).  
 
1.3. Asthma immunopathology   
Asthma is considered a heterogeneous disease and attempts have been made to 
differentiate asthma phenotypes depending on clinical presentation and pathological 
characteristics (Wenzel, 2012). In addition to severity based on symptom control, asthma is 
commonly classified as either atopic or non-atopic. Skin-prick test positivity or increased 
serum immunoglobulin E (IgE) levels are often used to define the association between 
asthma and atopy. A review of epidemiological asthma studies identified up to 72% of 
asthmatics exhibit positive skin-prick tests to common allergens and up to 80% exhibit 
increased total serum IgE (Pearce et al., 1999). Furthermore, elevated serum IgE has been 
shown to correlate with increased asthma symptoms in both children and adults (Burrows et 
al., 1989, Sears et al., 1991).  Over half of asthmatics were shown to exhibit a ‘high Th2’ 
signature in a molecular phenotyping study, indicating type 2 allergic immune mechanisms 
are likely to underlie disease pathology in the majority of asthma patients (Woodruff et al., 
2009). Established and emerging cellular mechanisms of type 2 immunopathology in asthma 
are summarised in figure 1.1 and discussed in further detail from herein.  
 
1.3.1. Allergic sensitisation  
It is considered that sensitisation to innocuous aeroallergens results in the development of 
chronic allergic airways inflammation, excess mucus secretion and airways remodelling that 
contribute to airways obstruction in asthma.  Allergic sensitisation is characterised by the 
development of CD4+ T helper type 2 lymphocytes (Th2 cells) and B lymphocyte class 
switching to producers of allergen-specific IgE. Lung mucosal dendritic cells (DCs) uptake 
and transport inhaled antigens to draining lymph nodes where antigenic peptides are 
presented to naïve CD4+ T lymphocytes through major histocompatibility complex (MHC) II 
and T-cell receptor (TCR) interactions. The resulting differentiation of naïve T cells to Th2 
cells in response to antigen-presentation is considered to be influenced by a number of 
factors. Toll-like receptor (TLR) 4 activation on airway epithelial cells at the time of antigen 
exposure has been shown to drive DC-antigen uptake in the airways and subsequent 
antigen-priming of T cells (Hammad et al., 2009). Within the lymph nodes, the presence of 
pro-Th2 soluble mediators, including interleukin (IL)-4 and co-stimulatory interactions, such 
as OX40–OX40 ligand (OX40L) engagement are also thought to drive Th2 cell development 
(Lambrecht and Hammad, 2010).  
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Upregulation of activated Th2 cells and production of type 2 cytokines IL-4, IL-5 and IL-13 
have been identified in asthmatic airways (Walker et al., 1992, Brightling et al., 2002, Berry 
et al., 2004). In addition to its effect on Th2 cell differentiation, IL-4 along with IL-13 exerts its 
effects on B cells by inducing IgE class-switching. IL-13 signalling has also been implicated 
in physiological features of asthma such as airways hyperresponsiveness (AHR), mucus 
secretion and subepithelial fibrosis contributing to airways remodelling (Wills-Karp, 2004). 
Periostin, an epithelial-derived protein with proposed roles in subepithelial fibrosis, has 
become increasingly utilised as a surrogate marker in serum for IL-4 and IL-13-mediated 
pathology in asthma due to challenges associated with the detection of some cytokines in 
the lower airways (Takayama et al., 2006, Woodruff et al., 2009, Hanania et al., 2013, 
Hanania et al., 2015). IL-5 has critical roles in mediating eosinophilic inflammation, a 
hallmark of the allergic inflammatory cell profile of asthmatic airways (Wardlaw et al., 2000).  
 
The roles of the epithelial-derived innate pro-Th2 cytokines thymic stromal lymphopoietin 
(TSLP), IL-25 and IL-33, are becoming increasingly recognised in asthma due to their ability 
to induce type 2 immune responses (Schmitz et al., 2005, Angkasekwinai et al., 2007, Zhou 
et al., 2005). In support of this, increased expression of TSLP (Ying et al., 2005), IL-25 
(Corrigan et al., 2011) and IL-33 (Préfontaine et al., 2010) have all been identified in 
asthmatic airways. Furthermore, a single nucleotide polymorphism in the IL-33 receptor 
gene was identified in a genome-wide association study as significantly associated with the 
development of asthma (Moffatt et al., 2010). Increasing interest has therefore been paid 
towards downstream effector mechanisms of these cytokines. In addition to the expression 
of their receptors on Th2 cells, recently characterised type 2 innate lymphoid cells (ILC2s) 
have been reported to respond to IL-25 and IL-33 (Neill et al., 2010, Saenz et al., 2010). 
ILC2s have been identified as potent sources of the type 2 cytokines IL-5 and IL-13 in a 
murine model of allergic airways inflammation, leading to their implication in the 
development of allergic immune pathology in asthma (Barlow et al., 2012). Recently, 
increased numbers of ILC2s have been identified in the airways of asthmatics, and were 
associated with increased IL-33 production (Christianson et al., 2015).  
 
1.3.2. Effector mechanisms  
1.3.2.1. Early asthmatic response 
Frequent exposure to allergens is considered to drive repeated inflammatory insults resulting 
in chronic airways inflammation in asthma. Recognition of inhaled allergens by high affinity 
Fc receptor (FcεRI)-bound IgE antibodies stimulates cross-linking of FcεRI on mast cells 
within the airway mucosa (Galli et al., 2008). Activated mast cells undergo degranulation of 
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mediators including histamine, prostaglandin D2 and leukotrienes C4, D4 and E4, which 
stimulate smooth muscle contraction resulting in acute bronchoconstriction. This constitutes 
the early asthmatic response to allergen exposure, occurring within 1 to 30 minutes, in which 
reliever treatment such as β2 adrenoreceptor agonists can be effective by inducing smooth 
muscle relaxation. These mediators also contribute to mucosal oedema and mucus 
secretion causing further airways obstruction. Mast cells also produce IL-4 and IL-13, which 
have led to the implication of mast cells in the maintenance of the allergic inflammatory 
response (Bradding et al., 2006).  
 
1.3.2.2. Late asthmatic response  
The late asthmatic response describes a delayed decline in lung function that usually peaks 
between 3 to 9 hours after allergen exposure (Kay, 2005). It has been postulated that the 
influx of inflammatory leukocytes including eosinophils and T cells contributes to this 
response; these cells migrate to the pulmonary compartment in response to their respective 
chemoattractants. Production of eosinophil-attracting chemokines CCL11, CCL24 and 
CCL26, in conjunction with increased IL-5 results in the activation and recruitment of 
eosinophils to the lungs (Pease and Williams, 2001). Activated eosinophils are another 
source of cysteinyl leukotrienes which can contribute to further bronchoconstriction, as well 
as toxic granule proteins and reactive oxygen species that are considered to damage the 
airway epithelium (Lambrecht and Hammad, 2015). In addition to allergen recognition by 
IgE-bound mast cells, lung DCs continuously sample inhaled antigens and traffic to draining 
lymph nodes (Holt et al., 2008). Cross-talk of DCs with primed allergen-specific Th2 cells 
results in Th2 cell activation. Innate pro-Th2 cytokines, such as TSLP, are also considered to 
influence DC-mediated Th2 cell effector functions during the allergen recall response 
(Hammad and Lambrecht, 2008). Activated Th2 cells migrate to the lungs in response to 
increased levels of Th2-attracting chemokines CCL17 and CCL22 (Medoff et al., 2009). 
Increased recruitment of ILC2s to the nasal mucosa has been observed 6 hours following 
nasal allergen challenge in atopic asthmatics, which coincided with a second peak of 
symptoms (Dhariwal et al, 2016 unpublished data). This finding suggests that ILC2s may 
contribute to the late effector response to allergen, and through their release of type 2 
cytokines function to propagate allergic inflammation.  
 
1.3.2.3. Airways obstruction  
Bronchoconstriction caused by bronchial smooth muscle contraction is considered a 
somewhat reversible mechanism and relief can be provided through the use of 
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bronchodilator therapy. However, perpetual inflammatory insults to the lungs can lead to 
extensive tissue damage and aberrant epithelial repair processes that result in fixed airways 
remodelling, and contribute to airways obstruction in asthma. Airways remodelling in asthma 
is characterised by increased airway smooth muscle mass, angiogenesis, extracellular 
matrix deposition and increased basement membrane thickening. Initially, processes such 
as increased epithelial cell and goblet cell differentiation aim to provide epithelial barrier 
function; however, it is thought that failure to degrade excess structural cells in asthma to 
restore normal airway architecture leads to fixed airways remodelling (Davies, 2009). Airway 
smooth muscle hypertrophy and hyperplasia are also evident in asthmatic airways, which 
may increase the extent of smooth muscle cell contraction and bronchoconstriction (James 
et al., 2012). Increased mucus secretion as a result of goblet cell metaplasia further 
contributes to narrowing of the airways. Moreover, mucus plugging of conducting airways 
has been identified in cases of fatal asthma (Carroll et al., 2002).  
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Figure 1.1. Cellular mechanisms of allergic airways inflammation. 
In the majority of asthmatics, sensitisation to inhaled allergens and activated type 2 immune 
responses are considered to play a pathological role. Repeated exposure to allergens 
results in chronic airways inflammation resulting from the accumulation of mast cells, 
eosinophils, Th2 cells and ILC2s. Airflow obstruction in asthma is attributed to 
bronchoconstriction, mucus hypersecretion and airways remodelling.  
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1.4. Current treatment strategies  
Current therapeutic approaches to asthma largely aim to control symptoms by targeting 
airflow limitation and the extent of airway inflammation. Treatment strategies vary depending 
on disease severity. A ‘stepwise’ pharmacotherapeutic treatment approach is generally 
accepted where patients are treated according to the guidelines for their assessed severity 
(Steps 1 to 5) and treatments are increased or reduced depending on response to treatment 
and level of symptom control achieved (BTS/SIGN, 2014). The British Thoracic Society 
(BTS) guidelines of the management of asthma in adults are summarised in figure 1.2.  
 
In mild intermittent asthma (Step 1), reliever therapies such as inhaled short-acting β2 
agonists, which induce bronchial smooth muscle relaxation, may be sufficient to manage 
symptoms. Treatment strategies for patients classified under Steps 2 to 5 involve a mainstay 
of inhaled anti-inflammatory corticosteroids, whereby add-on therapies including long-acting 
β2 agonists (LABA) are advocated as disease severity increases. Combination therapy with 
inhaled corticosteroids and LABA provides improved symptom control and lung function 
compared with steroid treatment alone (Pauwels et al., 1997). Other add-on therapies 
include: leukotriene receptor antagonists, which inhibit downstream effects of leukotriene 
signalling such as bronchial smooth muscle contraction and mucus secretion; theophylline, 
which induces bronchodilation, likely through the inhibition of phosphodiesterases in smooth 
muscle (Rabe et al., 1995, American Lung Association Asthma Clinical Research, 2007). In 
severe persistent asthma (Step 5), oral steroids may be required to achieve adequate 
asthma control. Furthermore, anti-IgE (omalizumab) or anti-IL-5 (mepolizumab) therapy is 
indicated in cases where allergy or eosinophilic asthma, respectively, is a demonstrated 
cause of uncontrolled asthma despite the use of high dose inhaled corticosteroids (GINA, 
2016). 
 
Ultimately, asthma treatment strategies aim to both manage and prevent asthma symptoms. 
Despite the ability to improve lung function in some cases, current treatments appear limited 
in their ability to prevent future asthma exacerbations, which account for the majority of the 
morbidity and mortality associated with asthma. It has been demonstrated that rates of 
exacerbations can be reduced by up to 63%, but only when standard doses of inhaled 
corticosteroids were quadrupled (Pauwels et al., 1997). Aside from concerns associated with 
adverse effects of high-dose steroids, these findings were reported in a controlled 
environment in the context of a clinical trial, and therefore may not be reflective of real-world 
responses to inhaled steroid therapy. Other treatment options are limited to omalizumab for 
patients with severe allergic asthma, which has been demonstrated to reduce rates of 
exacerbations by 52% (Soler et al., 2001); or mepolizumab for patients with severe 
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eosinophilic asthma, which has been shown to reduce exacerbation risk by up to 52% 
(Pavord et al., 2012). The limited efficacy of current available treatments on reducing the risk 
of asthma exacerbations indicates additional mechanisms to this debilitating feature of 
disease.  
 
 
Figure 1.2. British Thoracic Society summary of stepwise management of asthma in 
adults. 
It is recommended that asthma therapy is tailored to the level required to achieve adequate 
symptom control in individual patients. Table taken from BTS/SIGN Asthma Guidelines 
(BTS/SIGN, 2014).    
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1.2. Asthma exacerbations  
Current treatment strategies for acute asthma exacerbations include the administration of 
inhaled β2 agonists, systemic corticosteroids and oxygen supplementation. Additional 
bronchodilator therapy such as anti-cholinergics may be considered to assist airflow 
restoration (GINA, 2016). However, there are currently no specific targeted therapies for 
asthma exacerbations and current asthma treatments appear limited in their ability to reduce 
the risk of future exacerbations in patients. Multiple risk factors have been associated with 
the pathogenesis of asthma exacerbations, including allergen exposure, respiratory tract 
infections, environmental pollution, exercise and cold air, amongst others. Understanding 
how these individual risk factors cause disease may highlight potential therapeutic targets to 
address the unmet clinical need associated with asthma exacerbations.  
 
1.2.1. Virus-induced asthma exacerbations 
Numerous studies have reported that respiratory viral infections are most commonly 
associated with acute asthma exacerbations. Studies have identified respiratory viruses in 
up to 80% of hospital admissions due to asthma exacerbations (Green et al., 2002, Murray 
et al., 2006). In the past 20 years, the role of viruses in asthma exacerbations has been 
increasingly recognised through the improved detection of viruses by refined laboratory 
diagnostic tools. Through the addition of polymerase chain reaction (PCR) assays to analyse 
the prevalence of respiratory viruses, 44% of adults presented with an asthma exacerbation 
were confirmed for the presence of a virus infection (Nicholson et al., 1993). Two years later, 
a community study demonstrated a striking 80% of children suffering from an asthma 
exacerbation tested positive for a respiratory viral pathogen (Johnston et al., 1995). More 
recently, a study that examined a comprehensive range of viruses detected respiratory 
viruses in 63% of cases of asthma exacerbations in children (Khetsuriani et al., 2007). 
Rhinoviruses (RVs) have been consistently identified as the most prevalent viral pathogen, 
accounting for around 60% of virus-associated asthma exacerbations, while others include 
respiratory syncytial virus (RSV), coronaviruses and influenza viruses (Nicholson et al., 
1993, Johnston et al., 1995, Khetsuriani et al., 2007). A longitudinal study of naturally 
occurring colds found that although asthmatics did not have an increased frequency of RV 
infections, they did experience more severe and longer duration of lower respiratory tract 
symptoms than non-asthmatic counterparts (Corne et al., 2002). Experimental RV infection 
in asthma has been shown to enhance specific aspects of asthma, including AHR to 
histamine and lung inflammation (Grunberg et al., 1997b, Message et al., 2008, Jackson et 
al., 2014). Understanding the factors that underlie this increased severity of RV-induced 
illness in chronic respiratory diseases such as asthma requires insights into the virological 
mechanisms of this virus and the resulting host response.  
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1.2.2. Rhinoviruses  
 
1.2.3.1. Classification 
RVs are small, non-enveloped RNA viruses belonging to the Picornaviradae family. There 
are approximately 160 known strains of RV classified into three species: human rhinoviruses 
(HRV) -A, -B and -C, differentiated by their respective nucleotide sequences (Gern, 2015). 
Much of our knowledge of RVs to date is based largely on HRV-A and -B viruses since the 
first HRV-C strain was only identified in 2007 (McErlean et al., 2007). The majority (~90%) of 
HRV-A and -B strains utilise the intercellular adhesion molecule 1 (ICAM1) to enter the host 
cell, while a small proportion of RVs are known to bind to low density lipoprotein (LDL) 
receptors. Recently, the receptor utilised by HRV-C serotypes to gain host entry has been 
identified as cadherin-related family member 3 (Bochkov et al., 2015). Propagation of HRV-C 
species viruses by conventional tissue culture techniques has been limited due to lack of 
receptor expression by common epithelial cell types used. However, differentiated sinus 
epithelial cells have been shown to be permissive to HRV-C infection and replication has 
been reported in both sinus organ cultures and air-liquid interface cultures (Bochkov et al., 
2011, Ashraf et al., 2013).  
 
1.2.3.2. Entry and site of infection  
The primary site of RV infection is thought to be the epithelium of the nasal mucosa due to 
the propensity of some RV strains to replicate more effectively at sub-37°C temperatures 
(Papadopoulos et al., 1999). HRV-C strains have demonstrated a lack of temperature 
sensitivity and appear to grow well at 37°C, leading to suggestions that HRV-C strains may 
be associated with severe cases of RV-induced lower respiratory tract illnesses (Ashraf et 
al., 2013, Gern, 2015). Interestingly, a single nucleotide polymorphism in the gene encoding 
cadherin-related family member 3, which has been shown to facilitate HRV-C propagation in 
cells, was found to be associated with asthma-related hospitalisations in childhood (Bochkov 
et al., 2015). Nevertheless, experimental RV infection studies have verified the ability of the 
HRV-A strain RV16 to induce enhanced lower respiratory tract symptoms in asthma 
compared with healthy controls, indicating host factors must play an important role (Message 
et al., 2008, Jackson et al., 2014).  
 
1.2.3.3. Clinical presentation  
RVs are a major cause of the common cold, usually affecting the upper airways in healthy 
individuals for a relatively short duration. RV-induced symptoms are typical of a common 
cold including rhinorrhoea, nasal obstruction, sore throat and cough. However, it is well-
recognised that RVs have the potential to infect the lower airways and induce lower 
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respiratory tract symptoms in susceptible individuals. RV transmission occurs through 
aerosol inhalation or direct transfer of virus typically from contaminated hands to the nose or 
eyes, especially considering RV can survive on environmental surfaces for several hours. 
Experimental RV infection studies have detected virus shedding in nasal secretions peak 
between 48 and 72 hours after inoculation (Hendley and Gwaltney, 2004). Onset of 
symptoms has been reported to occur within hours of RV inoculation (Harris and Gwaltney, 
1996), but in general symptoms are considered to peak 48 hours after infection (Gwaltney et 
al., 2003).   
 
1.2.3.4. Structure and replication  
Each RV particle comprises 60 copies of each of the four structural viral proteins (VP 1 to 4). 
Structural organisation of VP1, VP2 and VP3 constitute the external viral capsid, forming the 
icosahedral shell of RV particles, while VP4 lies internally in close association with the viral 
RNA core. The RV genome is composed of a single strand positive-sense RNA molecule. In 
addition to the structural proteins, the RV genome encodes 7 non-structural proteins 
required for viral RNA synthesis and viral protein processing. Upon receptor binding, the viral 
particle enters the cell through receptor-mediated endocytosis to undergo viral replication. 
The viral capsid changes conformation within the host cell cytoplasm to allow release of the 
viral RNA. Host cell ribosomes are hijacked by the virus to initiate translation of viral RNA, 
initially into a large polyprotein. This single polyprotein is then cleaved into functional protein 
fragments by proteases that comprise some of the non-structural proteins encoded by RV. 
Viral RNA polymerase initially transcribes negative-sense viral RNA, which is then used to 
synthesise progeny positive-sense RNA to be assembled into new virus particles. Infected 
cells undergo cell lysis, which results in release of progeny RV virions that are able to infect 
neighbouring cells within the host (Bartlett and Johnston, 2014).  
 
1.2.3. Anti-viral immunity  
 
1.2.3.1. Detection of RV RNA  
Respiratory epithelial cells are the first point of contact of respiratory viruses and possess 
the ability to trigger anti-viral defences to reduce the burden of infection. RV-infected 
epithelial cells have been shown to produce pro-inflammatory cytokines and chemokines 
that propagate anti-viral immune responses, including type I and III interferons (IFNs) 
(Khaitov et al., 2009, Wang et al., 2009).  
 
Double stranded RV RNA present in the viral genome or generated during viral replication 
within the infected cell is detected by host pattern recognition receptors, (PRR) toll-like 
receptor-3 (TLR3) located within the endosome; retinoic acid-inducible gene-I (RIG-I) and 
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melanoma differentiation-associated gene-5 (MDA5), which are located in the cytoplasm. 
Single stranded RV RNA can also be detected by TLR7 and TLR8. Signalling from PRR 
leads to the activation of transcription factors NF-κB and Interferon Regulatory Factor (IRF)-
3, which result in the expression of pro-inflammatory mediators and anti-viral IFNs (Bowie 
and Unterholzner, 2008). The co-ordinated signalling of TLR3, RIG-I and MDA5 have been 
found to be important for the efficient induction of anti-viral immune responses to RV 
infection in human airway epithelial cells (Wang et al., 2009, Slater et al., 2010). TLR3 
signals through the adaptor protein Toll/IL-1R homologous region-domain-containing 
adapter-inducing IFNβ (TRIF), leading to recruitment of TRAF3 and TRAF6 that activate two 
NF-κB-associated kinase pathways. Activation of the canonical NF-κB pathway involves the 
kinase complex composed of IKKα and -β and NEMO subunits, whereby IKKβ 
phosphorylates the inhibitor of NF-κB, IκB, targeting it for degradation by the ubiquitin-
proteosome pathway. This licences NF-κB to translocate to the nucleus and induce 
inflammatory gene transcription (Bowie and Unterholzner, 2008). IKKα also has the ability to 
phosphorylate and activate IRF7, which promotes the induction of type I IFNs (Yan and 
Chen, 2012). In addition, the activation of the non-canonical NF-κB pathway involving IκB 
kinase-ε (IKKε) and TANK-binding protein-1 (TBK1), which results in phosphorylation and 
activation of IRF3, largely leads to the induction of innate IFNs (Fitzgerald et al., 2003). 
Additional PRRs RIG-I and MDA5 recognise viral RNA within the cell cytoplasm, which upon 
activation promote the recruitment and aggregation of MAVS adapter protein units. The 
formation of MAVS aggregates on the cell’s mitochondrial membrane also lead to the 
recruitment of TBK1 and IRF3 phosphorylation, thus induction of IFNs (Yan and Chen, 
2012).  
 
1.2.3.2. Role of interferons  
The immune response to virus infection comprises a network of direct anti-viral events and 
inflammatory responses that support host defences. IFNs are critical inducers of a large 
number of IFN-stimulated genes that function to limit virus-induced pathology. There are 
three classes of IFNs characterised by their affinity for different receptors including type I 
IFNs, consisting of 14 IFNα subtypes and a single IFNβ subtype; a single type II subtype 
IFNγ; type III IFNs, consisting of IFNλ1, 2, 3 and 4. Type I and III IFNs share similar roles in 
innate anti-viral immunity (Ivashkiv and Donlin, 2014, Wack et al., 2015). This is supported 
by the demonstration that treatment of lung epithelial cells with type I IFNβ and type III IFNλ1 
have been shown to reduce viral load and limit viral replication during RV infection in vitro 
(Gulraiz et al., 2014).  
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1.2.3.2.1. Interferon signalling  
Type I IFNs bind the heterodimeric IFNAR receptor complex composed of IFNAR1 and 
IFNAR2 subunits. IFNAR is expressed on all haematopoietic cells, allowing rapid 
amplification of anti-viral immune responses in infected and neighbouring host cells through 
the release of type I IFNs. Despite sharing similar roles, the relatively recently identified type 
III IFNs signal through the IFNλR receptor complex formed by IFNλR1 and IL-10R2 subunits. 
Binding of type I and III IFNs to their corresponding receptors leads to activation of Janus 
kinase (JAK)- signal transducer and activator of transcription (STAT) signalling cascades 
that result in the expression of a plethora of IFN-stimulated genes (ISG), of which over 380 
human ISGs have been identified (Schoggins et al., 2011). Activation of IFNAR and IFNλR 
receptors causes recruitment and activation of the receptor tyrosine kinases JAK1 and 
TYK2, which target and phosphorylate STAT1 and STAT2. Phosphorylation of STAT1 and 
STAT2 causes their dimerisation and subsequent translocation to the nucleus where they 
engage with IFN regulatory factor 9 (IRF9), forming a transcription factor complex termed 
ISG factor 3 (ISG3). The binding of ISG3 to IFN-stimulated response elements (ISREs) on 
genomic DNA allows the transcription of ISGs that mediate both direct and indirect anti-viral 
functions (Ivashkiv and Donlin, 2014).  
 
1.2.3.2.2. Interferon-Stimulated Genes  
Defined anti-viral effector mechanisms of some of ISGs have been identified and 
demonstrated to interfere with stages of the virus replication cycle (Schoggins et al., 2011). 
These include 2’5’-oligoadenylate synthetases (OAS1, 2 and 3) and ribonuclease-L 
(RNaseL), involved in viral RNA degradation; tripartite motif-containing (TRIM) and 
myxovirus resistance (Mx) proteins, which inhibit viral RNA transcription; double stranded 
RNA-dependent protein kinase (PKR), which inhibits translation (Bowie and Unterholzner, 
2008). Microarray analysis performed on nasal epithelial cells during in vivo RV infection 
demonstrated upregulation of a number of anti-viral ISGs including OAS1, 2 and 3 and Mx1. 
Another anti-viral ISG found to be highly upregulated was viperin, which was subsequently 
demonstrated to be functionally important for limiting RV replication in airway epithelial cells 
(Proud et al., 2008).   
 
1.2.3.3. Virus-induced inflammation  
In addition to ISGs that directly target the virus, IFN signalling also induces the production of 
pro-inflammatory mediators that cause recruitment of leukocytes to aid viral clearance. 
Likewise, activation of NF-κB following RV recognition regulates the expression of pro-
inflammatory mediators including granulocyte-macrophage colony-stimulating factor (GM-
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CSF), IL-6 and IL-8 (Kim et al., 2000). A pro-inflammatory role for NF-κB has been 
demonstrated in RV infection in mice, whereby impaired NF-κB signalling reduces neutrophil 
accumulation in the airways (Bartlett et al., 2012). RV infection in asthmatics has been 
associated with increased accumulation of inflammatory leukocytes in the airways (Jarjour et 
al., 2000, Message et al., 2008). However, depending on the extent of inflammation during 
RV infection, the leukocyte milieu may be considered detrimental and outweigh its protective 
function.   
 
Neutrophils are a common component of tissue inflammation due to their phagocytic ability 
and production of toxic proteins that target invading pathogens. However, the extent of the 
protective function of neutrophils during RV infection may be limited, especially considering 
increased neutrophil accumulation and degranulation have been associated with increased 
clinical severity during virus-induced asthma exacerbations (Wark et al., 2002). ICAM-1 
expression is increased during experimental RV infection in asthmatics, which through its 
role as an adhesion molecule for leukocytes may promote trafficking of circulating 
neutrophils to the airways (Grunberg et al., 2000).  
 
RV infection of human bronchial epithelial cells induces expression of the IFN-inducible 
chemokines CCL5 and CXCL10, which have roles in the chemotaxis of lymphocytes to sites 
of inflammation (Wark et al., 2007). Furthermore, RV-induced CXCL10 production in vivo 
was found to correlate with airway lymphocyte accumulation and viral replication (Spurrell et 
al., 2005). Lymphocytes typically associated with virus infections are natural killer (NK) cells 
and the development of CD4+ Th1 cells. IL-15 is an IFN-inducible cytokine with critical roles 
in NK cell recruitment and activation, and is upregulated during RV infection in vivo 
(Jayaraman et al., 2014). The importance of NK cells in anti-viral immunity is recognised 
through their ability to release perforins and granzymes, which target virus-infected cells and 
induce cellular apoptosis. Apoptosis of virus-infected cells is important for limiting the spread 
of virus by preventing cell lysis and release of viral progeny. NK cells are also a potential 
source of IFNγ, which may promote Th1 cell polarisation during the adaptive immune 
response to virus infection. Evidence suggests that RV infection leads to the generation of 
memory Th1 cells that may also be cross-reactive against additional RV serotypes (Gern et 
al., 1997, Wimalasundera et al., 1997, Glanville et al., 2013a). Interestingly, increased 
numbers of IFNγ-producing Th1 cells in peripheral blood prior to experimental RV infection 
were associated with reduced viral load and fewer symptoms following infection (Message et 
al., 2008).   
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1.3. Mechanisms of RV-induced Asthma Exacerbations  
 
1.3.1. Experimental RV infection  
The study of naturally occurring asthma exacerbations has provided important insight into 
the pathological role of respiratory viruses in asthma. In this context, the interpretation of the 
direct causal role of respiratory viruses specifically in asthma is limited by the absence of a 
comparative control and the lack of control of virus infection. Therefore, experimental RV 
infection models have been valuable to assess functional responses to RV infection in 
asthma under controlled conditions.  
 
1.3.1.1. Human RV infection model  
Experimental human RV infection studies have provided important evidence to support a 
causal role for RV in the pathogenesis of asthma exacerbations. Earlier experimental 
infection studies were carried out in mild atopic asthmatics, whereby responses to RV 
infection were compared with sham infection. Grunberg et al showed RV infection caused 
increased AHR assessed by bronchial provocation with histamine, as well as increased 
levels of eosinophil-cationic protein and inflammatory mediators IL-6 and IL-8. Considering 
AHR is unlikely to occur in healthy individuals, this suggests RV specifically worsens aspects 
of asthma (Grunberg et al., 1997a). In addition to increased IL-8 expression, Jarjour et al 
found upregulation of neutrophils in the airways following RV infection of asthmatics (Jarjour 
et al., 2000). These findings demonstrate the ability of RV infection to induce inflammatory 
responses in the airways, which when considered in the context of pre-existing allergic 
airways inflammation in asthmatics, may contribute to worse disease outcomes. A more 
comprehensive study carried out by Message et al compared the effects of RV infection 
between asthmatics and healthy volunteers and as a result enabled the assessment of RV-
induced pathology specifically in asthma. In addition to experiencing increased lower 
respiratory tract symptoms during RV infection, asthmatics also exhibited significant lung 
function decline that was not observed in healthy controls. RV-induced increase in AHR was 
identified exclusively in asthmatics. In support of earlier studies carried out in asthmatics 
only, RV infection increased inflammatory leukocytes in both asthmatics and healthy 
controls, although eosinophils were significantly enhanced in asthma only. Interestingly, total 
respiratory symptoms were found to correlate with viral load in the nasal lavage of 
asthmatics, but not healthy individuals (Message et al., 2008). Recently, Jackson et al 
detected significantly increased nasal RV viral load in asthmatics compared with healthy 
controls, as well as increased lower respiratory symptoms experienced exclusively by 
asthmatics (Jackson et al., 2014).  
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1.3.1.2. Mouse RV infection model  
Mouse models of RV infection have been established to allow for functional mechanistic 
insights into RV-induced pathology (Bartlett et al., 2008, Nagarkar et al., 2010, Glanville et 
al., 2013b, Traub et al., 2013). Inoculation of mice with RV1B, which binds to the LDL 
receptor, has been shown to mimic features of inflammatory responses in humans, including 
the recruitment of neutrophils and lymphocytes to the airways and the induction of IL-6, KC 
(murine ortholog of human IL-8), CCL5 and CXCL10 (Bartlett et al., 2008, Bartlett et al., 
2012). In particular, RV infection of allergen-sensitised and challenged mice resulted in 
enhanced AHR, infiltration of inflammatory cells to the airways and mucus abundance 
(Bartlett et al., 2008, Nagarkar et al., 2010). Taken together, these findings support the 
notion that RV not only stimulates virus-associated inflammatory pathways, but RV has the 
ability to augment pre-existing airway pathology associated with asthma, which may 
contribute to worse clinical outcomes for patients with asthma. 
 
1.3.2. Interferon Deficiency  
RV infection is largely contracted through the upper airways. Considering RV infection 
causes lower respiratory tract symptoms in asthmatics, it suggests that RV has the 
opportunity to spread further in to the respiratory tract of asthmatics. This has led to the 
hypothesis that asthmatics may be more permissive to RV replication. As discussed 
previously, induction of innate anti-viral IFN signalling serves to limit viral replication. 
However, accumulating evidence indicates that asthmatics have impaired anti-viral IFN 
responses (summarised in table 1.1).  
 
Several studies in ex vivo cultured airway epithelial cells derived from asthmatic patients 
have demonstrated reduced IFN responses. Wark et al demonstrated ex vivo cultured and 
RV infected bronchial epithelial cells (BECs) derived from asthmatics had reduced IFNβ 
expression, increased viral load and release of viral progeny into culture supernatants 
compared with healthy controls (Wark et al., 2005). A study in which BECs were stimulated 
with a synthetic double-stranded RNA analogue, polyinosine-polycytidylic acid (poly (I:C)), 
also detected less IFNβ expression in asthmatic cells compared with healthy controls (Uller 
et al., 2010). Furthermore, decreased RV-induced type I and III IFN expression ex vivo have 
also been demonstrated in BECs derived from atopic asthmatic children (Baraldo et al., 
2012, Edwards et al., 2013a).   
 
Additional studies have indicated that impaired ex vivo IFN responses correlate with 
increased virus-induced pathology and asthma disease severity in patients. Using asthmatic 
BECs and bronchoalveolar lavage (BAL) cells, Contoli et al demonstrated impaired RV-
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induced type III IFNλ production ex vivo correlated with increased symptoms and viral load 
and decline in lung function during RV infection in vivo in the same patients (Contoli et al., 
2006). Furthermore, deficient production of type I IFNα and IFNβ in asthmatic BAL cells 
have been related to increased AHR, indicating an association between IFN deficiency and 
disease severity (Sykes et al., 2012). In support of this, a later study conducted by Sykes et 
al showed that IFN responses were not impaired in lung cells derived from asthmatics with 
well-controlled disease (Sykes et al., 2014). Indeed others have also found no differences in 
cellular IFN expression between asthmatics and healthy volunteers (Lopez-Souza et al., 
2009, Bochkov et al., 2010). The discrepancies in identifying IFN deficiency in asthma has 
been attributed to asthma severity and particular phenotypes of asthma.  
 
In addition to airway cells, virus-induced type I IFN expression by peripheral blood 
mononuclear cells (PBMCs) also appears to be impaired in asthmatics compared with 
healthy controls (Bufe et al., 2002, Gehlhar et al., 2006, Iikura et al., 2011, Pritchard et al., 
2014). These findings suggest that circulating cells, which could be recruited to the airways 
upon a respiratory virus infection, may possess an inability to mount a systemic type I IFN-
mediated anti-viral response. However, the clinical impact of IFN deficiency during asthma 
exacerbations is uncertain, especially considering impaired IFN responses have not been 
demonstrated in vivo. 
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Table 1.1. Summary of studies supporting innate IFN deficiency in asthma  
 
Key finding  Reference 
Reduced Newcastle disease virus (NDV)-induced IFNα expression in 
PBMCs derived from allergic asthmatic children 
Bufe et al., 2002 
Delayed and decreased RV-induced IFNβ expression in asthmatic BECs   Wark et al., 2005 
Impaired RV-induced IFNλ production by asthmatic BECs and BAL 
macrophages 
Contoli et al., 2006  
Reduced RSV- and NDV-induced IFNα2 release by asthmatic PBMCs Gehlhar et al., 2006  
Decreased poly I:C-induced IFNβ expression in asthmatic BECs  Uller et al., 2010 
Reduced production of IFNα by RV-stimulated asthmatic PBMCs  Iikura et al., 2011 
Delayed and deficient IFNα and IFNβ production by RV-stimulated 
asthmatic BAL macrophages  
Sykes et al., 2012  
Deficient RV-induced IFNβ and IFNλ production by BECs derived from 
asthmatic children  
Baraldo et al., 2012  
Impaired RV-induced IFNβ and IFNλ expression in BECs derived from 
severe asthmatic children  
Edwards et al., 2013 
Reduced expression of IFNα and IFNβ in RV-stimulated asthmatic PBMCs  Pritchard et al., 2014  
 
 
1.3.3. Type 2 Immunity  
The contribution of type 2 immune responses to the pathogenesis of asthma exacerbations 
is supported by studies identifying allergen sensitisation and exposure as a risk factor for 
exacerbations. The presence of activated type 2 immunity, defined by elevated IgE or 
eosinophilic inflammation, has been identified as a major risk factor for severe wheezing 
attacks in children suffering from a respiratory viral infection (Duff et al., 1993, Rakes et al., 
1999). In particular, it has been shown that the combination of virus and allergen exposure 
results in the significantly increased risk of hospital admission due to an asthma 
exacerbation, which is not found in response to each individual factor alone (Green et al., 
2002, Murray et al., 2006). This indicates that virus and allergic responses interact, 
contributing to an asthma exacerbation.  
 
Comparative experimental infection studies in asthmatics and healthy volunteers have 
allowed for the specific characterisation of type 2 allergic responses during a RV infection in 
asthma. Increased Th2 cytokine expression in ex vivo stimulated BAL and peripheral blood 
cells prior to RV infection corresponded with increased lower respiratory tract symptoms 
during RV infection. Furthermore, RV infection significantly enhanced eosinophil 
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accumulation in the airways specifically in asthma, which was associated with greater 
decline in lung function (Message et al., 2008). More recently, Jackson et al found increased 
RV-induced production of Th2 cytokines IL-4, IL-5 and IL-13 in vivo in asthmatics correlated 
with increased symptom severity. In addition, enhanced production of RV-induced IL-33 was 
also detected in asthmatics and implicated in the induction of Th2 cytokine expression by T 
cells and ILC2s (Jackson et al., 2014). Another innate pro-Th2 cytokine IL-25 has recently 
been implicated in RV-induced asthma exacerbations, whereby increased IL-25 expression 
was found in asthmatic BECs compared with controls in response to RV infection ex vivo. 
Furthermore, the blockade of IL-25 signalling in mice inhibited RV-induced exacerbation of 
IL-4, IL-5 and IL-13 in the context of allergic airways inflammation, indicating a functional role 
for IL-25 in promoting Th2 responses during RV infection (Beale et al., 2014). In addition, it 
has been shown that asthmatic BECs have an increased tendency to express TSLP mRNA 
upon poly (I:C) stimulation, suggesting increased TSLP expression upon viral infection may 
contribute to enhanced type 2 responses during virus-induced asthma exacerbations (Uller 
et al., 2010). Proposed cellular mechanisms of RV infection in asthma are summarised in 
figure 1.3. 
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Figure 1.3. Summary of cellular mechanisms of RV-induced asthma exacerbations. 
Experimental RV infection studies in asthma have demonstrated that asthmatics experience 
both enhanced virus-induced inflammation and allergic airways inflammatory pathways. 
Augmented type 2 inflammatory responses in asthma have also been associated with 
increased symptom severity during RV infection.  
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1.3.4. Emerging treatments based on asthma mechanisms  
It is recognised that asthma symptom control may be not be entirely predictive of future 
asthma exacerbations and independent risk factors exist (GINA, 2016). Despite well-
controlled symptoms, some patients continue to suffer from asthma exacerbations. It is 
becoming increasingly apparent that the current treatment gap in asthma lies within asthma 
exacerbations, highlighting the need for new treatments that target this aspect of disease. 
This has been reflected in recent clinical trial designs for investigating new therapies for 
asthma, which have utilised the efficacy of treatments on the rate of asthma exacerbation as 
a primary outcome measure (Pavord et al., 2012, Wenzel et al., 2013, Hanania et al., 2015).  
 
1.3.4.1. Anti-Th2 therapies  
In support of the role of type 2 immune responses in the pathogenesis of asthma 
exacerbations, emerging treatments that target type 2 mechanisms have been shown to 
reduce the risk of exacerbations in clinical trials. A monoclonal antibody against IL-5 (anti-IL-
5; mepolizumab) was found to halve asthma exacerbation rates in patients with severe 
eosinophilic asthma (Pavord et al., 2012). However, earlier trials investigating the effects of 
blocking IL-5 found a lack of beneficial effect on lung function assessments, which was 
initially used as a primary outcome (Leckie et al., 2000). As a result, mepolizumab was not 
approved for the treatment of asthma at the time. While recent trials also demonstrated 
limited improvements on lung function, the clinical value of mepolizumab has been attributed 
to its ability to significantly reduce exacerbation rates and it is now licensed for use as add-
on therapy in patients with severe eosinophilic asthma. Considering the multifaceted role of 
IL-13 in asthma pathology, it has been considered as a potential therapeutic target. In recent 
phase 2 trials investigating anti-IL-13 (lebrikizumab), rates of exacerbations were reduced by 
60% compared with placebo, specifically in a subset of patients who exhibited high levels of 
periostin (Hanania et al., 2015). In addition to targeting a single cytokine, development of a 
blocking antibody specific to the IL-4 receptor alpha subunit (anti-IL-4Rα; dupilumab) aims to 
inhibit the effects of both IL-4 and IL-13 as both cytokines signal through this receptor 
subunit. Evidence from studies in patients with persistent eosinophilic asthma showed a 
striking 87% reduction in exacerbation rates. Interestingly, patients were able to maintain 
asthma control despite reduction and eventual discontinuation of corticosteroid therapy by 
the end of the trial period (Wenzel et al., 2013).  
 
In addition to new developments in anti-Th2 therapies, the impact anti-IgE has demonstrated 
on preventing a significant proportion of exacerbations has strengthened the notion that 
allergen-induced responses contribute to the pathogenesis of asthma exacerbations. 
However, limitations remain in the ability of such type 2 interventions to eliminate the risk of 
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asthma exacerbations, suggesting additional or at least alternative mechanisms must be 
involved in the pathogenesis of asthma exacerbations.  
 
1.3.4.2. Inhaled Interferon therapy 
Considering the wealth of evidence demonstrating a role for viruses in asthma 
exacerbations, a specific anti-viral treatment currently under clinical investigation is inhaled 
IFNβ therapy. The use of IFNβ is supported by evidence of impaired innate IFN expression 
in lung and peripheral cells from asthmatic donors. In addition, studies have confirmed intact 
type I IFN signalling mechanisms and downstream anti-viral pathways in asthmatic cells 
(Wark et al., 2005, Cakebread et al., 2011). Therefore, IFNβ therapy may serve to restore 
host anti-viral defences in asthma to reduce the burden of virus-induced pathology during 
asthma exacerbations.   
 
A recent phase 2 clinical trial investigated the efficacy of inhaled IFNβ on asthma symptom 
control during the onset of naturally occurring colds. In addition to boosting systemic anti-
viral responses, IFNβ treatment significantly improved symptom control and lung function 
specifically in patients with moderate-to-severe asthma (BTS Steps 4 to 5). Although IFNβ 
treatment demonstrated limited clinical benefits among mild asthmatics, it was recognised 
that moderate-to-severe asthmatics experience more frequent asthma exacerbations and 
are therefore more likely to require additional treatments (Djukanovic et al., 2014). 
Furthermore, these findings support the hypothesis that IFN deficiency is associated with 
increased asthma severity, hence the increased therapeutic benefit of restoring IFNβ in 
these patients.  
 
It has been shown that increased viral load is associated with increased symptom severity 
during RV infection in asthma (Message et al., 2008), while treatment of asthmatic BECs 
with exogenous IFNβ restored protection against viral replication (Wark et al., 2005, 
Cakebread et al., 2011). Although this evidence supports the therapeutic potential of 
boosting anti-viral immunity, it is unclear whether the clinical benefits of IFNβ therapy are 
directly attributed to this mechanism or if it can have a broader impact. Further evidence 
exists to indicate type I IFN signalling may possess immunological roles beyond its anti-viral 
capacity.  
 
1.3.5. Crosstalk between interferon and type 2 immunity 
Evidence suggests co-regulation of innate IFN signalling and allergen-induced type 2 
responses exists, supporting potential roles for IFN signalling beyond anti-viral immunity. A 
number of studies have demonstrated reduced IFN expression is associated with increased 
type 2 immune responses in asthma, suggesting this inverse relationship may play a role in 
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asthma pathogenesis. Impaired RV-induced type I IFNβ and type III IFNλ expression in 
BECs were related to increased abundance of eosinophils and IL-4 in bronchial biopsies of 
atopic asthmatic children (Baraldo et al., 2012). In a separate study, decreased type I IFN 
production in ex vivo stimulated BAL cells negatively correlated with increased number of 
skin-prick positive tests in asthmatics, indicating an association with increased type 2 allergic 
responses (Sykes et al., 2012). In plasmacytoid DCs (pDCs) from atopic asthmatics, 
impaired influenza-induced IFNα production inversely correlated with increased FcεRIα 
expression, which was also associated with elevated serum IgE (Gill et al., 2010). A similar 
inverse relationship has also been demonstrated for type III IFNs whereby deficient 
production of IFNλ by BAL cells ex vivo was associated with increased eosinophilic 
inflammation during RV infection in asthma in vivo in the same patients (Contoli et al., 2006). 
The mechanisms of this interplay between innate IFNs and type 2 immunity are not fully 
understood. Functional studies have demonstrated counter-regulatory roles for IFNs and 
type 2 signalling pathways; therefore, it is important to understand how these pathways may 
contribute to disease.  
  
1.3.5.1. Type 2 immunity regulates interferons  
Upregulation of type 2 responses in asthma may lead to suppression of IFNs and anti-viral 
responses that may pre-dispose asthmatics to virus infections. It has been shown that cross-
linking and activation of FcεRIα on the surface of pDCs suppresses virus-induced IFNα 
production, suggesting exposure to allergen could impair anti-viral defences rendering the 
host more susceptible to subsequent virus infection (Gill et al., 2010). In support of this, 
Contoli et al demonstrated IL-4 and IL-13 stimulation of BECs impaired IFNβ and IFNλ 
expression in response to RV infection through the inhibition of TLR3 and IRF3 (Contoli et 
al., 2015). Suppressor of cytokine signalling (SOCS) 1 is an IL-4/IL-13-inducible protein that 
was found to be upregulated in asthmatic BECs, which was also functionally shown to 
reduce RV-induced IFNβ expression in vitro (Gielen et al., 2015). Therefore, pre-exposure to 
allergen and activation of type 2 inflammatory responses could lead to suppression of IFN 
expression upon subsequent virus infection, resulting in increased viral burden in asthma. 
These mechanisms could underlie the mechanism by which therapies targeting type 2 
pathways have demonstrated the ability to partially reduce exacerbations rates in patients, 
potentially by removing the brake on IFN responses. However, these mechanisms do not 
appear to fully account for the exaggerated type 2 inflammatory response observed in 
asthmatics upon virus infection, which suggest that additional pathological mechanisms may 
exist.  
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1.3.5.2. Interferons regulate type 2 immunity  
Inhaled IFNβ therapy was found to improve asthma symptom control during a cold infection 
in a subset of moderate-to-severe asthmatics, supporting the clinical benefit of boosting IFN 
responses in disease. Increased expression of anti-viral molecules were detected in patients 
treated with inhaled IFNβ; however, whether this was directly related to improved symptom 
control in asthmatics was not defined (Djukanovic et al., 2014). Functional studies have 
demonstrated the role of IFN signalling in the negative regulation of type 2 immune 
responses (summarised in table 1.2); therefore, inhaled IFNβ therapy may have additional 
efficacy to supporting anti-viral defences in asthma.  
 
1.3.5.2.1. TLR7-associated IFN responses 
Studies that have modulated TLR7 signalling have indirectly supported regulatory roles for 
type I IFN signalling on Th2 pathways. Activation of TLR7 was reported to suppress IL-5 
expression in PHA-stimulated PBMCs via the stimulation of IFNα production (Edwards et al., 
2013b). Furthermore, activation of TLR7 signalling by administration of the agonist R848 
prior to or during allergen challenge in sensitised mice suppressed the development of 
allergic airways inflammation through the production of type I IFN (Xirakia et al., 2010). 
Recently, Hatchwell et al demonstrated that impaired IFN expression in TLR7 deficient mice 
was associated with profound RV-induced exacerbation of allergic airways inflammation, 
which was suppressed by the administration of type I or III IFN (Hatchwell et al., 2015).  
 
1.3.5.2.2. T-cell responses 
Several experimental models have indicated the ability of innate IFNs to exert its effects at 
the T-cell level. In T-cell cultures, treatment with IFNα inhibited Th2 cytokine production by 
committed Th2 cells through the suppression of GATA3, a transcription factor that drives 
Th2 cell polarisation (Huber et al., 2010). In PBMC cultures, Pritchard et al demonstrated 
that the presence of type I IFN signalling during RV stimulation constrained Th2 cytokine 
expression, whereby blockade of type I IFN receptor signalling or depletion of pDCs (as a 
source of IFNα) enhanced IL-13 production by T cells (Pritchard et al., 2012). In addition, 
type III IFN signalling has been shown to regulate T-cell activation in vivo. Overexpression of 
IL-28A (IFNλ2) suppressed the development of allergic airways inflammation and absence of 
type III IFN signalling resulted in enhanced allergen-induced type 2 inflammation. In these 
systems, type III IFN signalling was found to suppress OX40L expression on DCs; therefore, 
restraining Th2 cell priming and activation (Koltsida et al., 2011).   
 
Chapter 1: Introduction 
43 
 
1.3.5.2.3. Innate lymphoid cells  
Further to the emerging role of ILC2s in the development of type 2 inflammation and 
potentially allergic airways inflammation in asthma, recent publications have demonstrated 
the ability of type I IFN signalling to modulate ILC2 function. Influenza A virus infected 
IFNAR1-/- mice were found to exhibit enhanced pulmonary accumulation of ILC2s compared 
with wild-type mice and this was associated with enhanced type 2 pathology, including 
increased IgE, airway eosinophilia and evidence of airways remodelling (Duerr et al., 2016). 
Moro et al also demonstrated that IFNβ inhibits IL-2 and IL-25- or IL-33-induced IL-5 and IL-
13 production by ILC2s (Moro et al., 2016). These studies indicate that the presence of type 
I IFN signalling restrains ILC2 function, which could limit the pathological actions of IL-5 and 
IL-13 cytokines in a disease context.  
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Table 1.2. Summary of studies supporting IFN regulation of type 2 immunity 
 
Key finding Model used Reference 
Type I IFNα suppressed Th2 cell 
development and inhibited IL-4 secretion 
from activated Th2 cells  
Human purified CD4+ 
T-cell cultures  
Huber et al., 2010 
TLR7 stimulation of type I IFN production 
protected suppressed the development of 
allergic airways inflammation 
Mouse model of OVA-
induced allergic 
airways inflammation  
Xirakia et al., 2010 
Type III IFNλ suppressed allergen-induced 
Th2 cell development by down-regulation of 
OX-40 ligand on DCs 
Mouse model of OVA-
induced allergic 
airways inflammation  
Koltsida et al., 2011 
Blockade of IFNAR1 signalling resulted in 
enhanced RV-induced IL-13 expression by 
memory T cells  
RV stimulation of 
human PBMC 
cultures  
Pritchard et al., 2012 
IFNα production as a result of TLR7 
activation inhibited IL-5 expression by T cells 
PHA-stimulation of 
human PBMC 
cultures 
Edwards et al., 2013b 
Type I IFN treatment suppressed RV-induced 
exacerbation of allergic airways inflammation 
in TLR7 deficient mice 
Mouse model of RV 
and HDM allergen 
interactions  
Hatchwell et al., 2015  
Absence of type I IFN signalling leads to 
enhanced ILC2 activation during influenza 
infection  
Mouse model of 
influenza A infection  
Duerr et al., 2016 
IFNβ suppressed IL-5 and IL-13 release from 
stimulated ILC2s 
Murine ILC2 cultures  Moro et al., 2016 
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Collectively, this evidence suggests that lack of innate IFN signalling in asthma may lead to 
over-activation of type 2 responses that are considered central to the development of allergic 
airways inflammation, and become exacerbated during RV infections. Thus the therapeutic 
benefit of restoring IFNs in asthma may help to control the extent of type 2 inflammation, as 
well as reduce the burden of respiratory virus infections by boosting anti-viral responses, to 
improve clinical outcomes for asthma exacerbations.  
 
1.4. Experimental Rationale 
Augmented allergic type 2 inflammation and impaired anti-viral IFN responses are two 
potential mechanisms that could functionally contribute to the pathogenesis of virus-induced 
asthma exacerbations. Activation of allergic type 2 inflammatory pathways in asthma may 
impair IFN responses that pre-dispose asthmatics to virus infections. Impaired IFN 
responses may lead to over-activation of type 2 pathways in asthma that contribute to 
enhanced allergic airways inflammation. However, the mechanism that influences the 
specific augmentation of type 2 inflammation during RV infection in asthma is unknown. 
Previously published findings have largely demonstrated the impact of IFN on T-cell 
responses, particularly in relation to Th2 cell development and activation. Several studies in 
mice have demonstrated the ability of type I and III IFNs to regulate the development of 
allergen-induced type 2 immune responses in vivo, yet only one study has investigated such 
a role for IFN in the context of RV infection. At the time of writing of this thesis, Hatchwell et 
al published the ability of type I IFN treatment to suppress RV-induced exacerbation of type 
2 inflammation; however, this was in the context of impaired TLR7 signalling (Hatchwell et 
al., 2015). Therefore, a direct role for impaired type I IFN signalling in RV-induced 
exacerbation of allergen-induced pathology has yet to be investigated.  Considering 
accumulating evidence highlighting a role for enhanced type 2 inflammation in the 
pathogenesis of RV-induced asthma exacerbations, IFN deficiency in asthma may have a 
causal role in this pathological feature of disease. This thesis will therefore examine the 
regulatory role of type I IFN signalling on type 2 immunity and how this interaction may drive 
exacerbated type 2 inflammatory responses during RV infection in vivo. Insights into this role 
of type I IFN signalling may have important implications for the management of asthma 
exacerbations, not only in establishing an additional efficacious mechanism of inhaled IFNβ 
therapy, but also highlight novel therapeutic targets to address the unmet medical need 
associated with virus-induced asthma exacerbations.  
 
  
Chapter 1: Introduction 
46 
 
1.4.1. Hypothesis  
The central hypothesis of this thesis is that impaired type I IFN responses in asthma leads to 
reduced regulation of allergen-induced type 2 immune responses, resulting in exacerbation 
of type 2 inflammation during RV infection. The introduction to each results chapter in this 
thesis outlines a specific set of hypotheses and aims relevant to the experimental systems 
used in that chapter.  
 
1.4.2. Aims 
This thesis aimed to utilise experimental in vivo and in vitro models to investigate the 
regulatory role of type I IFN signalling on type 2 inflammatory responses during RV infection: 
i) To characterise the effects of type I IFN deficiency using IFNAR1-/- mice and strain-
matched wild-type C57 Bl/6 mice in a model of RV and allergen interactions.  
ii) To characterise the effects of impaired type I IFN signalling using an anti-IFNAR1 
receptor blocking antibody in a model of RV and allergen interactions in Balb/C mice.  
iii) To investigate the effects of administration of recombinant IFNβ in a model of RV and 
allergen interactions in Balb/C mice.  
iv) To characterise the mechanisms of type I IFN signalling on Th2 chemokine 
expression in a THP1-derived macrophage model.   
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Chapter 2: Materials and Methods   
 
2.1 Materials  
 
Table 2.1. Buffers and reagents used  
 
Reagent  Composition  
Ammonium-chloride-
Potassium (ACK) lysis 
buffer  
dH20 containing 0.155M Ammonium chloride (Sigma-
Aldrich, Shaftesbury, UK), 10mM potassium bicarbonate 
(Sigma-Aldrich) and 0.1mM disodium 
ethylenediaminetetraacetic acid (EDTA; Invitrogen). Filter-
sterilised through a 0.22μm filter.  
BAL media  
Roswell Park Memorial Institute (RPMI) medium (PAA) 
containing 5µM ethylenediaminetetraacetic acid (EDTA; 
Invitrogen) 
BAL and lung cell-culture 
medium  
RPMI medium (PAA) containing 10% FCS, 100μg/ml 
streptomycin and 100 units/ml penicillin (Gibco), 2% 
HEPES buffer and 1% sodium bicarbonate 
BAL and lung cell-
stimulation medium  
RPMI media containing 10% FCS, 100μg/ml streptomycin 
and 100 units/ml penicillin, 5ng/ml phorbol 12-myristate 
13-acetate (PMA), 500ng/ml ionomycin (Sigma-Aldrich) 
and 3µM monensin (‘GolgiStop’; BD Biosciences) 
2, 4 or 10% Dulbecco’s 
Modified Eagles Medium 
(DMEM) cell-culture 
medium 
DMEM (PAA) containing 2, 4 or 10% foetal calf serum 
(FCS; PAA), 2% HEPES buffer (Invitrogen) and 0.1% 
sodium bicarbonate (Gibco) 
ELISA wash buffer  
PBS (PAA) containing 0.05% Polyethylene glycol sorbitan 
monolaurate (‘Tween-20’; Sigma-Aldrich)  
ELISA reagent diluent  
PBS containing 1% bovine serum albumin (BSA; Sigma-
Aldrich)  
Fluorescence activated 
cell sorting (FACS) buffer  
PBS containing 1% BSA (Sigma-Aldrich)  
Laemmli buffer (6x) 
1.2g sodium dodecyl sulphate (SDS), 6ml glycerol and 
3.75ml (1M) Tris HCl (all Sigma-Aldrich)  
Lung digestion buffer  
BAL and lung cell-culture medium containing 1mg/ml 
collagenase type XI (Roche) and 80 units/ml bovine 
pancreatic DNAse type IV (Sigma-Aldrich).  
Lung homogenate buffer 
Tris-buffered saline (TBS) containing complete mini 
protease inhibitor cocktail (Roche), 10% glycerol and 0.1% 
Igepal (both Sigma-Aldrich) 
Reagent  Composition  
5 or 10% RPMI cell-
culture medium  
RPMI medium containing 5 or 10% FCS, 2% HEPES 
buffer and 1% sodium bicarbonate  
THP1-stimulation medium  
RPMI medium containing 5% FCS, 2% HEPES buffer, 1% 
sodium bicarbonate and 50nM PMA 
Tris-buffered saline (TBS) dH20 containing 20 mM Tris and 0.9% NaCl (Sigma-
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Aldrich) 
Trypsin EDTA  
PBS containing 0.01mM Trypsin and 0.3mM EDTA 
(Thermo Fisher)  
Trypan Blue  
0.01% trypan blue (Thermo Fisher) in PBS  
 
Western blot blocking 
buffer 
TBS containing 5% BSA  
Western blot running 
buffer  
dH20 containing 50mL NuPAGE MOPS SDS running 
buffer (Thermo Fisher) 
Western blot transfer 
buffer 
dH20 containing 25ml Tris-Glyine transfer buffer (Thermo 
Fisher) and 200ml methanol  
Western blot stripping 
buffer 
2% SDS, 62.5 mM Tris-HCL (pH 6.7), 100mM 2-β 
Mercaptoethanol (all Sigma-Aldrich)  
Western blot wash buffer TBS containing 0.1% Tween-20 
 
 
 
Table 2.2. Composition of reverse transcription reaction for mouse lung 
tissue  
 
Reagent  Volume per reaction (µl) Working concentration  
Buffer RT  3  
dNTP  3 0.5mM 
Random hexamers   1.5 10μM 
Omniscript RT  1.5 0.2units/μl 
Nuclease-free water  11  
RNA  10  
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Table 2.3. Sequences and concentrations of primer and probes for qPCR 
 
Gene  Sequence (5’- 3’)  
18S forward (300nM)  CGCCGCTAGAGGTGAAATTCT  
18S reverse (300nM)  CATTCTTGGCAAATGCTTTCG  
18S probe (100nM)  FAM-ACCGGCGCAAGACGGACCAGA -TAMRA 
mIFN-β forward (900nM)  CCATCATGAACAGGTGGAT  
mIFN-β reverse (900nM)  GAGAGGGCTGTGGTGGAGAA  
mIFN-β probe (100nM)  FAM-CTCCACGCTGCGTTCCTGCTGTG-TAMRA 
mIFNλ2 forward (900nM)  AAAGGATTGCCACATTGCTC  
mIFNλ2 reverse (900nM)  TCAAGCAGCCTCTTCTCGAT  
mIFNλ2 probe (100nM)  FAM-TCCCCAAAAGAGCTGCAGGC-TAMRA 
mMUC5AC forward (300nM)  AGAGGAGCGGAGAGAGACTCTGT  
mMUC5AC reverse (300nM)  CTCCATCTCTCTCTCAGGGTAGTTCT  
mMUC5AC probe (100nM)  
FAM-CGAGAGGAGATCACACAGTTGCAATGCA-
TAMRA 
mMUC5B forward (300nM) GAGCAGTGGCTATGTGAAAATCAG  
mMUC5B reverse (300nM) CAGGGCGCTGTCTTCTTCAT  
mMUC5B probe (100nM)  
FAM-ATCCGCCTAGTCCTCACCTTCCTGTGG-
TAMRA 
mOAS1a forward (900nM)  TCCTGGGTCATGTTAATACTTCCA  
mOAS1a reverse (900nM)  CCCCAGGGAGGTACATTCCT  
mOAS1a probe (100nM)  FAM-CAAGCCTGATCCCAGAATCTATGCC-TAMRA  
mPKR forward (900nM) CGGAACATCCTCTAGCGTTGTC 
mPKR reverse (900nM) GGGAAACACCATTACTTGTCATAGAC 
mPKR probe (100nM) FAM-AGCTGCTGGAAAAGCCACTGA-TAMRA 
RV forward (50nM)  GTGAAGAGCCSCRTGTGCT  
RV reverse (300nM)  GCTSCAGGGTTAAGGTTAGCC  
RV probe (100nM)  FAM-TGAGTCCTCCGGCCCCTGAATG-TAMRA 
mViperin forward (900nM)  CGAAGACATGAATGAACACATCAA  
mViperin reverse (900nM)  AATTAGGAGGCACTGGAAAACCT  
mViperin probe (100nM)  FAM-CCAGCGCACAGGGCTCAGGG-TAMRA  
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Gene  Sequence (5’- 3’)  
Human PTPN6 forward (900nM)  AGGCGGCCCGGCACT  
Human PTPN6 reverse (900nM) TCGGTGAAACCACCTCACCATCC  
Human PTPN6 probe (100nM)  
FAM-GCGCCCCCTTCCTCTCCGGAAGCCC-
TAMRA 
 
 
Table 2.4. Antibody staining cocktail for T cells utilised in chapter 3  
 
Antibody Clone Conjugate  
Working 
concentration (µg/ml) 
Supplier  
CD3 AF700 500A2 2 Biolegend 
CD4 RM4-5 V450 1.25 BD Horizon 
T1ST2  DJ8 FITC 2.5 MD Biosciences 
IL-4 11B11 PE 0.5 Biolegend 
IFNγ XMG1.2 PE-Cy7 0.5 Biolegend  
NK1.1 PK136 PerCPCY5.5 2 Biolegend 
 
 
Table 2.5. Antibody staining cocktail for T cells utilised in chapters 4 and 5 
 
Antibody Clone Conjugate  
Working 
concentration (µg/ml) 
Supplier  
CD3 AF700 500A2 2 Biolegend 
CD4 RM4-5 V450 1.25 BD Horizon 
T1ST2  DJ8 FITC 2.5 MD Biosciences 
IL-5 TRFK5 APC 1 Biolegend 
IL-13 eBio13A PE 1 eBiosciences 
IFNγ XMG1.2 PE-Cy7 0.5 Biolegend 
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Table 2.6. Antibody staining cocktail for ILC2 utilised in chapters 3 and 4  
 
Antibody Clone Conjugate  
Working 
concentration (µg/ml) 
Supplier  
CD11b M1/70 BV421 0.0625 Biolegend 
CD11c N418 BV421 0.5 Biolegend 
Siglec F E50-2440 BV421 0.5 BD Pharmingen 
GR1  RB6-8C5 PerCPCy5.5 0.25 Biolegend  
B220  RA3-6B2 PerCPCy5.5 1 Biolegend 
CD3 145-2C11 PerCPCy5.5 2 Biolegend  
NKp46 29A1.4 PerCPCy5.5  2 Biolegend  
FcεRI MAR1 PE 1 Biolegend 
ICOS C398.4A PE-Cy7  1 Biolegend 
T1ST2 DJ8 FITC 2.5 MD Biosciences 
IL-17RB*  AF647 5 Invitrogen 
CD69 H1.2F3 BV605 1 Biolegend 
*IL-17RB antibody was provided by Dr Andrew McKenzie and subsequently conjugated in-
house using AlexaFluor 647 Monoclonal Antibody Labelling Kit (Invitrogen).  
  
 
Table 2.7. Concentrations of western blot antibodies used in Chapter 6  
 
Antibody Isotype  Working dilution  Supplier  
STAT6-P(Y641) Mouse IgG1 1:1000  BD Pharmingen 
STAT6  Rabbit IgG 1:500 Abcam 
SHP1-P (Y536) Rabbit IgG 1:1000 Abcam  
SHP1-P (Y564) Rabbit IgG 1:1000 Cell Signalling 
SHP1  Rabbit IgG 1:10000 Abcam 
Β actin Rabbit IgG 1:1000 Abcam 
Rabbit Sheep IgG-HRP 1:5000 AbD Serotec 
Mouse  Goat IgG-HRP 1:5000 Santa Cruz 
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2.2. Rhinovirus culture and propagation 
Stocks of the LDL-R binding serotype RV-1B were obtained from American Type Culture 
Collection (ATCC, UK) and propagated in-house using the H1 HeLa human epithelial cell 
line (ATCC, UK). H1 HeLa cells were grown to ~90% confluency in 10% DMEM medium 
under sterile conditions. Twenty five flasks (T175; NUNC) of H1 HeLa cells were infected 
with RV-1B in 2% DMEM medium. Cells were incubated at room temperature for 1 hour with 
constant shaking to aid attachment of virus to cells.  Cells were then incubated at 37°C for 
up to 24 hours until it was observed that cells were easily detached upon striking of the flask 
(~90% cytopathic effect (CPE)). The infected cells were harvested and pelleted by 
centrifugation and washed several times with cold PBS until all pellets were concentrated in 
a total of 36ml of PBS. Cells were lysed to allow virus release by freezing and thawing twice. 
Remaining cell debris was removed by centrifugation and the supernatant harvested and 
filtered through a 0.2µm syringe filter. The virus was precipitated by dissolving 2.8g 
polyethylene glycol (Sigma-Aldrich) and 4ml 0.5M sodium chloride in the supernatant on ice 
for 1 hour. The precipitate was harvested by centrifugation and the pellet resuspended in 
15ml PBS, which was then concentrated to a volume of ~2.5ml using Amicon Ultra-15 
centrifugal filtration tube (Millipore). This concentrated virus stock was stored at -80°C until 
use in vivo. 
 
2.3. Rhinovirus titration 
A single batch of RV-1B was insufficient for multiple animal studies; therefore, new batches 
of RV-1B were produced prior to each experiment. The infectivity of each batch of virus was 
assessed by in vitro and in vivo methods. Ohio HeLa cells (ATCC) were seeded at 1x105 
cells/ml in 96-well cell culture plates (Costar Corning) in 4% DMEM media. Cells were 
exposed to 8 replicates of serial 10-fold dilutions of RV-1B and incubated at 37°C for 4 days. 
CPE was assessed and scored by observation under a light microscope. The Spearman-
Karber formula was used to calculate the tissue culture infective dose (TCID50). The in vivo 
infectivity of each RV-1B batch was assessed by inoculation of mice with serial dilutions of 
virus and measurement of airway neutrophilia 24 hours later. For primary infection 
experiments, the virus was required to induce >50% neutrophilia, which was typically used 
neat. For experiments in a model of virus and allergen interactions, the virus was required to 
induce ~30% neutrophilia; therefore, the virus was titrated to identify the appropriate dilution. 
For virus-inactivated controls, RV-1B was UV-irradiated for 30 minutes using a UV crosslink 
(CX-2000; UVP).  
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2.4. Animals  
IFNAR1KO mice on C57Bl/6 background were bred in-house and purchased wild-type C57 
Bl/6 mice (Harlan Laboratories, UK) were used at 6–8 weeks old. In other studies, female 
Balb/C mice were purchased (Harlan Laboratories, UK) and used at 6–8 weeks olds. All 
animal experiments were carried out in compliance with the UK Animals Scientific 
Procedures Act 1986.  
 
2.5. Model of primary RV infection  
Isoflurane-anaesthetised mice were inoculated with 50µl RV-1B or UV-inactivated RV-1B 
(controls) intranasally (i.n.).  
 
2.6. Model of allergen and RV interactions  
Mice were sensitised on day –12 with 50g ovalbumin (OVA) in 2mg aluminium hydroxide 
(alum) intraperitoneally (i.p.) in a volume of 200l. Isoflurane-anaesthetised mice were then 
challenged with either 30l PBS (controls) or 10g OVA in 30l PBS intranasally (i.n.) on 
three consecutive days (Days –2  to –0). During the third challenge, mice were inoculated 
with either 50l of RV-1B or UV-inactivated RV-1B.  
 
2.7. Blockade of IFNAR1 in models of primary infection and virus 
and allergen interactions  
Anti-IFNAR1 monoclonal antibody (clone MAR15A3; Leinco Technologies) and isotype-
matched mouse IgG1 antibody (clone MOPC21; Biolegend) were administered i.n. in a 
volume of 100µl to mice under anaesthesia, 2 hours prior to virus infection. For a model of 
virus and allergen interactions, a second dose of anti-IFNAR1 or control was administered 2 
days later (day 2).  
 
2.8. Administration of recombinant IFNβ in a model of virus and 
allergen interactions  
Recombinant IFNβ (R&D Systems) and vehicle PBS were administered i.n. in a volume of 
50µl to mice under anaesthesia, 2 and 8 hours after the third OVA challenge/virus infection.  
 
2.9. Measurement of airway hyperresponsiveness  
Conscious unrestrained mice were placed in whole body plethysmography chambers 
(EMMS) 24 hours post-RV infection/ final allergen challenge. Mice were exposed to 
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aerosolised dH20 (baseline) followed by aerosolised solutions of methacholine (MCh; Sigma-
Adlrich) dissolved in dH20 at concentrations of 3, 10, 30 and 100mg/ml for 1 minute at each 
dose. Bronchoconstriction in mice caused by MCh exposure changes the respiratory 
waveform, which is recorded over 5 minutes post-MCh nebulisation. The data is acquired 
and analysed by the eDaq v1.8 software (EMMS) and expressed as enhanced pause 
(Penh), a unit to indicate airway resistance. The average Penh value over 5 minutes was 
used to compare the airway responsiveness of mice exposed to bronchoconstrictor stimulus.  
Penh is calculated by the following formula:  
 
𝑃𝑒𝑛ℎ = (
𝑃𝐸𝐹
𝑃𝐼𝐹
) × (
𝑇𝑒
𝑅𝑡
− 1) 
 
PEF = Peak Expiratory flow (ml/s)  
PIF = Peak Inspiratory flow (ml/s)  
Te = Expiratory Time (Total)  
Rt = Relaxation Time (time taken for expiration of 65% total expiratory volume) 
 
2.10. Collection and Processing of Mouse Samples  
 
2.10.1. Collection of samples  
Mice were terminated by anaesthetic overdose with 200l pentobarbitone sodium 
(200mg/ml; Animalcare Limited) intraperitoneally (i.p). Trachea were cannulated and lavaged 
with 1.5ml BAL fluid media to obtain bronchoalveolar lavage (BAL) fluid for measurement of 
inflammatory cells and proteins. The right apical lung lobe was dissected and placed in 
‘RNAlater’ solution for RNA extraction and analysis of gene expression levels. The left lung 
lobe was dissected for dissociation into single cell suspensions for lymphocyte analysis. 
Remaining lung lobes were stored at -80° for lung homogenate cytokine analysis. 
 
2.10.2. BAL  
BAL fluid samples were centrifuged and supernatants collected and stored at -80°C for 
protein analysis. The cell pellets were resuspended in 100µl ACK lysis buffer for 1 minute to 
lyse red blood cells and neutralised with 1ml 10% RPMI media. BAL cells were centrifuged 
again and resuspended in 1ml BAL cell-culture medium (see table 2.1) and total live cell 
counts obtained by 0.01% trypan blue staining and a light microscope.   
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2.10.3. Lung cell suspension  
The left lung lobe was mechanically dissociated in gentleMACS C-Tubes by gentleMACS 
Dissociator (Miltenyi) and incubated at 37C for 45 minutes in lung digestion buffer (see 
table 2.1). Lung tissues were homogenised and centrifuged. Lung cells were resuspended in 
5mls ACK lysis buffer for 5 minutes and quenched in 10mls PBS. Cells were recovered by 
filtration through a 70m nylon strainer and centrifuged. Supernatants were removed, cells 
washed in 10mls PBS and centrifuged again. Supernatants were removed and cells were 
resuspended in 2mls lung cell-culture medium (see table 2.1). Total live cells were counted 
using 0.01% trypan blue staining and a light microscope.  
 
2.10.4. Lung RNA extraction and cDNA synthesis  
Lung tissue was homogenised and lysed in Buffer RLT (Qiagen) containing 1% β-
mercaptoethanol (Sigma-Aldrich) prior to RNA extraction. RNA was extracted from lung 
tissue using the RNeasy Mini Kit (Qiagen) following the manufacturer’s protocol and included 
the optional on-column DNase I digestion step. Purified RNA was resuspended in 30µl 
nuclease-free water. RNA was reverse transcribed using the Omniscript reverse 
transcription kit (Qiagen) and random hexamers as primers (Promega) to produce cDNA 
(composition of reverse transcription reaction detailed in table 2.2).  
 
2.10.5. Lung homogenate  
Lung lobes were homogenised 500µl in TBS containing complete protease inhibitor cocktail 
(Roche) and 10% glycerol. Igepal detergent was added to each sample to a final 
concentration of 0.1%. Samples were placed on ice for 30 minutes and vortexed every 10 
minutes. Samples were then centrifuged at 4°C for 20 minutes, supernatants collected and 
stored at -80°C. Concentration of protein in the supernatant was quantified using Bradford 
protein assay (Sigma-Aldrich) and the amount of cytokine detected in the sample was 
normalised to milligrams of protein.  
 
2.11. Analysis of differential leukocytes in BAL  
For the analysis of differential leukocytes, 70µl of BAL cell suspensions were loaded onto 
cytospin slides, dried and stained using Quick-Diff staining kit (Reagene). Eosinophils, 
neutrophils and lymphocytes were differentiated by cell morphology and counted using a 
light microscope.  
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2.12. Analysis of lymphocytes in BAL and lung by flow cytometry  
To stimulate intracellular cytokine production for the analysis of T cells, approximately 2x106 
lung cells per sample and remaining BAL cells (between 1-10 x 105 cells/ml) were stimulated 
in 200µl BAL and lung cell-stimulation medium (see table 2.1) for 4 hours at 37°C. Samples 
were centrifuged and washed twice with FACS buffer (see table 2.1). Cells were blocked 
with 50μl of 5μg/ml rat anti-mouse CD16/CD32 FcBlock (BD Biosciences) for 30 minutes. 
Cells were stained with 50µl antibody cocktail (2 x concentration) containing fluorochrome-
conjugated antibodies targeting cell-surface markers for 30 minutes. Cells were washed with 
PBS and stained with 100μl LIVE/DEAD Fixable Near IR Dead Cell Stain (Invitrogen) for 20 
minutes.  
 
For samples that only required cell surface analysis, cells were washed with PBS and fixed 
with 100μl 2% paraformaldehyde (Sigma-Aldrich) for 20 minutes. Cells were washed twice 
with PBS and resuspended in 150μl FACS buffer ready for analysis the following day.  
 
For intracellular cytokine staining, cells were fixed and permeabilised following LIVE/DEAD 
staining in 150µl of BD Cytofix/Cytoperm solution (containing PFA and saponin; BD 
Biosciences) for 20 minutes. Cells were washed twice with BD PermWash (containing 
saponin; BD Biosciences) and stained with 100µl of antibody cocktail targeted for 
intracellular proteins in PermWash for 30 minutes. Cells were washed twice and 
resuspended in 150µl FACS buffer ready for analysis the following day. 
 
Samples were acquired using a BD Fortessa Flow Cytometer and data collected using BD 
FACSDiva software. Data was analysed using FlowJo software (Tree Star Inc.). Dead cells 
were excluded from analyses and only single cells were investigated based on width and 
area. Total lymphocytes were gated on the basis of size and granularity by forward and side 
scatter, respectively, prior to determining cell populations by specific markers that are 
summarised in tables 2.4 to 2.6.   
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Figure 2.1. Flow cytometry gating strategy to determine live, single cells  
Cell populations identified in the following gating strategies were calculated as a percentage of live, single cells (‘Singlets gating-2’). The 
‘lymphocyte’ gate based on size (FSC-A) and granularity (SSC-A) was for reference only in order to improve visualisation of the relevant 
lymphocyte populations of interest and was not used in the calculation of actual total cell numbers.   
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Figure 2.2. Flow cytometry gating strategy to determine T-cell populations 
T cells were identified by the expression of cell-surface CD3. CD4+ T helper cell populations were identified by surface expression of CD4 and 
relevant markers of Th1 and Th2 cells. Th1 cells were identified by intracellular expression of IFNγ. Th2 cells were identified by surface 
expression of T1ST2 or intracellular expression of IL-4, IL-5 or IL-13.  All gating strategies were based on FMO, where relevant.   
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Figure 2.3. Flow cytometry gating strategy to determine ILC2 
Lineage (CD11b, CD11c, Siglec F, B220, NKp46, GR1, CD4, CD3) negative events were gated on ICOS positive expression to define ILC2s. 
Characteristics of ILC2 populations based on expression of IL-17RB, T1ST2 and CD69 were also identified. All gating strategies were based on 
FMO, where relevant. 
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2.13. Analysis of chemokines and cytokines by ELISA 
For the detection of murine IL-4, IL-5, IL-13, IL-25, IL-28, IL-33, TSLP, CCL11, CCL24, 
CCL17, CCL22, KC, CCL5, CXCL9, CXCL10 and CXCL11 levels in BAL fluid supernatants, 
sandwich ELISA kits were purchased from R&D Systems. 96-well maxi-sorp plates (Nunc-
Immuno) were coated with 100μl of the relevant working concentration of Capture Antibody 
in PBS overnight. Plates were washed with ELISA wash buffer (see table 2.1) and blocked 
with 250μl ELISA reagent diluent (see table 2.1) for 1 hour. Plates were washed again and 
100μl per well of sample and standards were added in duplicate for 2 hours. Following 
another wash, 100μl per well of the relevant concentration of detection antibody was added 
for 2 hours. Plates were washed again and 100μl per well of the working concentration of 
streptavidin-horse radish peroxidase (HRP) was added for 20 minutes. Plates were then 
washed and 100μl tetramethylbenzidine (TMB; Sigma-Aldrich) substrate was added and 
allowed to develop over 5–10 minutes. This was followed by the addition of 50μl stop 
solution (1M H2S04). Plates were analysed at 450–540nm optical densities using an 
automatic ELISA plate reader and data acquired with Softmax Pro software. Minimum 
detection limits were between 10–50pg/ml. 
 
For the detection of murine IFNα and IFNβ, ‘VeriKine’ sandwich ELISA kits were purchased 
from PBL Interferon Source. Plates were pre-coated with capture antibody. For the detection 
of IFNα, 100µl per well of sample or standards was added in duplicate before the direct 
addition of 50µl per well detection antibody and incubated for 1 hour at room temperature 
with shaking at 450rpm. This was followed by an overnight incubation at 4°C, after which 
plates were washed and streptavidin-HRP was added for 2 hours. For the detection of IFNβ, 
100µl per well of sample or standards was added in duplicate for 1 hour and washed before 
the addition of 100µl detection antibody for a further 1 hour. Plates were washed again and 
streptavidin-HRP was added for 1 hour. Following a further wash, 100µl TMB substrate was 
added and allowed to develop over 15 minutes. This was terminated by addition of 100µl 
stop solution and plates were analysed as described previously. The minimum detection limit 
of both IFN assays was 15.6pg/ml.  
 
2.14. Analysis of MUC5AC protein in BAL  
MUC5AC protein levels in BAL was measured by coating 96-well maxi-sorp plates with 
100µl per well with BAL fluid samples diluted 1:20 and allowing samples to evaporate at 
37°C overnight. Standard curve was generated by serial 1:2 dilutions of BAL supernatans 
taken from ovalbumin-induced allergic mice. Plates were washed 3 times with ELISA wash 
buffer and blocked for 2 hours at room temperature. Plates were washed again and coated 
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with 400pg/ml biotinylated anti-MUC5AC detection antibody (Thermo Fisher). Subsequent 
steps were as described previously in section 2.13 for other ELISA analyses.  
 
2.15. Analysis of RNA levels in lung tissue by Taqman qPCR 
Quantitative real time PCR was carried out using a reaction mix of Taqman master mix 
(Qiagen) containing specific forward and reverse primers and probe for each target gene 
(Invitrogen). For the detection of RV viral RNA, the primers span the part of the RV genome 
from the conserved 5’ untranslated region to the start of the VP4 polyprotein of human RV.  
11.5μl of reaction mix and 1μl of cDNA sample was added to each well of a 96-well qPCR 
plate in duplicate and sealed with an adhesive lid. For the detection of 18S, cDNA samples 
were diluted 1:100 in nuclease-free water prior to analysis. Plates were run on a 7500 Real 
Time PCR System (Applied Biosystems) for 45 cycles under the following conditions: 1 cycle 
of 50°C (2 minutes) and 95°C (10 minutes); 45 cycles at 95°C (15 seconds) and 60°C (1 
minute). The cycle number at which cDNA copies were detected above a given threshold (Ct 
value) was determined and used to calculate the concentration of cDNA. RNA expression 
levels were normalized to 18S RNA of the corresponding samples and compared to a 
standard curve, quantified as copies per μl. The minimum limit of detection for all Taqman 
assays was 10 copies/µl.  
 
2.16. THP1 Macrophage culture  
THP1 monocytes were cultured in suspension in RPMI medium containing 10% FCS. Cells 
were seeded in 6 or 12 well flat bottom cell culture plates at a concentration of ~4 x 105 
cells/ml in THP1-stimulation medium containing PMA (see table 2.1) for 24 hours to 
stimulate differentiation into a macrophage-like state. Cells were washed and replaced with 
5% RPMI media for a further 24 hours prior to commencing the experimental procedure. 
Cells were stimulated with recombinant IL-4 and recombinant TNFα (both R&D Systems) 
and supernatants were harvested 24 hours later. In IFNβ experiments, cells were either 
treated with recombinant IFNβ (R&D Systems) for 24 hours following PMA stimulation (pre-
treatment) prior to IL-4 and TNFα stimulation for a further 24 hours; treated with IFNβ at the 
same time as IL-4 and TNFα stimulation (co-treatment) for 24 hours. In experiments testing 
MG132 (Sigma-Aldrich) or protein tyrosine phosphate (PTP) inhibitors (sodium 
orthovanadate (SOV) and sodium stibogluconate (SSG); both Santa Cruz), cells were pre-
treated with inhibitor for 90 minutes before IL-4 and TNFα stimulation for 24 hours in the 
presence of inhibitor.   
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2.16.1. siRNA 
PTPN6 siRNA (SMARTpool ON-TARGET plus) and control siRNA (ON-TARGET non-
targeting pool) were reconstituted in 1 x siRNA Buffer (all Dharmacon) and mixed on a roller 
for 30 minutes at room temperature. siRNA was diluted in Optimem media (Gibco) to 
0.27ng/ml working concentration and mixed by gentle pipetting. ‘Interferin’ siRNA 
transfection reagent (Polyplus) was added to the siRNA master mix and vortexed for 10 
seconds each. Following incubation at room temperate for 10 minutes, siRNA transfection 
mix was added to THP1-derived macrophages in RPMI media containing 5% FCS. Cells 
were incubated at 37°C for up to 72 hours and PTPN6 gene expression and SHP1 protein 
abundance was assessed from 24 hours post-transfection.  
 
2.16. Microarray  
RNA was extracted from THP1-derived macrophages using the RNeasy Mini Kit (Qiagen) 
following the manufacturer’s protocol and included the optional on-column DNase I digestion 
step. Purified RNA samples were quantified using a Nanodrop spectrophotometre (Thermo 
Scientific) and the quality of the RNA was assessed using RNA nanochip Bioanalyser 
(Agilent Technologies). A total of 20ng purified RNA in a volume of 5µl was used for DNA 
synthesis and amplified using the Ovation PicoSL WTA system V2 (Nugen) following the 
manufacturer’s protocol. Briefly, the first strand cDNA was synthesised using a DNA/RNA 
chimeric primer mix of random and oligo primers and reverse transcriptase. The resulting 
first strand cDNA and mRNA hybrid molecule contains a unique RNA ‘SPIA’ tag at the 5’ 
end, which was used as a priming site for the ‘SPIA’ amplification process. The second 
strand cDNA was synthesised by DNA polymerase, resulting in double-stranded cDNA with 
a DNA/RNA heteroduplex SPIA tag sequence on one end. The cDNA was purified prior to 
amplification using magnetic Agencourt CleanXP beads (Beckman Coulter) and washed with 
ethanol. The purified cDNA was eluted in a SPIA primer mix ready for amplification. During 
the SPIA amplification process, the RNA portion of the SPIA tag sequence was removed by 
RNase H, which revealed the SPIA primer binding site. DNA polymerase synthesised cDNA 
from the 3’ end displacing the forward strand and generating a new SPIA tag, which initiated 
the next round of cDNA synthesis. Amplified DNA was purified using the Qiagen MinElute 
reaction cleanup kit and quantified using a Nanodrop spectrophotometre and quality 
assessed using the Bioanalyser. A total of 2.5µg purified cDNA in a volume of 25µl was 
biotinylated using the Encore BiotinIL module (Nugen) following the manufacturer’s protocol. 
Briefly, samples are treated with uracil-DNA glycosylase (UNG) to remove the urcil base 
incorporated during amplification resulting in an abasic site, which was labelled by chemical 
attachment of a biotin moiety. The samples were purified again using the Qiagen MinElute 
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cleanup kit and the resulting quantity of cDNA is assessed using the Nanodrop 
spectrophotometer. The labelled cDNA is hybridised on Illumina Whole Genome Expression 
Beadchips, stained with streptavidin-Cy3 and fluorescence emission by Cy3 was detected 
for downstream analysis. Expression analysis was performed using Partek Genomics Suite 
version 6.6 by Dr Paul Lavender (King’s College London).  
 
2.17. Western blots  
THP1-derived macrophages were washed twice with cold PBS then lysed with RIPA cell 
lysis buffer (Sigma) containing protease and phosphatase inhibitor cocktail (Thermo Fisher 
Scientific). Cells were agitated in lysis buffer for 30 minutes at 4°C. Samples were 
centrifuged and supernatants were collected. Protein concentration was determined using 
BCA Protein Assay Kit (Pierce Thermo Fisher) following the manufacturer’s instructions. The 
concentration of protein per sample was normalised to the sample containing the lowest 
concentration. Laemmli buffer and β-mecaptoethanol (10%) was added to each sample and 
heated at 95°C for 5 minutes to denature proteins. For polyacrylamide gel electrophoresis 
(PAGE), samples were loaded into a pre-cast 4–12% bis-tris gel (NuPage; Invitrogen) 
alongside SeeBlue Plus2 molecular weight markers (Invitrogen) in a gel tank containing 1X 
MOPS running buffer. Samples were run at 80V for approximately 2 hours. Following PAGE, 
protein within the gel was transferred to nitrocellulose membranes in Tris-glycine transfer 
buffer containing 20% methanol. Nitrocellulose membranes, filter paper and blotting pads 
were equilibrated in transfer buffer prior to assembly of the gel transfer. The gel was laid 
onto the nitrocellulose membrane and sandwiched either side by pre-wetted filter paper then 
blotting pads. The gel transfer was placed into a semi-wet transfer blot module (XCell II; 
Invtirogen) filled with transfer buffer and run at 60V for approximately 2 hours in the 
presence of an ice pack with continuous stirring. The nitrocellulose membrane was removed 
and incubated in western blot blocking buffer (see table 2.1) for 1 hour at room temperature 
with agitation. Blocking buffer was removed and primary antibody solution was added to the 
membrane and incubated at 4°C with agitation overnight. The concentrations of primary 
antibodies used for western blot are summarised in table 2.6.  
 
The next day, membranes were washed 3 times (5 minute washes) with TBS tween before 
adding the HRP-conjugated secondary antibody solution at room temperature for 1 hour The 
concentrations of secondary antibodies used for western blot are summarised in table 2.7. 
Membranes were washing 3 times (30 minute washes) before adding 2mls enhanced 
chemiluminescence (ECL) substrate solution (Pierce Thermo Fisher) and revealed using a 
Fusion FX7 chemiluminescence imager (Villber). In cases where multiple proteins were 
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analysed in the same nitrocellulose membrane, bound antibodies were stripped by 
incubation with stripping buffer for 1 hour at 60°C and washed 3 times (30 minute washes). 
Membranes were blocked again and antibody steps repeated as above. In cases where 
protein quantification was required, densitometry analysis was conducted using Image J 
software and compared to β actin controls within the same nitrocellulose membrane.  
 
2.18. Statistical analysis  
For animal studies, group sizes of least 4 mice per experimental condition were used. Data 
shown represents mean ± SEM for each group and was analysed using GraphPad Prism 4.0 
(GraphPad Software Inc.). Statistical significance was determined by one-way analysis of 
variance (ANOVA) followed by Bonferroni multiple comparison post-test, where appropriate. 
In instances where means were compared with a single control mean, a Dunnett post-test 
was used. Lung function (Penh) results were analysed by two-way ANOVA followed by 
Bonferroni multiple comparison post-test. For in vitro studies, data represents mean ± SEM 
of at least 3 experimental replicates or data is representative of 3 replicates. Statistical 
significance was determined by one-way ANOVA followed by Dunnett multiple comparison 
post-test, where means were compared with the control mean.  
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Chapter 3: Results: Model of RV and allergen 
interactions in IFNAR1-/- mice and strain-matched 
wild-type C57 Bl/6 mice 
 
3.1. Introduction 
Impaired innate IFN responses in asthma have been postulated as a potential mechanism 
for the increased severity and duration of respiratory viral infections in asthma that contribute 
to acute exacerbations. Studies have detected impaired RV-induced type I IFN expression in 
lung cells from asthmatics (Wark et al., 2005, Sykes et al., 2012, Baraldo et al., 2012, 
Edwards et al., 2013a). Considering the role of innate IFN signalling in host anti-viral 
immune responses, this could result in reduced viral clearance, suggesting a possible 
mechanism for the increased susceptibility to RV infection in asthma. In support of this, 
evidence from experimental RV infection studies have demonstrated increased viral load in 
asthma compared with healthy volunteers (Jackson et al., 2014).  
 
To date, there is little evidence demonstrating a causal role for deficient type I IFN signalling 
in asthma exacerbations. Much of our knowledge of innate IFN deficiency in asthma derives 
from cultured human cells that have been stimulated ex vivo with virus. Impaired RV-induced 
IFN expression corresponds with increased viral load and reduced virus-induced cell 
apoptosis in vitro (Wark et al., 2005). Additionally, deficient IFNα and IFNβ production in RV-
infected BAL cells inversely correlated with AHR in the same asthmatic patients, indicating 
an association with disease severity (Sykes et al., 2012). However, innate IFN deficiency 
has not been demonstrated in the context of a respiratory viral infection in asthma in vivo; 
therefore, the role of IFN deficiency in the pathology of asthma exacerbations is unknown. 
 
A potential mechanism in the pathogenesis of asthma exacerbations is the role of type 2 
allergic inflammation. Experimental infection studies have supported a link between virus 
infection and exacerbation of pre-existing type 2 immune responses in asthma (Message et 
al., 2008, Jackson et al., 2014). Furthermore, evidence from clinical trials investigating the 
efficacy of therapies targeting type 2 mechanisms, including IgE activity and type 2 
cytokines, have demonstrated reduced rates of exacerbations in specific asthmatic patient 
subsets (Pavord et al., 2012, Hanania et al., 2015, Busse et al., 2011, Soler et al., 2001). 
The magnitudes of type 2 responses have been found to correlate with increased symptom 
severity following RV infection (Jackson et al., 2014). Together, these findings support roles 
for enhanced type 2 immunity as a pathological feature of RV-induced asthma 
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exacerbations. Whether there is a causal role for innate IFN deficiency in the specific 
exacerbation of type 2 responses during virus infections in asthma is yet to be determined.  
 
Accumulating evidence suggests an association between impaired innate IFN signalling and 
type 2 responses in asthma. Deficient type III IFN responses in asthmatic BECs and 
macrophages has been physiologically related to increased symptom severity, as well as 
decline in lung function following experimental RV infection in vivo in the same patients. Of 
particular relevance to type 2 immune responses was the observation that the ability to 
produce IFNλ ex vivo negatively correlated with increased eosinophils in induced sputum 
after RV infection (Contoli et al., 2006). Mice with impaired type III IFN signalling developed 
increased type 2 responses following allergen sensitisation and challenge, supporting a link 
between innate IFN signalling and type 2 immunity (Koltsida et al., 2011). In terms of type I 
IFN responses specifically, Sykes et al revealed type I IFN production in ex vivo stimulated 
BAL cells negatively correlated with the increased number of skin-prick positive tests, 
indicating an association with increased type 2 allergic responses (Sykes et al., 2012). 
Furthermore, Baraldo et al demonstrated impaired RV-induced type I IFNβ and type III IFNλ 
expression in asthmatic epithelial cells were related to increased abundance of eosinophils 
and IL-4 in bronchial biopsies (Baraldo et al., 2012).  
 
Functionally, type I IFN signalling has been shown to constrain type 2 cytokine production in 
RV-stimulated PBMCs in vitro. Blockade of type I IFN signalling in PBMCs enhanced RV-
induced IL-13 production, which was also supported by the ability of IFNβ to constrain IL-5 
and IL-13 (Pritchard et al., 2012). The lack of innate IFN in asthma may therefore result in 
the over-activation of type 2 responses that are considered central to the development of 
allergic airways inflammation. Furthermore, in the context of RV infection, the application of 
IFN deficiency may be beyond impaired anti-viral capacity in asthma, but responsible for the 
augmentation of type 2 inflammation seen specifically in asthma. 
 
In order to investigate functional causality of type I IFN deficiency in virus-induced asthma 
exacerbations, we have utilised mouse models of RV-induced airways disease. Recently, 
our group demonstrated that RV-infected type I IFN receptor deficient (IFNAR1-/-) mice have 
abrogated type I and III IFN production, which resulted in reduced viral clearance, indicating 
the importance of type I IFN signalling in anti-viral immunity in vivo (Bartlett et al., 2012). 
This chapter aimed to study the interactions between virus infection and allergen exposure in 
the absence of type I IFN receptor signalling using IFNAR1-/- mice. The effects of impaired 
type I IFN responses during RV infection in the context of allergic airways inflammation are 
unknown. In addition, the development of allergen-induced type 2 inflammation in the 
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airways has not been investigated in the absence of IFNAR1 signalling. These findings 
aimed to provide insights into the role of type I IFN deficiency on type 2 allergic airways 
inflammation in asthma and virus-induced exacerbations. Early innate (day 1 p.i.) and late 
adaptive (day 5 p.i.) immune responses that were assessed in IFNAR1-/- mice were 
compared with responses strain-matched wild-type C57 Bl/6 mice. 
 
3.1. Hypotheses 
In the absence of type I IFN signalling, RV-infected mice will: 
i) Have deficient innate IFN expression. 
ii) Have abrogated anti-viral ISG expression. 
iii) Have increased viral load. 
 
During RV infection in the context of allergic airways inflammation, IFNAR1-/- mice will: 
iv) Have increased type 2 allergic airways inflammation in response to allergen 
sensitisation and challenge, compared with wild-type mice. 
v) Exhibit exaggerated type 2 allergic airways inflammation during RV infection 
following allergen sensitisation and challenge, compared with wild-type mice. 
 
3.2. Aims 
To investigate the role of type I interferon signalling in a mouse model of RV-induced 
exacerbation of allergic airways inflammation using type I IFN receptor deficient mice. 
i) To examine the effect of type I IFN receptor deficiency on virus-induced lung 
responses. 
ii) To assess the effect of impaired type I IFN signalling on allergen-induced type 2 
pulmonary inflammation. 
iii) To investigate the effects of impaired type I IFN signalling on RV infection in allergen-
sensitised and challenged mice. 
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3.4. Results 
 
Figure 3.1. Model of RV and allergen interactions in IFNAR1-/- mice and wild-type C57 
Bl/6 mice. 
IFNAR1-/- mice and wild-type C57 Bl/6 mice were sensitised with 50µg OVA in 2mg alum i.p. 
and challenged i.n. with either 10µg OVA or PBS (controls). Mice were then infected with 
RV1B or UV-inactivated RV1B (controls).  
 
 
3.4.1. Effects of type I IFN receptor deficiency on RV-induced IFN responses 
 
3.4.1.1. Innate interferon gene expression 
Previous investigations found that IFNAR1-/- have impaired RV-induced IFNα and IL-28 
production in the airways compared with wild-type mice, demonstrating suppression of IFN 
expression in the absence of type I IFN receptor signalling (Bartlett et al., 2012). The 
induction of innate type I and III IFN gene expression in the lung tissue 1 day following RV 
infection was assessed in wild-type and IFNAR1-/- mice (figure 3.2). IFNβ and IFNλ2 mRNA 
were significantly induced following RV-PBS treatment in wild-type mice, which was 
significantly impaired in IFNAR1-/- mice. RV infection in allergen-sensitised and challenged 
wild-type mice resulted in significantly reduced IFNβ and IFNλ2 expression compared with 
RV infection alone.  
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Figure 3.2. Effect of type I IFN receptor deficiency on innate IFN gene expression in 
lung tissue 1 day p.i. 
IFNAR1-/- mice and wild-type C57 Bl/6 mice were sensitised and challenged with OVA and 
infected with RV1B. RNA was extracted from the apical lung lobe harvested 1 day p.i. and 
cDNA synthesised. Type I IFNβ (a) and type III IFNλ2 (b) mRNA copies were assessed by 
Taqman qPCR. Data represents mean ± SEM of 4–6 mice per group, representative of at 
least two independent experiments. (# UV-PBS vs RV-PBS, UV-OVA or RV-OVA within 
genotypes; ɸ RV-PBS vs RV-OVA within genotypes and * C57 Bl/6 vs IFNAR1-/-) 
 
3.4.1.2. Interferon-stimulated gene expression 
Innate IFN signalling results in the induction of a host of ISGs with direct anti-viral capacity. 
Figure 3.3 shows anti-viral ISGs OAS, PKR and viperin mRNA expression levels in response 
to RV infection. Although OAS expression was not significantly upregulated in the context of 
RV infection compared with UV-PBS, wild-type mice expressed significantly greater levels of 
OAS compared with IFNAR1-/- mice in the contexts of allergy and virus infection (figure 
3.3a). In wild-type mice, RV infection significantly induced PKR and viperin expression 1 day 
p.i., which was not detected in IFNAR1-/- mice (figure 3.3b and c). Similar to findings with 
IFN gene expression previously, RV infection in combination with allergen exposure resulted 
in significantly reduced PKR and viperin expression. Furthermore, RV-OVA-induced PKR 
was significantly lower than levels expressed by UV-PBS controls. Despite these 
observations, IFNAR1 deficiency results in significantly impaired OAS, PKR and viperin 
induction during RV infection alone. 
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Figure 3.3. Effect of type I IFN receptor deficiency on IFN-stimulated gene expression 
in lung tissue 1 day p.i. 
IFNAR1-/- mice and wild-type C57 Bl/6 mice were sensitised and challenged with OVA and 
infected with RV1B. RNA was extracted from the apical lung lobe harvested 1 day p.i. and 
cDNA synthesised. OAS (a), PKR (b) and viperin (c) mRNA copies were assessed by 
Taqman qPCR. Data represents mean ± SEM of 4–6 mice per group, representative of at 
least two independent experiments. (# UV-PBS vs RV-PBS, UV-OVA or RV-OVA within 
genotypes; ɸ RV-PBS vs RV-OVA within genotypes; * C57 Bl/6 vs IFNAR1-/-) 
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3.4.1.3. Interferon-inducible chemokine production 
In addition, CXCL10 and CCL5 are ISGs with pro-inflammatory roles, which can be detected 
at the protein level in BAL. In wild-type mice, RV infection induced significant CXCL10 
production. Interestingly, there was a non-significant trend for increased CXCL10 following 
UV-OVA treatment. In IFNAR1-/- mice, there were non-significant trends for decreased 
CXCL10 production following RV infection and allergen exposure; however, significant levels 
of CXCL10 were still produced by IFNAR1-/- mice in response to RV-OVA. Interestingly, RV 
infection in allergen-sensitised and challenged mice resulted in exacerbated CCL5 
production, which was significantly impaired in the absence of IFNAR1 signalling (figure 
3.4b). 
 
 
Figure 3.4. Effect of type I IFN receptor deficiency on IFN-inducible lymphocyte 
chemokine production in BAL fluid 1 day p.i.  
IFNAR1-/- mice and wild-type C57 Bl/6 mice were sensitised and challenged with OVA and 
infected with RV1B. Protein levels of IFN-inducible lymphocyte chemokines IP-10/CXCL10 
(a) and RANTES/CCL5 (b) were measured in BAL fluid supernatants by ELISA 1 day p.i.  
Data represents mean ± SEM of 4–6 mice per group, representative of at least two 
independent experiments. (# UV-PBS vs RV-PBS, UV-OVA or RV-OVA within genotypes; ɸ 
RV-PBS vs RV-OVA within genotypes; Ψ UV-OVA vs RV-OVA within genotypes; * C57 Bl/6 
vs IFNAR1-/-) 
 
  
U
V-
PB
S
R
V-
PB
S
U
V-
O
V
A
R
V-
O
V
A
U
V-
PB
S
R
V-
PB
S
U
V-
O
V
A
R
V-
O
V
A
0
25
50
75
100
125
150
175
***
R
A
N
T
E
S
 /
  
C
C
L
5
 (
p
g
/m
l 
B
A
L
)
C57 Bl/6 IFNAR1-/-
##

###

U
V-
PB
S
R
V-
PB
S
U
V-
O
V
A
R
V-
O
V
A
U
V-
PB
S
R
V-
PB
S
U
V-
O
V
A
R
V-
O
V
A
0
500
1000
1500
IP
-1
0
 /
 C
X
C
L
1
0
 (
p
g
/m
l 
B
A
L
)
C57 Bl/6 IFNAR1-/-
p=0.056
##
###
#
(a) (b)
Chapter 3: Results 
74 
 
3.4.1.4. RV viral load 
Significant levels of viral RNA were detected 1 day p.i. in both wild-type and IFNAR1-/- mice 
following RV-PBS treatment, with no differences observed between genotypes. However, 
RV-OVA-treated mice were found to have less RV RNA at this time point. However, by day 5 
p.i., only levels of viral RNA detected in IFNAR1-/- mice receiving RV-OVA treatment were 
found to be statistically significant. 
 
Figure 3.5. Effect of type I IFN receptor deficiency on total RV viral load in lung tissue 
1 and 5 days p.i. 
IFNAR1-/- mice and wild-type C57 Bl/6 mice were sensitised and challenged with OVA and 
infected with RV1B. RNA was extracted from the apical lung lobe harvested 1 and 5 days p.i. 
and cDNA synthesised. RV RNA copies were assessed by Taqman qPCR. Data represents 
mean ± SEM of 4–6 mice per group, representative of at least 2 independent experiments. 
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3.4.2. Effects of type I IFN receptor deficiency on type 2 allergic airways 
inflammatory responses 
 
3.4.2.1. Pulmonary leukocyte accumulation 
A hallmark of allergic asthma is the accumulation of eosinophils in the airways and the 
majority of mouse models of allergic asthma mimic this feature. Interestingly, it has been 
shown that RV infection results in increased pulmonary eosinophils in asthma compared with 
healthy individuals (Fraenkel et al., 1995, Message et al., 2008, Jackson et al., 2014). 
Furthermore, trends for increased neutrophil and lymphocyte infiltration during experimental 
RV infection were also demonstrated in asthma (Message et al., 2008). In addition to 
eosinophils, neutrophil and lymphocyte responses in the airways have also been shown to 
be modulated by the combination of RV and allergen in mice (Bartlett et al., 2008). Analysis 
of inflammatory leukocyte infiltration in the BAL fluid at day 1 p.i. found allergen-sensitised 
and challenged mice exhibit significant induction of eosinophils, with no differences with 
additional RV infection or between genotypes (figure 3.6a). By day 5 p.i. however, only the 
levels of eosinophils detected in IFNAR1-/- mice were found to be statistically significant, 
with RV-OVA-treated IFNAR1-/- mice exhibiting significantly enhanced eosinophil 
accumulation compared with wild-type controls (figure 3.6b). RV infection and allergen 
exposure resulted in increased airway neutrophilia 1 day p.i., which was determined as 
statistically significant following UV-OVA treatment in IFNAR1-/- mice (figure 3.6c). Levels of 
neutrophils detected 5 days p.i. were not statistically significant, although there were trends 
towards the presence of more neutrophils in IFNAR-/- mice (figure 3.6d). Wild-type mice 
sensitised and challenged with OVA exhibited increased lymphocyte infiltration 1 day p.i., 
with no difference following RV infection (figure 3.6e). Interestingly, impairment of IFNAR1 
signalling significantly reduced lymphocyte infiltration in response to RV-OVA, with UV-OVA-
treated IFNAR1-/- mice exhibiting a trend for decreased lymphocytes. These differences 
between genotypes were not observed up to 5 days p.i., where all mice exposed to OVA had 
increased lymphocytes in the BAL, with levels of lymphocytes in RV-OVA-treated IFNAR1-/- 
mice detected as statistically significant (figure 3.6f). 
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Figure 3.6. Effect of type I IFN receptor deficiency on inflammatory leukocyte 
accumulation in BAL fluid 1 and 5 days p.i.  
IFNAR1-/- mice and wild-type C57 Bl/6 mice were sensitised and challenged with OVA and 
infected with RV1B. BAL fluid was collected and cytospins prepared 1 and 5 days p.i. and 
differential eosinophils (a and b), neutrophils (c and d) and lymphocytes (e and f) were 
enumerated. Data represents mean ± SEM of 4–6 mice per group, representative of at least 
two independent experiments. (# UV-PBS vs RV-PBS, UV-OVA or RV-OVA within 
genotypes; ɸ RV-PBS vs RV-OVA within genotypes; * C57 Bl/6 vs IFNAR1-/-) 
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Th2 cell differentiation is a critical component in the development of allergic airways 
inflammation. Previous investigations showed that T cells constitute a major component of 
pulmonary lymphocyte responses during RV infection and allergen exposure in combination 
in Balb/c mice (Glanville et al., 2013b). To investigate the role of type I IFN signalling on T 
helper cell responses, lung cells were stimulated ex vivo to induce intracellular cytokine 
production to differentiate type 1 and 2 T helper subsets. Allergen-sensitised and challenged 
mice exhibited increased accumulation of CD3+ (figure 3.7a) and CD4+ (figure 3.7b) T cells 
in both wild-type and IFNAR1-/- mice 5 days p.i., with no significant differences in the context 
of RV infection or between genotypes. Th1 cells were analysed by their expression of IFNγ 
to assess the effects of innate IFN signalling on adaptive Th1 immunity (figure 3.7c). 
Allergen exposure resulted in the robust upregulation of IFNγ+ Th1 cells in wild-type mice, 
whereby the addition of RV infection appeared to suppress this response, although this 
effect was not significant. Th2 cells were identified by cell surface expression of T1ST2 
(figure 3.7d) or intracellular IL-4 expression (figure 3.7e). Allergen sensitisation and 
challenge resulted in the upregulation of Th2 cells, but only levels of T1ST2+ Th2 cells 
detected in IFNAR1-/- mice following UV-OVA treatment were found to be statistically 
significant. Trends for reduced Th2 cell accumulation were observed in the presence of RV 
infection in allergen challenged mice. 
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Figure 3.7. Effect of type I IFN receptor deficiency on T-cell responses in lung tissue 5 
days p.i.  
IFNAR1-/- mice and wild-type C57 Bl/6 mice were sensitised and challenged with OVA and 
infected with RV1B. The left lung lobe was harvested and processed 5 days p.i. Lung cell 
suspensions were stimulated with PMA and ionomycin and stained for surface and 
intracellular markers for CD4+ T cells (a), T1ST2+ Th2 cells (b), IL-4+ Th2 cells (c) and 
IFNγ+ Th1 cells (d). Data represents mean ± SEM of 4–6 mice per group, representative of 
at least two independent experiments. (# UV-PBS vs RV-PBS, UV-OVA or RV-OVA within 
genotypes) 
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In addition to the role of T cells in the development of allergic airways inflammation, it is of 
increasing relevance to assess the roles that ILC2s play in type 2 immunity during RV 
infection. This is supported by recent publications from our laboratory demonstrating 
induction of innate type 2 cytokines IL-25 and IL-33, which have established roles in ILC2 
activation, during RV infection in mice and humans, respectively (Jackson et al., 2014, Beale 
et al., 2014). It was also shown that blockade of IL-25 signalling in vivo resulted in the 
reduction of features of type 2 responses in mice, including Th2 cells and associated 
cytokines (Beale et al., 2014).  
 
ILC2 recruitment to the lungs has been reported in a mouse model of OVA-induced allergic 
airways inflammation and was associated with the AHR due to their IL-13-producing 
function. Pulmonary ILC2s were defined as lineage-negative, ICOS-positive cell populations 
that have variable expression of IL-25 and IL-33 receptors, IL-17RB and T1ST2, respectively 
(Barlow et al., 2012). Based on these methods, pulmonary ILC2s following RV infection were 
investigated for the first time in vivo. The combination of RV infection and allergen exposure 
caused significant upregulation of total ICOS+ ILC2 (figure 3.8a). Levels of ILC2 induced by 
allergen challenge alone were not found to be statistically significant. The absence of 
IFNAR1 signalling did not impact on ILC2 accumulation in the lungs. Similar patterns of 
responses were seen upon further analysis of ILC2 based on cell surface IL-17RB (figure 
3.8b), T1ST2 (figure 3.8c) and dual IL-17RB and T1ST2 (figure 3.8d) expression. 
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Figure 3.8. Effect of type I IFN receptor deficiency on ILC2 in lung tissue 1 day p.i.  
IFNAR1-/- mice and wild-type C57 Bl/6 mice were sensitised and challenged with OVA and 
infected with RV1B. The left lung lobe was harvested and processed 1 day p.i. Lung cell 
suspensions were stained for surface marker expression and gated on lineage negative, 
ICOS positive (a), T1ST2 and IL-17RB dual positive (b), T1ST2 positive (c) and IL-17RB 
positive (d). Data represents mean ± SEM of 4–6 mice per group. (# UV-PBS vs RV-PBS, 
UV-OVA or RV-OVA within genotypes; ɸ RV-PBS vs RV-OVA within genotypes) 
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3.4.2.2. Type 2 chemokines 
In addition to cellular components of the allergic inflammatory response in this model, 
associated soluble mediators were assessed in the airways at relevant time points. The 
functional roles of the eosinophil chemokines in the development of allergen-induced 
eosinophilic lung inflammation have been demonstrated in vivo (Gonzalo et al., 1996); 
therefore, CCL11 and CCL24 were analysed in BAL fluid supernatants at both time points in 
this model (figure 3.9). The combination of allergen exposure and RV infection resulted in 
significant production of CCL11 1 day p.i., with no significant differences in IFNAR1-/- mice 
under these conditions (figure 3.9a). Interestingly, UV-OVA treatment in IFNAR1-/- mice 
induced levels of CCL11 that were significantly greater than those produced in wild-type 
mice. Analysis of CCL24 in the BAL found statistically insignificant levels in wild-type mice in 
response to UV-OVA and RV-OVA (figure 3.9b). However, IFNAR1-/- displayed profound 
exacerbations of CCL24 in response to both allergen exposure and in combination with RV 
infection compared with wild-type controls. Considering the profound effects of IFNAR1 
deficiency on eotaxin production 1 day p.i., it was of interest to assess whether IFNAR1-/- 
mice maintained greater levels of eotaxins up to 5 days after immune stimulation. Attempts 
to measure CCL11 at the later time point found levels were below the limit of detection of the 
assay (data not shown). By day 5 p.i., IFNAR1-/- mice maintained significant production of 
CCL24 in response to RV-OVA, which was significantly greater than levels produced by wild-
type mice, complementing the patterns of eosinophil responses described previously at this 
time point (figure 3.9c). 
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Figure 3.9. Effect of type I IFN receptor deficiency on eosinophil chemokine 
production in BAL fluid 1 and 5 days p.i.  
Protein levels of eosinophil-associated chemokines eotaxin-1/CCL11 (a) and eotaxin-
2/CCL24 (b) were measured in BAL fluid supernatants by ELISA at the indicated time points 
p.i. Data represents mean ± SEM of 4–6 mice per group, representative of two independent 
experiments. (# UV-PBS vs RV-PBS, UV-OVA or RV-OVA within genotypes; ɸ RV-PBS vs 
RV-OVA within genotypes; Ψ UV-OVA vs RV-OVA within genotypes; * C57 Bl/6 vs IFNAR1-
/-) 
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Th2 cell chemokines CCL17 and CCL22 are involved in the trafficking of CCR4-expressing 
lymphocytes, primarily Th2 cells. The upregulation of CCL17 and CCL22 following allergen 
challenge has been indicated as an important mechanism in the pulmonary influx of Th2 
cells during allergic airways inflammation (Pilette et al., 2004). Allergen exposure alone 
caused significant production of CCL17 in wild-type mice, whereas levels detected upon the 
addition of RV infection were not found to be statistically significant (figure 3.10a). IFNAR1-/- 
mice exhibited exacerbation of CCL17 production compared with wild-type mice following 
both UV-OVA and RV-OVA treatment. This enhanced CCL17 production in response to RV-
OVA was maintained up to 5 days p.i. (figure 3.10b). Similar trends were seen in CCL22 
levels, whereby UV-OVA treated IFNAR1-/- produced more CCL22 than wild-type controls 1 
day p.i. (figure 3.10c). By day 5 p.i., IFNAR1-/- produced significant levels of CCL22 in 
response to UV-OVA and RV-OVA, which was not observed in wild-type mice (figure 3.10d). 
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Figure 3.10. Effect of type I IFN receptor deficiency on Th2 cell chemokine production 
in BAL fluid 1 and 5 days p.i.  
IFNAR1-/- mice and wild-type C57 Bl/6 mice were sensitised and challenged with OVA and 
infected with RV1B. Protein levels of Th2-cell associated chemokines TARC/CCL17 (a) and 
MDC/CCL22 (b) were measured in BAL fluid supernatants by ELISA at the indicated time 
points p.i. Data represents mean ± SEM of 4–6 mice per group, representative of at least 
two independent experiments. (# UV-PBS vs RV-PBS, UV-OVA or RV-OVA within 
genotypes; ɸ RV-PBS vs RV-OVA within genotypes; * C57 Bl/6 vs IFNAR1-/-) 
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3.4.2.3. Type 2 cytokines 
The canonical type 2 cytokines IL-4, IL-5 and IL-13 are considered key mediators in type 2 
immunity, which is supported by their functional association in the development of allergic 
lung inflammation in vivo (Coyle et al., 1995, Shardonofsky et al., 1999, Tomlinson et al., 
2010). In the context of virus infection, it has been shown that pre-existing type 2 cytokines 
in asthma are significantly elevated following RV infection in the airways, indicating their 
potential role in asthma exacerbations (Jackson et al., 2014). This response has also been 
modelled in mouse models of allergen and rhinovirus exposure (Bartlett et al., 2008, Beale et 
al., 2014). 
 
Allergen challenge in the absence and presence of RV infection induced production of all 
three type 2 cytokines analysed; however, levels detected in wild-type mice were not found 
to be statistically significant (figure 3.11). In IFNAR1-/- mice, allergen exposure alone 
resulted in significant production of IL-4, IL-5, and IL-13, whereby IL-5 levels were 
significantly greater than that found in wild-type controls (figure 3.11b). Similar trends were 
observed in IL-13 production, although this was not statistically significant (figure 3.11c). RV-
OVA-induced responses in IFNAR1-/- mice were no different to those observed in wild-type 
controls. 
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Figure 3.11. Effect of type I IFN receptor deficiency on type 2 cytokine production in 
BAL fluid 1 day p.i.  
IFNAR1-/- mice and wild-type C57 Bl/6 mice were sensitised and challenged with OVA and 
infected with RV1B. Protein levels of type 2 cytokines IL-4 (a), IL-5 (b) and IL-13 (c) were 
measured in BAL fluid supernatants by ELISA 1 day p.i. Data represents mean ± SEM of 4–
6 mice per group, representative of at least two independent experiments. (# UV-PBS vs 
RV-PBS, UV-OVA or RV-OVA within genotypes; * C57 Bl/6 vs IFNAR1-/-) 
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3.4.2.4. BAL Mucin 
Mucus hypersecretion is a functional hallmark of asthmatic airways obstruction, contributing 
to the formation of mucus plugs which have been associated with asthma fatalities (Carroll et 
al., 2002). Furthermore, increased MUC5AC expression was found following RV infection, 
which was associated with increased viral load specifically in asthmatic patients (Hewson et 
al., 2010). Increased mucin expression has been found in mouse models of RV infection, 
whereby mucin production was exacerbated by RV infection in the context of allergic airways 
inflammation (Bartlett et al., 2008). Significant differences in mucin expression in the 
absence and presence of virus has previously been found at 7 and 14 days p.i. in Balb/c 
mice. In this present study, protein abundance of MUC5AC was assessed at the later day 5 
time point (figure 3.12). Allergen exposure caused non-significant increases in MUC5AC in 
wild-type mice, which was not significantly different in the presence of virus at this time point. 
Significant upregulation of MUC5AC production was found in IFNAR1-/- in response to UV-
OVA and RV-OVA treatment. 
 
 
Figure 3.12. Effect of type I IFN receptor deficiency on on MUC5AC production in BAL 
fluid 5 days p.i.  
Mice were sensitised and challenged with OVA and infected with RV1B. MUC5AC protein 
levels were measured in BAL fluid supernatants collected 5 days p.i. by ELISA. Data 
represents mean ± SEM of 4–6 mice per group. (# UV-PBS vs RV-PBS, UV-OVA or RV-
OVA within genotypes) 
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3.5. Discussion 
The major function of innate IFN deficiency in asthma is considered to be impaired host ant-
viral defences, which could result in increased viral load and virus-induced inflammation, 
contributing to acute exacerbations. The direct impact of impaired IFN responses during RV 
infection in asthma is currently unknown. In light of observations in the specific augmentation 
of type 2 responses during RV infection in asthma, we postulated whether lack of IFN 
signalling in asthmatics played a role in this pathological feature of acute exacerbations. The 
use of IFNAR1-/- mice in this chapter provided the opportunity to investigate RV and allergen 
interactions in the absence of type I IFN signalling, analogous to RV infection in IFN deficient 
asthmatic patients. The lack of type I IFN signalling and subsequent impaired anti-viral 
responses had no effect on viral load in this model. However, the absence of type I IFN 
receptor signalling resulted in enhanced features of type 2 responses during RV infection in 
the context of allergic airways inflammation, including eosinophilic inflammation and 
production of eotaxins and Th2 chemokines. The functional relevance of IFN deficiency in 
asthma may therefore include roles in the loss of regulation of type 2 inflammation observed 
during RV infections. Importantly, this is the first demonstration of a functional link between 
impaired type I IFN responses and enhanced airway eosinophilic inflammation during RV 
infection in vivo. 
 
3.5.1. Impaired IFN responses in IFNAR1-/- mice 
In this chapter, we described constrained type I and III IFN expression at the genomic level 
in the absence of intact IFNAR1 signalling, which was associated with abrogated ISG 
expression during RV infection. These findings support published data demonstrating 
impaired secretion of type I and III IFN proteins in the airways of RV-infected IFNAR1-/- mice 
(Bartlett et al., 2012). Despite these compromised anti-viral pathways, there were no 
differences in viral load between IFNAR1-/- mice and wild-type controls in these studies, 
indicating that intact IFN responses are not critical for the clearance of RV infection in this 
mouse model. This is likely to be reflective of the limitation of using a human RV strain in 
mice that are relatively less permissive to RV replication. Therefore, inoculation of mice with 
RV1B may not be an appropriate model to address mechanisms of RV replication 
specifically, and the clinical relevance of observations in mice should be interpreted with 
caution, especially considering type I IFN has been shown to suppress RV replication in 
human cells in vitro (Cakebread et al., 2011).  
 
Further to inhibition of mRNA expression of some ISGs, impaired IFNAR1 signalling resulted 
in reduced protein production of CXCL10 and CCL5 chemokines, most notably in the context 
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of RV-OVA treatment. During the same time point, IFNAR1-/- mice also exhibited a reduced 
influx of lymphocytes in the airways in response to RV-OVA. Both CXCL10 and CCL5 have 
roles in the recruitment of lymphocytes during virus infections. Impaired NK cell infiltration 
could contribute to this lymphocyte deficit, which has previously been reported in IFNAR1-/- 
mice during RV infection alone (Jayaraman et al., 2014, Bartlett et al., 2012). In addition to 
this, preliminary studies in IFNAR1-/- mice also demonstrated abrogated BAL NK cell 
infiltration in response to RV-OVA treatment (data not shown; unpublished findings). Since 
CXCL10 and CCL5 are also important in the recruitment of T cells, we cannot rule out that T-
cell impairments may also contribute to this early deficit in total lymphocyte numbers. 
However, this is considered unlikely as differences in Th1 or Th2 cell responses were not 
observed, albeit at a later time point.  
 
Consistent with findings in the Balb/c model (Bartlett et al., 2012), the combination of RV and 
allergen synergises to exacerbate CCL5 production in wild-type C57 Bl/6 mice. Despite the 
affinity of CCL5 to bind to and activate multiple chemokine receptors, and therefore playing 
roles in the recruitment of multiple inflammatory cell types, we did not find eosinophil or 
lymphocyte infiltrates to correspond to this exacerbation of CCL5 in wild-type mice. Likewise, 
despite the role of CCL5 in eosinophil recruitment in the development of allergic airways 
inflammation (Gonzalo et al., 1998), its deficit in IFNAR1-/- was associated with increased 
eosinophil infiltration. These findings indicate a potential redundancy in CCL5 in the 
recruitment of eosinophils in our model of virus and allergen interactions. Although, as 
described by Gonzalo et al, allergen-induced eosinophil trafficking to the airways can be 
dependent on a co-ordinated network of the actions of multiple chemokines, including the 
eotaxins as well as CCL5, in addition to the upregulation of VCAM1, an adhesion molecule 
that allows for the migration of eosinophils into the pulmonary compartment from peripheral 
blood (Gonzalo et al., 1996).  
 
3.5.2. Effects of impaired IFN signalling on type 2 inflammation 
 
3.5.2.1. Eosinophils 
The most striking finding to emerge from these studies is that only in the absence of intact 
IFNAR1 signalling do allergen sensitised and challenged mice exhibit enhanced eosinophil 
infiltration following RV infection. This response mirrors the augmented eosinophilia 
observed specifically in asthmatics experimentally infected with RV (Message et al., 2008, 
Jackson et al., 2014). This effect was not seen in the presence of intact type I IFN signalling, 
which leads us to infer that this is a specific function of type I IFN deficiency and not the 
result of RV-induced exacerbation of pre-existing allergic airways inflammation, as described 
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in Balb/C mice by others (Bartlett et al., 2008, Beale et al., 2014). Our findings also support 
human studies whereby impaired innate IFN expression in cultured epithelial cells is 
associated with increased eosinophilic inflammation in asthmatic airways (Baraldo et al., 
2012).    
 
These findings indicate a role for type I IFN signalling in the regulation of eosinophilic 
inflammation specifically during RV infection. Interestingly, recombinant IFNα therapy is 
used for the treatment of some cases of hypereosinophilic syndrome (Schwartz et al., 2010, 
Schandene et al., 1996). IFNα has also been shown to suppress eosinophil infiltration in 
mouse models of allergic airways inflammation (Nakajima et al., 1994, Xirakia et al., 2010). 
The mechanism of action of type I IFNs on eosinophil responses is supported by their ability 
to suppress T-cell production of IL-5, which has been demonstrated in studies utilising in 
vitro PBMC cultures (Schandene et al., 1996, Pritchard et al., 2012). However, despite 
observing increased allergen-induced IL-5 production in the BAL of IFNAR1-/- mice, we did 
not observe corresponding eosinophil infiltration in response to UV-OVA treatment. It should 
be considered that IL-5 was only measured at a single time point in this study, which does 
not reveal the full kinetics of IL-5 in response to allergen. Our assessment of IL-5 in the BAL 
also does not illustrate peripheral responses which might be more indicative of the impact of 
impaired type I IFN signalling on IL-5 responses at the level of T-cell activation comparable 
to those observed in vitro by others. Analysis of T-cell responses in the lymph nodes may 
allow us to determine whether the effects on type 2 responses in the airways of IFNAR1-/- 
mice is due to the lack of type I IFN signalling during peripheral Th2 cell development.  
 
3.5.2.2. Type 2 chemokine expression  
Enhanced eosinophil infiltration in IFNAR1-/- mice was also associated with the profound 
exacerbation of CCL24 production in response to RV-OVA, indicating a role for type I IFN in 
the regulation of eosinophil chemokine expression. Similarly, exposure to RV and allergen 
resulted in the profound induction of CCL17 in the absence of type I IFN signalling up to 5 
days p.i., with similar trends in CCL22 production at this time point. This supports a 
mechanism for type I IFN signalling in the regulation of Th2 chemokine production. This may 
have important implications in RV-induced asthma exacerbations due to the role of Th2 
chemokines in the trafficking of Th2 cells, which could be abundant sources of type 2 
cytokines that are upregulated following RV infection in asthma (Jackson et al., 2014). 
CCL17 and CCL22 are agonists of the CCR4 chemokine receptor expressed on and 
involved in the migration of Th2 cells. As a result, CCR4 is considered a pharmacological 
target of interest in the treatment of asthma (Solari and Pease, 2015). 
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Although we observed a profound induction of Th2 chemokines, we saw no differences in 
the accumulation of Th2 cells in the lung tissue. The relationship between chemokine 
concentration and target cell migration may not be linear in this model; therefore, increased 
CCL17 and CCL22 may not directly result in a relative magnitude of increase in pulmonary 
Th2 cells. Bell-shaped concentration-response curves are typical of chemokine-induced 
migration assays in vitro and have been described for CCL17 and CCL22 in a human T-cell 
line (Viney et al., 2014, Ajram et al., 2014). A potential mechanism for this phenomenon may 
be due to the ability of chemokine receptors to undergo receptor desensitisation following 
ligand binding and subsequently termination of receptor signalling (Solari and Pease, 2015). 
Interestingly, the CCR4 receptor has been demonstrated to undergo receptor internalisation 
upon binding of CCL17 and CCL22 (Mariani et al., 2004, Ajram et al., 2014). Therefore, 
there may be a threshold concentration to which Th2 chemokines can positively induce 
CCR4 signalling to result in Th2 cell migration in our mouse model. 
 
Furthermore, chemokines are responsible for the migration of cells by generating a 
concentration gradient from the target inflammatory site; therefore, the level of Th2 cells that 
result in infiltrating the lungs will depend on the number of Th2 cells available at the source 
from which they are activated and recruited, for example the mediastinal lymph nodes (Kool 
et al., 2008). We found that the addition of virus infection did not enhance allergen-induced 
Th2 cell accumulation even in wild-type mice, leading to the speculation that the OVA-
sensitisation and challenge protocol in these mice induced a maximal Th2 cell response that 
could not be enhanced further. Assessment of Th2 cells in the lymph nodes could help 
determine whether this lack of difference seen, whether between UV-OVA and RV-OVA or 
wild-type and IFNAR1-/- mice, is caused by limitations in the number of activated Th2 cells 
or limitations in Th2 chemokine-induced migration in the model. 
 
Additional effects on type 2 responses in this chapter have indicated differential roles for 
type I IFN signalling in allergic airways inflammation in the absence of virus infection. Similar 
to Th2 chemokine production in response to RV-OVA, IFNAR1-/- mice produced significantly 
greater amounts of CCL17 and CCL24 following UV-OVA treatment. Additionally, impaired 
type I IFN signalling resulted in the augmentation of IL-5 production only in the context of 
allergen challenge alone, with similar trends in IL-13 levels. This would align with in vitro 
investigations demonstrating direct suppression of T-cell production of IL-5 by IFNα in PMBC 
cultures (Pritchard et al., 2012, Schandene et al., 1996). However, we have not 
demonstrated that this source of IL-5 in our mouse model is T-cell dependent. 
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3.5.2.3. ILC2s 
In addition to T cells, ILC2s are described as sources of IL-5 and IL-13 cytokines and we 
investigated their presence in the lung tissue following RV infection and allergen challenge. 
As these are innate cell populations, we attempted to capture ILC2s during the early time 
point of 1 day p.i. in our studies. Consistent with findings by Barlow et al in a model of OVA-
induced allergic airways inflammation, we found a two-fold increase in ILC2s following 
allergen exposure alone (Barlow et al., 2012). Furthermore, we demonstrated for the first 
time a significant upregulation of ILC2s in wild-type mice exposed to the combination of RV 
infection and allergen exposure. However, absence of type I IFN signalling did not appear to 
have any significant effects on ILC2 accumulation in the lungs. At the time of writing of this 
thesis, two studies were published demonstrating a role for type I IFN signalling in regulating 
ILC2 function (Duerr et al., 2016, Moro et al., 2016). In particular, it was found that  
IFNAR1-/- mice had enhanced pulmonary ILC2 accumulation in response to influenza A 
virus infection compared with wild-type mice (Duerr et al., 2016). The lack of consistency in 
our model with published studies could be due to model-specific mechanisms and 
differences in immune stimuli utilised.  
 
Both publications also demonstrated the ability of type I IFN to suppress IL-5 and IL-13 
production by ILC2s in vitro, which we have not directly addressed in our experiments. 
However, we did observe significantly increased IL-5 and trends for increased IL-13 in 
IFNAR1-/- mice in our studies; therefore, this could be due to the loss of regulation of ILC2 
function. It should be considered that the methods used to analyse these cell types are not 
indicative of their ability to produce cytokines in vivo. We assessed Th2 cells by non-specific 
stimulation of intracellular cytokine production by PMA and ionomycin, which bypasses T cell 
receptor signalling. IL-4-producing cells were used as an index of activated Th2 cells and 
although it shows that these cells are capable of producing the type 2 cytokine, it does not 
confirm that they produce IL-4 within the physiological context. Furthermore, despite the lack 
of differences in total cell numbers, both ILC2s and Th2 cells may possess different 
activation statuses that lead to more or less cytokine secretion in the in vivo context. 
Therefore, at this stage, we cannot ascertain the specific cell type in which type I IFN 
signalling regulates IL-5 expression in our model. The use of IL-5eGFP reporter mice could 
help elucidate this, whereby the assessment of GFP expression in cells ex vivo more 
accurately represents IL-5 expression in vivo. 
 
3.5.2.4. Development of type 2 inflammation 
The mechanism of action of type I IFN in the context of allergic airways inflammation could 
depend on two processes in this current model; systemic allergen sensitisation or airway 
Chapter 3: Results 
93 
 
allergen challenge. As IFNAR1-/- mice model inherent IFN deficiency, lack of IFN signalling 
could influence events during peripheral allergen sensitisation, which could underlie 
increased features of type 2 inflammation following UV-OVA treatment. Type I IFN has been 
shown to inhibit Th2 cell commitment and Th2 cytokine secretion by suppression of GATA3 
in human PBMCs in vitro; however, this was not shown in mice (Huber et al., 2010). Type III 
IFN signalling has been found to modulate DC function to promote Th1 cell development in 
mice, thereby suppressing Th2 allergic responses by skewing the immune response towards 
a Th1 profile (Koltsida et al., 2011). However, differences in Th1 and Th2 cells in the lung 
tissue were not found between genotypes in our studies; therefore, such mechanisms seem 
unlikely sources of increased type 2 responses in the airways of IFNAR1-/- mice. Although, 
this could be a function of limitations in T-cell migration into the lung tissue; therefore, 
assessment of differentiated T helper cell subsets in the lymph nodes may reveal further 
mechanisms of type I IFN signalling in vivo. 
 
3.5.3. RV and allergen interactions in wild-type C57 Bl/6 mice 
In this chapter, we utilised the C57 Bl/6 strain to model allergic airways inflammation and RV 
infection primarily due to the availability of IFNAR1-/- mice on this strain background. This is 
different to the Balb/C strain used in published reports on RV and allergen interactions in 
mice. The original model established in Balb/c mice demonstrated concomitant RV infection 
and allergen exposure in allergen sensitised mice leads to exacerbation of AHR compared 
with allergen exposure alone. This was also associated with prolonged allergic airways 
inflammation following RV infection (Bartlett et al., 2008, Beale et al., 2014, Nagarkar et al., 
2010). Unlike findings in Balb/C mice, the combination of RV infection and OVA challenge in 
C57 Bl/6 mice did not enhance eosinophil, neutrophil or lymphocyte infiltration compared 
with either stimulus alone. Assessment of T helper cell responses found the addition of RV 
infection resulted in trends for decreased T-cell accumulation in the context of allergic 
airways inflammation. This has been observed by others in our laboratory when using this 
strain of mice (Peel, 2013).  
 
Analysis of lung RV RNA found decreased viral load in wild-type mice exposed to the 
combination of RV and OVA, compared with RV infection alone. This was an unexpected 
finding, as clinical studies have shown that asthmatics have an increased susceptibility to 
respiratory virus infections (Corne et al., 2002); therefore, the presence of pre-existing 
allergic airways inflammation should lead to more permissive RV infection, and therefore 
enhanced viral load. In support of this hypothesis, it has been shown that atopic asthmatics 
have an increased viral load in response to experimental RV infection (Jackson et al., 2014). 
Furthermore, therapeutic blockade of the type 2 cytokine IL-5 has been found to reduce the 
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risk of asthma exacerbations in patients; considering the majority of exacerbations are 
associated with virus infections, this indicates that dampening down type 2 immune 
responses could boost anti-viral immunity (Pavord et al., 2012). The reduced level of virus in 
the lungs of RV-OVA treated mice may therefore be insufficient to generate a significant 
immune response to exacerbate pre-existing allergic airways inflammation in wild-type mice. 
Reduced viral load in RV-OVA treated mice may be due to one of two reasons: the presence 
of allergic airways inflammation caused by two previous OVA challenges may limit the 
infectivity of the airways; or the presence of allergic airways inflammation enhances viral 
clearance in C57 Bl/6 mice. Measurement of RV-induced innate immune responses found 
reduced innate IFN and ISG expression in RV-OVA treated mice. Since these responses are 
expected downstream of RV infection, it would suggest that a lower level of initial RV 
infection resulted in reduced stimulation of innate signalling pathways. The presence of 
ongoing allergic airways inflammation could result in increased mucus in the airways thus 
preventing RV accessing and infecting the airway epithelium. Alternatively, increased 
presence of inflammatory leukocytes following allergen challenge may result in the increased 
capacity to phagocytose RV-infected apoptotic cells to prevent propagation of infectious viral 
particles. Such a mechanism of action of neutrophils and macrophages has been described 
in the context of influenza virus infection (Hashimoto et al., 2007). Allergen-challenged mice 
in our model exhibit increased neutrophil infiltration; therefore, their presence in the airways 
during the time of infection may result in enhanced viral clearance in RV-OVA treated mice 
specifically. However, this role for neutrophils has not yet been determined in the context of 
RV infection. Furthermore, without assessing viral load from the time of infection, we cannot 
confirm whether differences in viral load 1 day p.i. are caused by initial infectivity or 
subsequent viral clearance. 
 
One of the key outcomes of RV and allergen interactions in Balb/C is the enhancement of 
AHR to direct bronchial smooth muscle stimuli (Bartlett et al., 2008), which models the 
worsening of lung function in asthmatics experimentally infected with RV (Jackson et al., 
2014). However, one of the limitations to the use of C57 Bl/6 mice is their relative 
insensitivity to methacholine stimulation of the airways compared with Balb/C mice, reported 
in-house (Peel, 2013) and by others (Takeda et al., 2001, Nagarkar et al., 2010). We were 
therefore unable to measure differences in lung function changes following allergen 
exposure and RV infection in this chapter.  
 
Subsequently, the abundance of mucus in the airways was measured as a clinically relevant 
assessment of airway pathology in our model, in addition to airway leukocyte infiltration. 
Allergen-sensitised and challenged mice exhibited a two-fold increase in MUC5AC, but we 
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found no differences upon additional RV infection. Bartlett et al observed significant 
exacerbation of MUC5AC abundance 7 days p.i. (Bartlett et al., 2008); therefore, our 
assessment at 5 days p.i. may not be sufficient to reveal distinct differences between RV-
OVA and UV-OVA treatments. 
 
3.5.3. Summary  
Despite the limitations in the use of C57 Bl/6 strain to model RV and allergen interactions, 
we were able to directly observe the functional consequences of impaired type I IFN 
signalling on pulmonary inflammation caused by allergen and RV. Ultimately, the absence of 
type I IFN signalling results in increased eosinophilic inflammation during RV infection, with 
increased production of type 2 soluble mediators CCL24, CCL17 and CCL22. Therefore, 
type I IFN deficiency in asthma may result in enhanced features of type 2 inflammation 
during RV infection that could contribute to acute exacerbations. Therapeutic strategies to 
restore type I IFN signalling may have the ability to prevent enhancement of type 2 
inflammatory responses during virus infections that are considered pathogenic in acute 
exacerbations. Furthermore, absence of type I IFN signalling resulted in enhanced allergen-
induced IL-5 and Th2 chemokine production, which are clinically relevant targets for 
therapeutic intervention in allergic asthmatic disease due to their roles in the recruitment of 
eosinophils and Th2 cells, respectively. Therefore, restoration of type I IFN signalling in 
asthma may also have the potential to reduce the magnitude of type 2 allergic airways 
inflammation following allergen exposure.  
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Chapter 4: Results: Characterisation of anti-IFNAR1 
monoclonal antibody in mouse models of RV-
induced airways disease  
 
4.1. Introduction 
Insights into the mechanisms of RV and allergen interactions in the airways provide scope 
for therapeutic interventions for virus-induced asthma exacerbations, which constitute a 
major unmet clinical need. Impaired innate IFN responses and increased type 2 
inflammatory pathways have been postulated as pathogenic mechanisms of asthma 
exacerbations. In addition to emerging treatments that target type 2 mechanisms in asthma, 
inhaled IFNβ therapy is currently under clinical investigation for the treatment of asthma 
exacerbations  (Djukanovic et al., 2014). Our attempts to understand the role of type I IFN in 
the regulation of type 2 responses during RV infection will help establish the therapeutic 
potential of inhaled IFNβ therapy, thus providing new treatment strategies for asthma 
exacerbations.  
  
In the context of concomitant RV infection and allergen exposure, IFNAR1-/- mice exhibited 
enhanced features of type 2 inflammation including eosinophilic inflammation and Th2 
chemokine production compared with wild-type C57 Bl/6 mice. However, limitations were 
posed by the use of the C57 Bl/6 strain due to disparities with published studies of the model 
of RV and allergen interactions in Balb/C mice, as well as failure to assess AHR in C57 Bl/6 
due to their decreased sensitivity to MCh challenge.  Furthermore, the inherent IFNAR1 
receptor deficiency in IFNAR1-/- mice presented limitations in the interpretation of the effects 
of IFN deficiency during different stages of immune stimulation in our model among allergen 
sensitisation, allergen challenge and RV infection.  
 
Published studies have demonstrated the effects of type I IFN signalling in the regulation of 
type 2 responses in peripheral cells. Type I IFN has been shown to prevent Th2 cell 
polarisation in human PBMC cultures, as well as inhibit type 2 cytokine secretion by 
committed Th2 cells via the direct suppression of GATA3, a transcription factor that drives 
Th2 cell commitment  (Huber et al., 2010). The ability of type I IFN to suppress type 2 
cytokine secretion was also demonstrated by Prichard et al, in which type I IFNs produced 
by DCs suppressed RV-induced T-cell expression of IL-13 (Pritchard et al., 2012). These 
studies describe the potential for type I IFN signalling in the modulation of type 2 pathways 
that could be implicated in the development of type 2 allergic immune responses in asthma.  
In support of this, the lack of type I IFN expression in asthmatic lung cells has been 
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associated with increased allergic type 2 responses (Sykes et al., 2012, Baraldo et al., 
2012).  
 
Although these studies have indicated a role for type I IFN in the modulation of type 2 
pathways in peripheral cell interactions, the interpretation of these responses with relevance 
to the role of IFN deficiency in the lungs and respiratory viral infections are somewhat 
limited. In particular, the direct infection of PBMCs with RV is not physiologically relevant to 
respiratory viral infections. Furthermore, whether these mechanisms studied in ex vivo-
manipulated peripheral cells translate to lung pathology in vivo is also unknown. The lung 
epithelium is considered the primary site of RV infection and impaired type I IFN production 
in response to RV in asthmatic bronchial epithelial cells has been demonstrated (Wark et al., 
2005). Additionally, asthmatic BAL macrophages exhibited deficient type I IFN production 
following RV infection (Sykes et al., 2012), further supporting the clinical relevance of 
investigating the mechanisms of IFN deficiency in the lungs in response to RV infection.  
 
In order to address the impact of impaired IFN signalling in the lungs on RV and allergen 
interactions in vivo, an IFNAR1 receptor blocking antibody was employed to inhibit the 
effects of type I IFN signalling. The delivery of this antibody locally to the airways will allow 
for the assessment of deficient IFN responses in the lungs upon exposure to RV and 
allergen. This approach may also provide further insights into the enhanced type 2 
inflammatory responses observed in IFNAR1-/- mice in the previous chapter. Furthermore, 
the opportunity to exogenously block the effects of type I IFN allowed for the use of Balb/C 
mice in this chapter, and therefore assessment of AHR in vivo to fully characterise the 
pathological lung response.  
 
As the aim of this thesis is to address the mechanisms of IFN deficiency on RV-induced 
asthma exacerbations, we wanted to assess the effects of impaired IFN signalling 
specifically during the time of RV infection, in the context of allergic airways inflammation. A 
dosing strategy was first optimised in a model of primary RV infection to assess the efficacy 
of the anti-IFNAR1 blocking antibody on innate IFN responses. Upon characterisation of an 
efficacious dose to block the effects of type I IFN signalling, the kinetics of a single dose 
were investigated over a timecourse of RV infection. From this, we were able to identify the 
requirement for a second dose of antibody in our model of RV and allergen interactions to 
ensure that the effects of type I IFN receptor signalling were sufficiently inhibited during 
assessment of key type 2 inflammatory responses for up to 4 days.  
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4.2. Hypotheses 
Blockade of the type I IFN receptor during primary RV infection will:  
i) Decrease RV-induced innate type I and type III IFN expression.  
ii) Inhibit RV-induced interferon-stimulated gene expression.  
iii) Increase RV-induced airways inflammation.  
 
Inhibition of type I IFN receptor during RV infection in the context of allergic airways 
inflammation will:  
iv) Increase type 2 soluble mediators in the airways  
v) Enhance pulmonary accumulation of eosinophils and Th2 cells  
 
4.3. Aims 
Characterise the effects of exogenous blockade of type I IFN signalling in model of RV-
induced airways disease. 
i) To identify the most appropriate isotype-matched control antibody for mouse anti-
IFNAR1 IgG1 antibody that possesses minimal immunogenic effects.  
ii) To determine a sub-maximal dose of anti-IFNAR1 and dosing regimen for use in 
other RV-induced airways disease models.  
iii) To perform a timecourse of the effects of a single dose of anti-IFNAR1 during 
primary RV infection.  
iv) To characterise the effects of blocking type I IFN signalling on RV-induced anti-
viral immune responses and airways inflammation.  
v) To explore the effects of blocking type I IFN signalling on allergen and RV 
interactions on type 2 allergic airways inflammation.   
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4.4. Results: Characterisation of anti-IFNAR1 in primary RV 
infection 
 
4.4.1. Dose-response of the effects of anti-IFNAR1 on RV-induced responses 
To establish an effective dose of anti-IFNAR1 for further investigations in RV-induced 
airways disease models, a dose response experiment was carried out examining the effects 
of 10, 30 and 100µg anti-IFNAR1 i.n. A mouse IgG1 isotype control (clone MOPC21) was 
selected to control for the administration of immunoglobulin directly to the airways. The 
decision to use MOPC21 isotype control was following an assessment of the effects of a 
selection of mouse IgG1 isotype control antibodies during RV infection to ensure there were 
minimal biological effects (supplementary figures s4.1–s4.3).  
 
4.4.1.1. Innate interferon production  
Type I IFN signalling induces further IFN production in a positive feedback manner in host 
and neighbouring cells to prolong and initiate anti-viral defences, respectively. To 
understand whether exogenous blockade of IFNAR1 can impair IFN expression, similar to 
that observed in IFNAR1-/- mice, protein levels of innate type I and III IFNs were assessed in 
the BAL fluid 1 day p.i. (figure 4.1). RV infection in isotype control treated mice caused 
significant production of type I IFNα and IFNβ and type III IFNλ2/3, which was no different to 
levels observed in RV-PBS treated mice. Treatment with anti-IFNAR1 during RV infection 
significantly inhibited type I and III IFN production in a dose-dependent manner.  
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Figure 4.1. Effects of blocking type I IFN receptor during primary RV infection on RV-
induced innate interferon production in BAL fluid 1 day p.i.  
Wild-type Balb/c mice were treated with 10, 30 or 100µg anti-IFNAR1 (clone MAR15A3), 
100µg isotype control antibody (MOPC21) or PBS (100µl) i.n 2 hours prior to RV infection. 
Protein levels of type I IFNα (a), IFNβ (b) and type III IFNλ2/3 (c) were measured in BAL fluid 
supernatants collected 1 day p.i. Data represents mean ± SEM of 5 mice per group from one 
independent experiment. (* compared with RV-Isotype) 
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4.4.1.2. Interferon-stimulated gene expression  
In addition to the effects of anti-IFNAR1 on innate IFN expression, the effects on 
downstream IFN pathways were analysed by lung tissue anti-viral ISG expression (figure 
4.2). RV infection significantly induced OAS, PKR and viperin expression and the 
administration of isotype control antibody had no effects on ISG expression. Anti-IFNAR1 
treatment dose-dependently inhibited RV-induced OAS, PKR and viperin expression.  
 
Figure 4.2. Effects of blocking type I IFN receptor during primary RV infection on ISG 
expression in lung tissue 1 day p.i.  
Wild-type Balb/c mice were treated with 10, 30 or 100µg anti-IFNAR1 (clone MAR15A3), 
100µg isotype control antibody (MOPC21) or PBS (100µl) i.n 2 hours prior to RV infection. 
RNA was extracted from the apical lung lobe harvested 1 day p.i. and cDNA synthesised. 
OAS (a), PKR (b) and viperin (c) mRNA copies were assessed by Taqman qPCR. Data 
represents mean ± SEM of 5 mice per group from one independent experiment. (* compared 
with RV-Isotype) 
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4.4.1.3. Interferon-inducible chemokine production  
RV infection in vivo stimulates the release of various pro-inflammatory soluble mediators. 
The effects of anti-IFNAR1 administration on a host of IFN-inducible chemokines induced 
during RV infection were investigated to further characterise the impact of IFNAR1 inhibition. 
Interestingly, in addition to impaired ISG expression, anti-IFNAR1 treatment caused partial, 
but significant inhibition of CXCL10 (figure 4.3a) and CXCL9 (figure 4.3c) compared with RV-
isotype control. Furthermore, IFNAR1 blockade during RV infection significantly abrogated 
CCL5 (figure 4.3b) and CXCL11 (figure 4.3d) production.  
 
 
Figure 4.3. Effects of blocking type I IFN receptor during primary RV infection on RV-
induced lymphocyte chemokine production in BAL fluid 1 day p.i.  
Wild-type Balb/c mice were treated with 10, 30 or 100µg anti-IFNAR1 (clone MAR15A3), 
100µg isotype control antibody (MOPC21) or PBS (100µl) i.n 2 hours prior to RV infection. 
Protein levels of lymphocyte chemokines IP-10/CXCL10 (a), RANTES/CCL5 (b), 
MIG/CXCL9 (c) and ITAC/CXCL11 (d) were measured in BAL fluid supernatants collected 1 
day p.i. Data represents mean ± SEM of 5 mice per group from one independent 
experiment. (* compared with RV-Isotype) 
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4.4.1.4. RV viral load 
RV infection resulted in significant viral load 1 day p.i. in isotype control treated mice, which 
was not significantly different to viral load detected in RV-PBS treated mice. Surprisingly, 
despite impairments of innate IFN and anti-viral responses observed previously, mice 
treated with 30 and 100µg anti-IFNAR1 had significantly less viral load compared with RV-
isotype treatment.  
 
Figure 4.4. Effects of blocking type I IFN receptor during primary RV infection on total 
RV viral load 1 day in lung tissue p.i.  
Wild-type Balb/c mice were treated with 10, 30 or 100µg anti-IFNAR1 (clone MAR15A3), 
100µg isotype control antibody (MOPC21) or PBS (100µl) i.n 2 hours prior to RV infection. 
RNA was extracted from the apical lung lobe harvested 1 day p.i. and cDNA synthesised. 
RV RNA copies were assessed by Taqman qPCR. Data represents mean ± SEM of 5 mice 
per group from one independent experiment. (* compared with RV-Isotype) 
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4.4.1.5. RV-induced pulmonary leukocyte infiltration  
Analysis of airway inflammatory cell accumulation found anti-IFNAR1 treated mice (10 and 
30µg) had increased neutrophil infiltration in response to RV infection compared with isotype 
control treatment (figure 4.5a). Although levels of lymphocytes detected in the BAL at this 
time point following RV infection was not statistically significant, anti-IFNAR1 treated mice 
displayed non-significant trends towards decreased lymphocyte infiltration (figure 4.5b).  
 
Figure 4.5. Effects of blocking type I IFN receptor during primary RV infection on RV-
induced airways inflammation 1 day p.i.  
Wild-type Balb/c mice were treated with 10, 30 or 100µg anti-IFNAR1 (clone MAR15A3), 
100µg isotype control antibody (MOPC21) or PBS (100µl) i.n 2 hours prior to RV infection. 
Accumulation of neutrophils (a) and lymphocytes (b) were numerated in BAL fluid collected 
and cytospins prepared 1 day p.i. Data represents mean ± SEM of 5 mice per group from 
one independent experiment. (* compared with RV-Isotype) 
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4.4.1.6. Type 2 chemokine production  
In line with the overall hypothesis to understand the effects of type I IFN signalling on type 2 
immunity, attempts were made to measure type 2-associated responses during RV infection. 
RV infection was found to induce production of Th2 cell chemokines CCL17 and CCL22 in 
isotype control treated mice; levels were comparable to RV-PBS treatment. Interestingly, 
anti-IFNAR1 treatment dose-dependently augmented both CCL17 (figure 4.6a) and CCL22 
(figure 4.6b) production in the airways.  
 
Figure 4.6. Effects of blocking type I IFN receptor during primary RV infection on RV-
induced type 2 chemokine production in BAL fluid 1 day p.i.  
Wild-type Balb/c mice were treated with 10, 30 or 100µg anti-IFNAR1 (clone MAR15A3), 
100µg isotype control antibody (MOPC21) or PBS (100µl) i.n 2 hours prior to RV infection. 
Protein levels of type 2 lymphocyte chemokines TARC/CCL17 (a) and MDC/CCL22 (b) were 
measured in BAL fluid supernatants collected 1 day p.i. Data represents mean ± SEM of 5 
mice per group from one independent experiment. (* compared with RV-Isotype) 
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4.4.2. Timecourse of the effects of anti-IFNAR1 on RV-induced responses  
Investigations into the dose-response of anti-IFNAR1 antibody treatment 1 day post-RV 
infection determined a sub-maximal dose of 30µg. The utilisation of a sub-maximal dose in 
further experiments would allow for observations of the effects of this antibody within the 
known biological range. This dose appeared to sufficiently block the effects of type I IFN 
signalling, demonstrated by the significant suppression of IFN production and expression of 
IFN-inducible genes and proteins. Furthermore, 30µg anti-IFNAR1 significantly augmented 
RV-induced Th2 chemokine production in the airways, which is an endpoint of relevance to 
the hypothesis under examination. A 30µg dose was then used to characterise the kinetics 
of a single dose of anti-IFNAR1 during RV infection from 8 to 96 hours p.i., prior to 
determining a dosing strategy in a model of RV and allergen interactions.  
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4.4.2.1. Interferon-stimulated gene expression  
A time course analysis of the effects of 30µg anti-IFNAR1 antibody on RV-induced ISG 
expression found significant suppression of OAS and PKR mRNA from as early as 8 hours 
p.i. (figure 4.7). At 24 hours p.i., anti-IFNAR1 caused a non-significant trend for reduced 
OAS expression and significant inhibition of PKR. Both OAS and PKR were significantly 
inhibited at 48 and 96 hours p.i.  
 
Figure 4.7. Effects of blocking type I IFN receptor during primary RV infection on lung 
ISG expression 8 to 96 hours p.i.  
Wild-type Balb/c mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg 
isotype control antibody (MOPC21) i.n 2 hours prior to RV infection. RNA was extracted from 
the apical lung lobe harvested 8, 24, 48 and 96 hours p.i. and cDNA synthesised. OAS (a) 
and PKR (b) mRNA copies were assessed by Taqman qPCR. Data represents mean ± SEM 
of 9 mice per group, comprising two independent experiments. (# UV-PBS vs RV-Isotype; * 
RV-Isotype vs RV-Anti-IFNAR1) 
0
1.0105
2.0105
3.0105
4.0105
5.0105
O
A
S
 c
o
p
ie
s
 /

l 
c
D
N
A
8 24 48 96
Hours p.i.
** *** ***
RV - Anti-IFNAR1 30ug
RV - Isotype 30g
UV-PBS
###
##
###
##
0
1.0106
2.0106
3.0106
P
K
R
 c
o
p
ie
s
 /

l 
c
D
N
A
8 24 48 96
Hours p.i.
*
*
*** *
***
###
###
###
#
(a)
(b)
Chapter 4: Results 
109 
 
4.4.2.2. Interferon-inducible chemokine production  
In addition to measuring lung ISG expression, the production of CXCL10 and CCL5 in the 
BAL were assessed (figure 4.8). These protein analyses found RV significantly induced 
CXCL10 at 8, 24, 48 and 96 hours p.i. and CCL5 at 24, 48 and 96 hours p.i., with the 
production of both chemokines peaking at 24 hours p.i. Treatment with anti-IFNAR1 
significantly suppressed CXC10 from 8 hours p.i. and CCL5 from 24 hours p.i., up to 96 
hours.  
 
Figure 4.8. Effects of blocking type I IFN receptor during primary RV infection on IFN-
inducible lymphocyte chemokine production 8 to 96h p.i.  
Wild-type Balb/c mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg 
isotype control antibody (MOPC21) i.n 2 hours prior to RV infection. Protein levels of IFN-
inducible lymphocyte chemokines IP-10/CXCL10 (a) and RANTES/CCL5 (b) were measured 
in BAL fluid supernatants collected at the indicated time points p.i. Data represents mean ± 
SEM of 4 mice per group, representative of two independent experiments. (# UV-PBS vs 
RV-Isotype; * RV-Isotype vs RV-Anti-IFNAR1) 
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4.4.2.3. RV viral load  
Anti-IFNAR1 dose response experiments found 30 and 100µg antibody treatment resulted in 
reduced viral load 1 day p.i. compared with isotype control treatment. In order to address 
whether presence of anti-IFNAR1 affects infectivity of the lungs, viral load was assessed 
from 8 hours p.i., which found no significant differences from 8 to 96 hours p.i. 
 
Figure 4.9. Effects of blocking type I IFN receptor during primary RV infection on total 
RV viral load in lung tissue 8 to 96 hours p.i.  
Wild-type Balb/c mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg 
isotype control antibody (MOPC21) i.n 2 hours prior to RV infection. RNA was extracted from 
the apical lung lobe harvested 8, 24, 48 and 96 hours p.i. and cDNA synthesised. RV RNA 
copies were assessed by Taqman qPCR. Data represents mean ± SEM of 9 mice per group, 
comprising two independent experiments. (# UV-PBS vs RV-Isotype) 
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4.4.2.4. RV-induced pulmonary leukocyte infiltration  
RV infection caused significant neutrophil infiltration to the airways 24 and 48 hours p.i. and 
anti-IFNAR1 treatment had no significant effects on this (figure 4.10a). Significant RV-
induced lymphocyte recruitment to the airways was found at 24 and 96 hours p.i. (figure 
4.10b). In support of earlier observations in anti-IFNAR1 antibody dose-response studies, 
BAL lymphocyte accumulation was significantly inhibited by anti-IFNAR1 treatment 96 hours 
p.i.  
 
Figure 4.10. Effects of blocking type I IFN receptor during primary RV infection on 
BAL leukocyte accumulation 8 to 96 hours p.i.  
Wild-type Balb/c mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg 
isotype control antibody (MOPC21) i.n 2 hours prior to RV infection. Accumulation of 
neutrophils (a) and lymphocytes (b) were numerated in BAL fluid collected and cytospins 
prepared 8, 24, 48 and 96 hours p.i. Data represents mean ± SEM of 9 mice per group, 
comprising two independent experiments. (# UV-PBS vs RV-Isotype; * RV-Isotype vs RV-
Anti-IFNAR1) 
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As dose-response studies found anti-IFNAR1 treatment enhanced neutrophilic inflammation 
during RV infection, the neutrophil-chemokine KC was assessed in the BAL fluid at 8 and 24 
hours p.i. RV infection induced significant production of KC; however, inhibition of IFNAR1 
significantly suppressed KC production at both time points.  
 
 
Figure 4.11. Effects of blocking type I IFN receptor during primary RV infection on KC 
production 8 and 24h p.i.  
Wild-type Balb/c mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg 
isotype control antibody (MOPC21) i.n 2 hours prior to RV infection. Protein levels of the 
neutrophil chemoattractant KC was measured in BAL fluid supernatants collected the 
indicated time points p.i. Data represents mean ± SEM of 4 mice per group, representative 
of two independent experiments. (# UV-PBS vs RV-Isotype; * RV-Isotype vs RV-Anti-
IFNAR1) 
 
 
4.4.2.5. Type 2 chemokine production  
Dose-response studies demonstrated blockade of IFNAR1 signalling increased the 
production of Th2 cell chemokines CCL17 and CCL22, which were supported by similar 
findings in IFNAR1-/- mice in the previous chapter. RV infection induced significant levels of 
CCL17 and CCL22 up to 96 hours p.i. compared with UV controls (figure 4.12). A single 
dose of anti-IFNAR1 antibody during RV infection significantly enhanced RV-induced CCL17 
production 24 hours p.i. However, anti-IFNAR1 treatment resulted in reduced CCL22 
production compared with isotype control treatment 96 hours p.i.  
 
 
  
0
3000
6000
9000
K
C
 /
 C
X
C
L
1
 (
p
g
/m
l 
B
A
L
)
*
***
8 hours 24 hours
RV-Anti-IFNAR1 30ug
RV-Isotype 30g
UV-PBS
******
Chapter 4: Results 
113 
 
 
Figure 4.12. Effects of blocking type I IFN receptor during primary RV infection on 
type 2 chemokine production 8 to 96h p.i.  
Wild-type Balb/c mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg 
isotype control antibody (MOPC21) i.n 2 hours prior to RV infection. Protein levels of type 2 
lymphocyte chemokines TARC/CCL17 (a) and MDC/CCL22 (b) were measured in BAL fluid 
supernatants collected at the indicated time points p.i. Data represents mean ± SEM of 4 
mice per group, representative of two independent experiments. (# UV-PBS vs RV-Isotype;  
* RV-Isotype vs RV-Anti-IFNAR1) 
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4.5. Results: Characterisation of anti-IFNAR1 in a model of RV and 
allergen interactions 
Following time-course studies of the effects of a single dose of 30µg anti-IFNAR1 antibody, 
a dosing regimen consisting of two 30µg doses, administered 48 hours apart was 
implemented to investigate RV and allergen interactions in the absence of IFNAR1 
signalling, as depicted in figure 4.13.  
 
 
Figure 4.13. Dosing regimen of anti-IFNAR1 (MAR15A3) blocking antibody in a model 
of RV and allergen interactions.  
Wild-type Balb/c mice were sensitised with 50µg OVA in 2mg alum i.p and challenged i.n 
with either 10µg OVA or PBS (controls). Mice were then infected with RV1B or UV-
inactivated RV1B (controls). The first dose 30µg anti-IFNAR1 blocking antibody or isotype 
control antibody was administered 2 hours prior to RV1B infection (day 0) and a second 
dose was administered on day 2 p.i.  
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4.5.1. Effect of anti-IFNAR1 on RV-induced IFN responses  
 
4.5.1.1. Innate interferon production  
Here, the efficacy of 30µg anti-IFNAR1 was characterised in the context of allergen 
exposure and RV infection by measuring IFNs and associated responses. Protein levels of 
IFNα and IFNλ2/3 were assessed in the BAL 1 day p.i. In this model, RV infection alone did 
not stimulate significant IFNα or IFNλ2/3 levels, although the combination of virus and 
allergen exposure resulted in significant production of innate IFNs in isotype control treated 
mice (figure 4.14). Furthermore, anti-IFNAR1 treatment significantly inhibited type I and III 
IFN production in response to RV-OVA.  
 
Figure 4.14. Effects of anti-IFNAR1 on RV-induced innate interferon production in BAL 
fluid 1 day p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. Protein levels of type I IFNα (a) and type III IFNλ2/3 (b) were measured 
in BAL fluid supernatants collected 1 day p.i. by ELISA. Data represents mean ± SEM of 11–
17 mice per group, comprising 3 independent experiments. (# All groups vs UV-PBS; ɸ RV-
PBS vs RV-OVA within isotype or anti-IFNAR1-treated; * isotype vs anti-IFNAR1 for 
indicated groups) 
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4.5.1.2. Interferon-stimulated gene expression  
The effects of blocking type I IFN signalling on ISG expression induced by RV infection in 
the context of allergic airways inflammation was assessed. RV-OVA resulted in significantly 
increased OAS mRNA, compared with RV infection alone in isotype control treated mice 
(figure 4.15a). In contrast, RV-OVA treatment resulted in significantly reduced PKR 
expression compared with RV-PBS (figure 4.15b), whereas viperin expression levels were 
comparable in response to RV-PBS and RV-OVA in isotype control treated mice (figure 
4.15c). Anti-IFNAR1 treatment significantly suppressed OAS expression in response to RV-
OVA and viperin expression caused by RV infection with and without allergen. Non-
significant trends towards decreased PKR expression were observed in response to RV-
PBS following anti-IFNAR1 treatment.  
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Figure 4.15. Effects of anti-IFNAR1 on ISG expression 1 day p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. RNA was extracted from the right apical lung lobe harvested 1 day p.i. 
and PKR (a), viperin (b) and OAS (c) mRNA copies were assessed by Taqman qPCR. Data 
represents mean ± SEM of 11–17 mice per group, comprising 3 independent experiments. 
(# All groups vs UV-PBS; ɸ RV-PBS vs RV-OVA within isotype or anti-IFNAR1-treated; Ψ 
UV-OVA vs RV-OVA within isotype or anti-IFNAR1-treated; * isotype vs anti-IFNAR1 for 
indicated groups) 
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4.5.1.3. Interferon-inducible chemokine production  
Similar to analysis of innate IFN proteins in the airways, RV-OVA treatment resulted in 
significant production of IFN-inducible chemokines CXCL10 and CCL5, which was 
significantly suppressed by 30µg anti-IFNAR1 antibody treatment (figure 4.16).  
 
 
Figure 4.16. Effects of anti-IFNAR1 on IFN-inducible chemokine production 1 day p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection.  Protein levels of IFN-inducible lymphocyte chemokines IP-10/CXCL10 
(a) and RANTES/CCL5 (b) were measured in BAL fluid supernatants by ELISA 1 day p.i.  
Data represents mean ± SEM of 11–17 mice per group, comprising 3 independent 
experiments. (# All groups vs UV-PBS; ɸ RV-PBS vs RV-OVA within isotype or anti-IFNAR1-
treated; * isotype vs anti-IFNAR1 for indicated groups) 
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4.5.1.4. RV viral load  
RV viral RNA was detected in all groups that were inoculated with live RV1B virus, and not in 
those that received UV-inactivated virus. Although the copies of RV RNA detected were not 
significantly different compared with UV-PBS, at 1 day p.i. there was a non-significant trend 
for increased viral RNA in the lungs of mice that were infected in conjunction with allergen 
challenge compared with RV-PBS (figure 4.17). Anti-IFNAR1 treatment had no significant 
effects on viral load at either time points.  
 
Figure 4.17. Effects of anti-IFNAR1 on total RV viral load in lung tissue 1 day p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. RNA was purified from the right apical lung lobe and cDNA was 
synthesised by reverse transcription at the indicated time points. The level of RV RNA was 
measured by Taqman qPCR. Data represents mean ± SEM of 11–17 mice per group, 
comprising 3 independent experiments.  
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4.5.2. Effects of anti-IFNAR1 on type 2 allergic airways inflammatory responses 
 
4.5.2.1. Airways hyperresponsiveness  
Assessment of airways responsiveness to direct bronchoconstrictor stimuli is often used as a 
tool in the clinical assessment of asthma (Lotvall et al., 1998). In addition to modelling type 2 
pulmonary inflammation using allergen sensitisation and challenge protocols, there is the 
potential to model and measure AHR to bronchoconstrictor stimulus in mice. In these 
studies, changes to lung function following allergen exposure and RV infection was 
investigated by unrestrained whole body plethysmography using enhanced pause (Penh) as 
an index of AHR. It has previously been reported that RV infection exacerbates OVA-
induced increase in Penh in response to methacholine (MCh), which was supported by direct 
measurement of lung function by invasive resistance and compliance analysis (Bartlett et al., 
2008). Statistical analysis was performed in the context of all seven treatment groups, 
consistent with other endpoints, with relevant comparisons depicted separately in figures 
4.18a–d. Figure 4.18a shows Penh responses to increasing doses of MCh in isotype control 
treated mice. All mice infected with RV and/or challenged with OVA demonstrated significant 
AHR in response to 100mg/ml MCh compared with UV-PBS. RV-OVA treated mice also 
exhibited significant AHR following exposure to 30mg/ml MCh compared with UV-PBS. The 
combination of RV and allergen exposure significantly augmented AHR compared with 
allergen challenge alone (at 30 and 100mg/ml MCh) and RV infection alone (at 100mg/ml 
MCh). Comparisons of RV-OVA treated mice found that treatment with anti-IFNAR1 antibody 
caused trends for decreased AHR, but this was not found to be significantly different (figure 
4.18b). Anti-IFNAR1 treatment also had no impact on changes to lung function in UV-OVA 
treated mice (figure 4.18c). In RV-PBS treated mice, there were no differences in Penh 
responses up to 30mg/ml MCh between isotype and anti-IFNAR1 treatments; however, anti-
IFNAR1 treatment significantly inhibited AHR to 100mg/ml MCh.  
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Figure 4.18. Effects of anti-IFNAR1 on AHR to methacholine 1 day p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. Penh was measured in response to 1 minute inhalation challenge with 
increasing doses of nebulised methacholine (3, 10, 30 and 100mg/ml MCh). Penh is 
expressed as an average over a 5 minute log period post-MCh challenge; isotype control-
treated groups (a), anti-IFNAR1-treated groups (b), isotype vs anti-IFNAR1 for RV-OVA 
groups (c), UV-OVA groups (d) and RV-PBS groups (e). Data represents mean ± SEM of 8–
12 mice per group, comprising two independent experiments. (Statistical analysis was 
performed in the context of all 7 treatment groups by two-way ANOVA; Δ UV-PBS vs RV-
PBS, Ω UV-PBS vs UV-OVA, # UV-PBS vs RV-OVA, ɸ RV-PBS vs RV-OVA, Ψ UV-OVA vs 
RV-OVA, * isotype vs anti-IFNAR1) 
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4.5.2.2. Pulmonary leukocyte infiltration  
The effects of blocking type I IFN receptor signalling on RV and allergen-induced leukocyte 
infiltration in the airways was determined in the BAL 1 and 4 days p.i. OVA sensitisation and 
challenge in both isotype and anti-IFNAR1 treated mice resulted in significant airway 
eosinophilia 1 and 4 days p.i., with enhanced levels of eosinophils detected at the later time 
point, similar to observations in the C57 Bl/6 strain in the previous chapter. The addition of 
RV infection did not significantly affect eosinophil responses. Interestingly, anti-IFNAR1 
treated mice displayed enhanced eosinophil accumulation in response to RV-OVA at day 1 
p.i., compared with isotype control treated mice (figure 4.19a). Non-significant trends for 
increased eosinophils were also observed in anti-IFNAR1 treated mice following UV-OVA 
treatment at this earlier time point. Interestingly, by day 4 p.i., anti-IFNAR1 treatment 
significantly augmented UV-OVA-induced eosinophilia (figure 4.19b). The combination of RV 
infection and allergen exposure causes significant airway neutrophilia in isotype control 
treated mice 1 day p.i., which was significantly greater than levels induced by either RV or 
OVA alone (figure 4.19c). Levels of neutrophils detected at the later time point were not 
found to be statistically significant (figure 4.19d). Treatment with anti-IFNAR1 had no 
significant effects on neutrophil accumulation at either time points. In isotype control treated 
mice, OVA challenge caused significant accumulation of lymphocytes 1 and 4 days p.i. 
Although the effects of RV infection on OVA-induced lymphocyte responses were not 
statistically significant, there were trends towards enhanced lymphocytes 1 day p.i. in RV-
OVA treated mice (figure 4.19e). At day 4 p.i., mice treated with anti-IFNAR1 exhibited 
increased lymphocytes in the airways in response to allergen exposure (4.19f).  
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Figure 4.19. Effects of anti-IFNAR1 on inflammatory leukocyte infiltration in BAL fluid 
1 and 4 days p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. BAL fluid was collected and cytospins prepared 1 and 4 days p.i. and 
differential eosinophils (a and b), neutrophils (c and d) and lymphocytes (e and f) were 
enumerated. Data represents mean ± SEM of 11–17 mice per group, comprising 3 
independent experiments. (# All groups vs UV-PBS; ɸ RV-PBS vs RV-OVA within isotype or 
anti-IFNAR1-treated; Ψ UV-OVA vs RV-OVA within isotype or anti-IFNAR1-treated; * isotype 
vs anti-IFNAR1 for indicated groups) 
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Further analysis of lymphocyte responses in mice 4 days p.i. were carried out by flow 
cytometry on BAL and lung cells. In the BAL, UV-OVA and RV-OVA treated mice exhibited 
significant accumulation of total CD3 and CD4+ T cells, as well as Th1 cells identified by 
IFNγ production (figure 4.20c) and Th2 cells identified by surface expression of T1ST2 
receptor (figure 4.20d) or production of IL-5 (figure 4.20e) or IL-13 (figure 4.20f). The 
addition of RV infection had no significant effects on T-cell responses in the BAL. 
Furthermore, anti-IFNAR1 treatment had no significant effects on Th1 or Th2 responses, 
although there were non-significant trends towards a decrease in Th1 cells in response to 
RV-OVA.  
 
In the lung tissue, UV-OVA and RV-OVA increased CD4+ T cells in isotype control treated 
mice (figure 4.21b). Anti-IFNAR1 treatment had no significant effects on the accumulation of 
total CD3+ and CD4+ T cells (figure 4.21a and b). In isotype control treated mice, both UV-
OVA and RV-OVA significantly upregulated IFNγ+ Th1 cells, which was significantly 
suppressed by anti-IFNAR1 treatment in response to UV-OVA (figure 4.21c). Significant 
levels of T1ST2+, IL-5+ and IL-13+ Th2 cells were detected in response to UV-OVA and RV-
OVA in isotype control treated mice (figures 4.21d to f). Blockade of IFNAR1 had no effects 
on Th2 cell responses in the lung tissue.  
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Figure 4.20. Effects of anti-IFNAR1 on T-cell responses in BAL fluid 4 days p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. BAL fluid was collected and processed 4 days p.i. BAL cells were 
stimulated with PMA and ionomycin in the presence of monensin for 4 hours to induce 
intracellular cytokine production. BAL cells were stained for surface marker expression of 
CD3+ T cells (a), CD3+ CD4+ T cells (b), then differentiated into T cell sub-populations by 
IFNγ+ Th1 cells (c), T1ST2+ Th2 cells (d), IL-5+ Th2 cells (e) and IL-13+ Th2 cells (f). Data 
represents mean ± SEM of 11–17 mice per group, comprising 3 independent experiments. 
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Figure 4.21. Effects of anti-IFNAR1 on T-cell responses in lung tissue 4 days p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. The left lung lobe was harvested and processed 4 days p.i. Lung cell 
suspensions were stimulated with PMA and ionomycin in the presence of monensin for 4 
hours to induce intracellular cytokine production. Lung cells were stained for surface marker 
expression of CD3+ T cells (a), CD3+ and CD4+ T cells (b), then differentiated into T cell 
sub-populations by IFNγ+ Th1 cells (c), T1ST2+ Th2 cells (d), IL-5+ Th2 cells (e) and IL-13+ 
Th2 cells (f). Data represents mean ± SEM of 11–17 mice per group, comprising 3 
independent experiments. (# All groups vs UV-PBS; ɸ RV-PBS vs RV-OVA within isotype or 
anti-IFNAR1-treated; Ψ UV-OVA vs RV-OVA within isotype or anti-IFNAR1-treated; * isotype 
vs anti-IFNAR1 for indicated groups) 
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ILC2 responses 1 day p.i. were assessed in the Balb/c model of RV and allergen-induced 
allergic airways inflammation for the first time. In isotype control treated mice, the 
combination of RV and allergen resulted in the significant upregulation of total ILC2s, defined 
by cell surface expression of ICOS and absence of other lineage markers (figure 4.22a). 
ILC2s were analysed further by assessing their expression of CD69 activation marker, 
T1ST2 receptor, IL17RB receptor or dual expression of T1ST2 and IL17RB (figures 4.22b to 
e), which were all upregulated following RV-OVA treatment, but not altered by blocking 
IFNAR1 signalling.     
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Figure 4.22. Effects of anti-IFNAR1 on ILC2 responses in lung tissue 1 day p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. The left lung lobe was harvested and processed 4 days p.i. Lung cell 
suspensions were stained for surface marker expression and gated on lineage negative, 
ICOS-positive ILC2 (a), CD69-positive ILC2 (b), T1ST2-positive ILC2 (c), IL-17RB-positive 
ILC2 (d) and T1ST2 and IL-17RB dual-positive ILC2 (e). Data represents mean ± SEM of 4–
6 mice per group from one independent experiment. (# All groups vs UV-PBS; ɸ RV-PBS vs 
RV-OVA within isotype or anti-IFNAR1-treated) 
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4.5.2.3. Type 2 chemokines  
Following the effects of anti-IFNAR1 on eosinophil accumulation in response to RV-OVA or 
UV-OVA at day 1 and 4, respectively, the production of eosinophil chemokines was 
assessed in the BAL fluid at both time points. Firstly, the combination of RV and OVA 
resulted in the significant production of CCL11 1 day p.i., which was significantly greater that 
levels induced by either RV or OVA alone (figure 4.23a). Surprisingly, considering anti-
IFNAR1 augmented RV-OVA-induced eosinophil infiltration at this time point, anti-IFNAR1 
treatment resulted in the suppression of RV-OVA-induced CCL11. Isotype control treated 
mice exhibited increased CCL24 in response to UV-OVA and RV-OVA 1 day p.i., but these 
levels were not statistically significant (4.23b). Mice treated with anti-IFNAR1 displayed a 
trend for increased CCL24 production in response to RV-OVA. Interestingly, CCL24 
responses 4 days p.i. reflected eosinophil responses at this time point, whereby anti-IFNAR1 
treatment augmented CCL24 levels in response to UV-OVA compared with isotype controls 
(figure 4.23c). CCL11 was not detected at the later time point in this model (data not shown).   
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Figure 4.23. Effects of anti-IFNAR1 on eosinophil chemokine production in BAL fluid 1 
and 4 days p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. Protein levels of eosinophil associated chemokines eotaxin-1/CCL11 (a) 
and eotaxin-2/CCL24 (b) were measured in BAL fluid supernatants collected 1 day p.i. by 
ELISA. Data represents mean ± SEM of 6-12 mice per group, comprising two independent 
experiments. (# All groups vs UV-PBS; ɸ RV-PBS vs RV-OVA within isotype or anti-IFNAR1-
treated; Ψ UV-OVA vs RV-OVA within isotype or anti-IFNAR1-treated; * isotype vs anti-
IFNAR1 for indicated groups) 
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It was found that total lymphocytes in the BAL in response to UV-OVA were augmented by 
anti-IFNAR1 antibody treatment 4 days p.i.; therefore, it was of interest to assess additional 
lymphocyte chemoattractants. Of particular relevance was the analysis of Th2 chemokines 
supported by the profound effects observed in IFNAR1-/- mice in the previous chapter. 
Treatment with a type I IFN receptor blocking antibody at the time of infection profoundly 
exacerbated CCL17 production in response to RV-OVA 1 day p.i. (figure 4.24a). By day 4 
p.i., UV-OVA-induced CCL17 was significantly enhanced in mice treated with anti-IFNAR1 
compared with isotype control (figure 4.24b). Similar patterns of response were observed in 
CCL22 induction; anti-IFNAR1 treatment resulted in enhanced CCL22 induced by RV-OVA 1 
day p.i. (figure 4.24c) and UV-OVA 4 days p.i. (figure 4.24d).  
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Figure 4.24. Effects of anti-IFNAR1 on Th2 cell chemokine production in BAL fluid 1 
and 4 days p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. Protein levels of Th2-cell associated chemokines TARC/CCL17 (a) and 
(b) and MDC/CCL22 (c) and (d) were measured in BAL fluid supernatants collected at both 
timepoints p.i. by ELISA. Data represents mean ± SEM of 11–17 mice per group, comprising 
3 independent experiments. (# All groups vs UV-PBS; ɸ RV-PBS vs RV-OVA within isotype 
or anti-IFNAR1-treated; Ψ UV-OVA vs RV-OVA within isotype or anti-IFNAR1-treated; * 
isotype vs anti-IFNAR1 for indicated groups) 
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4.5.2.4. Type 2 cytokines  
Type 2 cytokines were assessed in the BAL of mice 1 day p.i., which found significant 
induction of IL-4, IL-5 and IL-13 following allergen sensitisation and challenge (figure 4.25a 
to c). The addition of RV infection had no significant effects on the production of any of these 
cytokines, nor did the treatment with anti-IFNAR1.  
 
Figure 4.25. Effects of anti-IFNAR1 on type 2 cytokine production in BAL fluid 1 day 
p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. Protein levels of Th2-cell associated cytokines IL-4 (a), IL-5 (b) and IL-
13 (c) were measured in BAL fluid supernatants collected 1 day p.i. by ELISA. Data 
represents mean ± SEM of 11–17 mice per group, comprising 3 independent experiments. 
Data represents mean ± SEM of 11–17 mice per group. (# All groups vs UV-PBS; ɸ RV-PBS 
vs RV-OVA within isotype or anti-IFNAR1-treated) 
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In addition to the relevance of the classical type 2 cytokine signature in asthma, there has 
been recent focus on the role of innate, epithelial-derived type 2 cytokines IL-25, IL-33 and 
TSLP in asthma exacerbations. A role for IL-25 in the modulation of type 2 responses during 
RV infection has been demonstrated in a mouse model of RV and allergen-induced allergic 
airways inflammation (Beale et al., 2014). Furthermore, elevated levels of IL-33 were 
detected in asthmatics in response to RV infection (Jackson et al., 2014). Indeed these 
epithelial-derived cytokines are measurable in the lung homogenate of mice. Trends for 
increased IL-25 were found in UV-OVA and RV-OVA treated mice; although, these levels 
were not significant compared with UV-PBS (figure 4.26a). However, significant levels of IL-
33 and TSLP were induced by UV-OVA and RV-OVA in isotype control treated mice (figure 
4.26b and c). Furthermore, the addition of RV infection caused a trend for increased IL-33 
production, but this effect was not statistically significant. Anti-IFNAR1 treatment had no 
significant effects on the level of induction of any of these cytokines in the lung homogenate 
at this time point.  
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Figure 4.26. Effects of anti-IFNAR1 on innate type 2 cytokine production in lung 
homogenate 1 day p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. Protein levels of Th2-cell associated cytokines IL-4 (a), IL-5 (b) and IL-
13 (c) were measured in BAL fluid supernatants collected 1 day p.i. by ELISA. Data 
represents mean ± SEM of 8-12 mice per group, comprising two independent experiments. 
Data represents mean ± SEM of 7–11 mice per group, comprising two independent 
experiments. (# All groups vs UV-PBS; ɸ RV-PBS vs RV-OVA within isotype or anti-IFNAR1-
treated) 
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4.5.2.5 BAL mucin  
The abundance of MUC5AC mucin protein was assessed at the later time point in these 
studies. Significant production of MUC5AC was found in all mice sensitised and challenged 
with OVA. The addition of RV caused a trend for increased MUC5AC, which was not 
statistically significant. Treatment with anti-IFNAR1 had no significant effect on mucin 
abundance.  
 
Figure 4.27. Effects of anti-IFNAR1 on MUC5AC production in BAL fluid 4 days p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B. 
Mice were treated with 30µg anti-IFNAR1 (clone MAR15A3) or 30µg isotype control antibody 
(MOPC21) i.n twice, 48 hours apart starting from 2 hours prior to the final OVA challenge 
and/or RV infection. MUC5AC protein levels were measured in BAL fluid supernatants 
collected 4 days p.i. by ELISA. Data represents mean ± SEM of 7–11 mice per group, 
comprising two independent experiments. (# All groups vs UV-PBS; ɸ RV-PBS vs RV-OVA 
within isotype or anti-IFNAR1-treated) 
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4.6. Discussion  
The use of an anti-IFNAR1 blocking antibody in this chapter provided the opportunity to 
exogenously impair type I IFN responses in the lungs specifically during the time of RV 
infection. The administration of anti-IFNAR1 antibody prior to RV infection inhibited virus-
induced IFN responses including the induction of innate IFNs and ISGs. During primary RV 
infection, impaired IFN responses were associated with increased virus-induced neutrophilic 
inflammation and reduced lymphocytic inflammation. In addition, blockade of IFNAR1 
signalling augmented Th2 chemokine production in response to RV infection. Progressing 
into a model of RV and allergen interactions with a dosing regimen consisting of two 
antibody doses two days apart found blockade of IFNAR1 signalling exacerbated airway 
eosinophilic inflammation in response to allergen challenge alone and in addition to RV 
infection. Consistent with findings in IFNAR1-/- mice, impaired IFNAR1 signalling resulted in 
enhanced eosinophil and Th2 chemokine production. Additionally, increased type 2 
inflammation in anti-IFNAR1 treated mice was associated with reduced Th1 cell 
accumulation in the lung tissue.  
 
4.6.1. Effects of anti-IFNAR1 in primary RV infection  
In this chapter, we have established an efficacious dosing strategy to inhibit the effects of 
type I IFN signalling locally in the airways to allow the assessment of pulmonary responses 
during respiratory virus infections. Intranasal administration of an IFNAR1-specific blocking 
antibody significantly impaired innate anti-viral pathways downstream of type I IFN signalling 
in the lungs during RV infection. IFN-inducible molecules were inhibited at the gene and 
protein level. In initial dose-response studies, mice treated with anti-IFNAR1 exhibited lower 
RV RNA levels 1 day p.i. despite the loss of anti-viral ISG expression. We postulated 
whether this was a result of reduced infectivity caused by the presence of anti-IFNAR1 
antibody in the airways.  Viral load was therefore assessed at an earlier time point to 
investigate whether mice were inoculated with different levels of RV1B; although there was a 
trend in reduced viral load 8 hours p.i. of anti-IFNAR1 treated mice, this was not statistically 
different. Additional experiments in this chapter also demonstrated no significant differences 
in viral load between anti-IFNAR1 and isotype control treated mice. Similar to findings in the 
previous chapter, absence of type I IFN signalling and decreased downstream anti-viral 
ISGs had limited effects on RV viral load in mice. However, the lack of impact on viral load is 
likely a limitation of mouse models of RV infection, whereby virus replication is relatively 
short-lived in mice. The role of type I IFN signalling in virus control has been established; 
type I IFN treatment of human epithelial cells suppresses RV replication in vitro (Cakebread 
et al., 2011, Becker et al., 2013); IFNAR1-/- mice exhibit increased viral load and 
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corresponding weight loss in a model of respiratory syncytial virus infection (Goritzka et al., 
2014). Considering our findings utilising IFNAR1-/- mice and anti-IFNAR1 treatment, 
inoculation of mice with RV1B may not be an appropriate model to address mechanisms of 
RV replication specifically, or at least the clinical relevance of RV replication in mice should 
be interpreted with caution. Nevertheless, this should not detract from the importance of 
mouse models of RV in the characterisation of pathological features of disease including 
airway inflammatory profiles comprising neutrophil and lymphocytes (Message et al., 2008, 
Fraenkel et al., 1995).  
 
Treatment of mice with anti-IFNAR1 augmented airway neutrophilia during RV infection, 
which is consistent with published findings in primary RV infection in IFNAR1-/- mice 
demonstrating IFN-independent virus-driven inflammatory pathways (Bartlett et al., 2012). 
This response was not considered a result of bacterial contaminants in the anti-IFNAR1 
antibody preparation due to early preliminary investigations of anti-IFNAR1 administration in 
naïve mice, which found no effects on neutrophil responses (data not shown). In subsequent 
studies in both the time course of primary infection and the model of virus and allergen 
interactions, neutrophil responses were not significantly modulated by anti-IFNAR1 
treatment. Nevertheless, we measured the neutrophil chemokine KC 8 and 24 hours p.i., 
which surprisingly found inhibition of IFNAR1 signalling impaired KC production. This is 
consistent with findings by Goritzka et al, in which absence of IFNAR1 signalling diminishes 
pro-inflammatory chemokine responses, indicating a role for type I IFNs in driving 
inflammation during virus infections (Goritzka et al., 2014).   
 
The primary aim of studies of anti-IFNAR1 antibody during primary RV infection were to 
characterise its efficacy in the suppression of type I IFN signalling, thereby allowing us to 
subsequently assess the impact of impaired IFN signalling on type 2 immune responses in 
the lungs. In addition to establishing the inhibitory effects on innate IFN responses up to 4 
days p.i., we found increased CCL17 and CCL22 production following anti-IFNAR1 
treatment during primary RV infection. Despite the well-established role of CCL17 and 
CCL22 in Th2 cell mechanisms, significant levels were detected in response to RV in the 
absence of allergic airways disease. In addition to Th2 cells, CCR4 can also be expressed 
on regulatory T cells, NK cells and B cells (Solari and Pease, 2015). CCL17 and CCL22 
induction during virus infections may have roles in the recruitment of various different 
leukocytes, for example their role in the recruitment of regulatory T cells during hepatitis C 
infection has been demonstrated (Riezu-Boj et al., 2011). Regardless, our interest in this 
IFN-induced modulation of Th2 chemokine production in RV infection lies in its implications 
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in the context of established allergic airways inflammation in asthma, which we were able to 
model in subsequent experiments.  
 
4.6.2. Effects of anti-IFNAR1 in a model of allergen and virus interactions  
A model of RV infection of allergen sensitised and challenged mice was utilised in this 
chapter to model mechanisms of RV-induced asthma exacerbations. Consistent with 
published studies in this model (Bartlett et al., 2008), we found RV-induced exacerbation of 
neutrophilic inflammation in the context of allergic airways inflammation. Furthermore, mice 
exposed to the combination of RV and allergen exhibited BAL infiltrates that included a 
mixture of eosinophils and lymphocytes, although these were not significantly enhanced 
compared with allergen challenge alone. The mixed inflammatory cell profile corresponds 
with that found during RV infection in asthma (Fraenkel et al., 1995, Message et al., 2008, 
Grunberg et al., 1997a).   
 
4.6.2.1. Lung function  
Of particular clinical relevance is the measure of functional pulmonary responses in Balb/C 
mice following virus infection and allergen exposure. In this chapter, we showed that the 
combination of RV and allergen enhanced AHR to MCh compared with either stimuli alone, 
supporting findings by others (Nagarkar et al., 2010, Bartlett et al., 2008). RV-induced 
increased AHR was associated with trends for increased viral load in RV-OVA treated mice. 
This corresponds with findings in experimental RV infection in which increased bronchial 
hyperreactivity was significantly related to viral load in asthma but not healthy controls 
(Message et al., 2008). In accordance with this trend for increased viral load in the context of 
allergic airways inflammation, RV-OVA treated mice also produced enhanced levels of 
innate type I and III IFNs and ISGs OAS, CXCL10 and CCL5. Administration of anti-IFNAR1 
abrogated virus-induced IFN responses in both RV-PBS and RV-OVA treated mice in this 
model, but this did not influence lung viral load.  
 
Blockade of IFNAR1 had no significant impact on UV-OVA or RV-OVA induced AHR to 
MCh. However, between RV-PBS groups, anti-IFNAR1 treatment inhibited airway 
responsiveness to 100mg/ml MCh. This was surprising considering there were no detectable 
differences in inflammatory responses between RV-PBS treated groups in this model. 
However, the singular airway response to only the highest dose of MCh exhibited by RV-
PBS treated mice may not be pathologically relevant. This group of mice did not respond to 
three previous lower doses of MCh, whereas UV-OVA and RV-OVA treated mice exhibited 
significant airway responses to at least 30mg/ml MCh, as well as trends for increased Penh 
in response to 10mg/ml. Clinically, AHR in asthma is defined as a provocative dose of direct 
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bronchoconstrictor stimulus required to induce a 20% fall in FEV1, expressed as PD20; the 
more hyperresponsive the patient’s airways, the lower the PD20 value (Lotvall et al., 1998). 
The equivalent doses required to reduce FEV1 by 20% in asthmatics are unlikely to elicit the 
same magnitude of FEV1 reduction in healthy individuals (Lotvall et al., 1998). Considering 
this, we can hypothesise that airway responses to low doses of bronchoconstrictor stimulus 
may be more representative of AHR. It may therefore be more clinically relevant to stop 
Penh measurements after the first dose of MCh that differentiates airway responses 
between treatment groups, in this case 30mg/ml. However, in the experimental context, it 
was considered more appropriate to capture the full range of MCh responses in all mice to 
provide a full characterisation of lung function changes between treatment groups.   
 
4.6.2.2. Innate type 2 responses  
In line with investigating type 2 inflammatory responses relevant to asthma exacerbations, 
innate type 2 responses were assessed in this model. Considering the recently described 
roles for innate type 2 cytokines IL-25 and IL-33 in RV-induced asthma exacerbations (Beale 
et al., 2014, Jackson et al., 2014), we also assessed whether type I IFN signalling modulates 
their expression in the context of virus and allergen exposure. Allergen challenge 
upregulated IL-25, IL-33 and TSLP production, with no significant differences caused by the 
addition of RV 1 day p.i., which is consistent with findings by Beale et al at this time point 
(Beale et al., 2014). In addition, unlike influenza virus stimulation (Chang et al., 2011), IL-33 
was not upregulated by RV alone in our experiments; however, trends for increased IL-33 
was seen in the context of allergic airways inflammation, which would align with clinical 
findings that RV-induces IL-33 in asthma specifically (Jackson et al., 2014).  
  
Utilising the same gating strategy described in the previous chapter with the addition of the 
CD69 activation marker, we also identified ILC2s in the lung tissue of Balb/C mice exposed 
to the combination of allergen and RV for the first time. RV-OVA treatment consistently 
induced significant accumulation of ILC2s in the lung tissue. Assessment of activation status 
of ILC2s by CD69 expression did not establish differences between allergen and virus 
exposure or antibody treatment. Even though innate type 2 responses are considered 
pathological in asthma exacerbations (Jackson et al., 2014, Beale et al., 2014), the lack of 
effect of inhibiting type I IFN in our model does not exclude roles for IFN deficiency in other 
mechanisms of asthma exacerbations.  
 
4.6.2.3. Eosinophils 
Consistent with findings in IFNAR1-/- mice, anti-IFNAR1 blocking antibody studies also 
found augmented airway eosinophil infiltration in response to RV-OVA treatment, which was 
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detected at the earlier time point of day 1 p.i. in this chapter. Similar to IFNAR1-/- mice, 
enhanced eosinophilia in response to RV infection was only observed upon inhibition of type 
I IFN signalling and not in addition to allergen challenge in control mice. We found isotype 
control treated mice produced profound levels of IFNα in response to RV-OVA. This 
induction of endogenous IFNα may therefore act to prevent exacerbation of type 2 
responses in during RV infection including eosinophilia, which is consistent with its 
demonstrated function in models of allergic airways inflammation (Nakajima et al., 1994, 
Xirakia et al., 2010).   
 
Augmented eosinophil accumulation to RV infection was observed during experimental RV 
infection in asthma, which was associated with decreased lung function (Message et al., 
2008). However, we did not observe corresponding increased AHR in mice with exacerbated 
airway eosinophilia, indicating mechanisms of AHR during RV infection that may be 
independent of eosinophilic inflammation in this model. Eosinophil-dependent AHR has been 
indicated in a model of OVA-induced allergic airways inflammation, in which inhibition of IL-5 
abolished eosinophils and reduced AHR (Shardonofsky et al., 1999). However, the 
mechanisms that contribute to RV-induced exacerbation of allergen-induced AHR in our 
model are unknown. Furthermore, considering the lack of effect of anti-IFNAR1 treatment on 
AHR, despite increasing eosinophil infiltration, suggests RV-OVA-induced AHR may be 
dissociated from leukocyte function in this model. However, it is important to consider 
limitations in the interpretation of Penh measurements to represent AHR as whole body 
plethysmography merely provides an indirect assessment of bronchoconstriction. Although 
Penh has been shown to correspond with direct measurements of lung responses by 
resistance and compliance methods, it is valuable to corroborate Penh observations by 
direct methods before making firm conclusions.  
 
In addition to the effect of impaired IFN responses during RV infection, we demonstrated 
striking effects of blocking type I IFN signalling in response to allergen challenge, most 
notably at the later time point of day 4 p.i. IFNAR1 blockade maintained increased levels of 
CCL24 and Th2 chemokines up to 4 days p.i., which corresponded with enhanced infiltration 
of eosinophils at the same time. The modulation of type 2 responses by inhibition of type I 
IFN signalling in the absence of virus infection is remarkable especially considering we did 
not find detectable levels of type I IFNα following UV-OVA treatment. Although the assay 
used to measure mouse IFNα protein detects all 14 subtypes of IFNα, it has a lower 
detection limit of 12.5pg/ml; therefore, we cannot rule out that UV-OVA treated mice produce 
low levels of IFNα that are below the detection limit. Furthermore, IFNβ protein was not 
measured in this model. It is therefore plausible to hypothesise that low level expression of 
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type I IFNs in the context of allergic airways inflammation may act to control overexpression 
of type 2 responses.  
 
4.6.2.3. T cells   
Despite increased total lymphocyte accumulation follow anti-IFNAR1 treatment, we found 
decreased allergen-induced IFNγ-producing Th1 cells in the lung tissue. Interestingly, a role 
for type III IFN signalling in skewing T-cell responses towards a Th1 profile by modulating 
antigen presentation and co-stimulatory function of DCs has been shown in an OVA model 
of allergic lung inflammation (Koltsida et al., 2011). Although our antibody blocked type I IFN 
receptor signalling, it also suppressed IFNλ2/3 production; therefore, the reduction in Th1 
cells could be a result of the knock-on effect of impaired type III IFN signalling. However, the 
resulting effect on reduced Th1 cell accumulation in the lung tissue as a function of impaired 
Th1 cell polarisation in the absence of innate IFNs appears unlikely. Koltsida et al utilised 
methods that modulated type III IFN signalling before allergen challenge, either by direct 
administration or overexpression of IL-28A (IFNλ2), or utilising IL-28Rα-/- mice (Koltsida et 
al., 2011). Our blocking antibody was administered after two allergen challenges because 
the main priority was to assess the effects of impaired type I IFN signalling during RV 
infection in the context of allergic airways inflammation. The process of presentation of 
inhaled antigen by lung DCs to OVA-specific T cells in the lymph nodes are expected to 
occur soon after the first allergen challenge; therefore, the timing of administration of anti-
IFNAR1 may be too late to significantly impact directly on T-cell stimulation. The 
experimental system described in this chapter is not sufficient to specifically address 
mechanisms of allergen-induced T-cell activation considering anti-IFNAR1 was administered 
locally in the airways during established allergic lung inflammation.  
 
4.6.2.3. Th2 cell chemokines 
Our findings support an alternative mechanism of innate IFN signalling in the modulation of 
allergen-induced type 2 responses by controlling Th2 chemokine expression. The studies in 
this chapter have provided further insights into the mechanism of type I IFN signalling in 
response to allergen exposure observed in the previous chapter, whereby IFNAR1-/- mice 
exhibited enhanced CCL17 and CCL22 following UV-OVA treatment. The anti-IFNAR1 
antibody was administered during the third allergen challenge in this model; therefore, we 
can deduce that the impact of type I IFN on the induction of Th2 chemokines is a function of 
the effector phase of the allergic immune response and not events during peripheral allergic 
sensitisation.  
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Considering this, exploration of events involved in allergen challenge in our model could 
provide further insights into the mechanism of type I IFN signalling. Lung DCs are 
considered critical for the orchestration of allergic airways inflammation, whereby conditional 
depletion of DCs before airway OVA challenges in sensitised mice abolishes development of 
allergic airways inflammation (van Rijt et al., 2005). During allergen challenge, lung DCs 
uptake and present allergen to primed OVA-specific Th2 cells in OVA-sensitised mice to 
induce effector Th2 cell function, including type 2 cytokine expression. During early stages of 
allergen challenge, T-cell activation is considered to occur in the mediastinal lymph nodes, 
which then require migratory signals to reach the effector site of inflammation (van Rijt et al., 
2005). Lung DCs have been demonstrated as functional sources of chemokines including 
CCL17 and CCL22, which promote the migration of activated  CCR4-expressing Th2 cells 
into the pulmonary compartment (Medoff et al., 2009, Mikhak et al., 2009). Of particular 
relevance, studies by Medoff et al demonstrated CD11b+ DCs as critical sources of CCL17 
and CCL22, as well as CCL24, specifically during the effector phase of an OVA-driven 
model of allergic lung inflammation (Medoff et al., 2009). Interestingly, we have 
demonstrated that impairment of type I IFN signalling strongly influences the expression of 
CCL17, CCL22 and CCL24 in the airways after allergen challenge. Thus it is reasonable to 
suggest that type I IFN signalling modulates chemokine expression by DCs during allergic 
airways inflammation. In fact, the role of type I IFN in the regulation of DC function has been 
described, particularly in relation to maturation of DCs and functional antigen-presenting 
capacity, thereby supporting intact type I IFN receptor expression on DCs (Kurche et al., 
2012, Montoya et al., 2002) 
 
Exacerbated chemokine responses in UV-OVA treated mice occurred at the later time point 
of day 4 p.i., which supports the relevance of inducing migratory signals following activation 
of Th2 lymphocytes upon allergen challenge. However, anti-IFNAR1 treatment caused 
exacerbated Th2 chemokine induction 1 day p.i. in RV-OVA treated mice, demonstrating 
differential mechanisms of Th2 chemokine regulation in the presence of virus. Similar effects 
on Th2 chemokine production were also seen in the absence of allergic airways 
inflammation in earlier primary infection studies. If we consider DCs as the main producers 
of Th2 chemokines in this context, upregulation of CCL17 and CCL22 in the BAL may 
indicate the presence of more DCs in the airways at the time of RV infection in anti-IFNAR1 
treated mice. Interestingly, CCL5 has been demonstrated as a critical signal for lung DC 
migration to draining lymph nodes during respiratory viral infection (Grayson et al., 2007). 
RV-OVA treated mice resulted in profound production of CCL5, which was abrogated 
following treatment with anti-IFNAR1. Therefore, absence of IFNAR1 signalling could impair 
CCL5-mediated migration of DCs out of the lungs following virus infection, leading to 
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increased accumulation of DCs in the lung compartment and thus release of pro-
inflammatory chemokines. Since anti-IFNAR1 was administered after two allergen 
challenges, existing lung DCs may be programmed to respond in a manner that promotes 
type 2 inflammation, hence produce vast amounts of Th2 chemokines at this stage. Kinetic 
analysis of DC populations in the pulmonary compartment and mediastinal lymph nodes in 
this model would be insightful to determine the role of type I IFN signalling on DC function in 
vivo.  
 
4.6.3. Summary  
We have described the ability of type I IFN signalling to control the expression of eosinophil 
and Th2 cell chemokines, which ultimately regulates leukocyte trafficking to the effector 
inflammatory site. Increased eosinophil infiltration was observed following inhibition of 
IFNAR1 both in the absence and presence of RV infection in allergic airways. Despite the 
presence of increased Th2 chemokines in the airways, IFNAR1 blockade did not cause 
increased Th2 lymphocyte infiltration, though this could be due to limitations of chemokine-
mediated cell migration in our model, as discussed in the previous chapter. Allergen 
challenge has been found to upregulate CCL17 and CCL22 specifically in asthma, which 
were associated with increased lymphocyte accumulation and clinical symptoms (Pilette et 
al., 2004). As previously discussed, the implication of CCR4 in asthma pathology is well-
established and is considered a clinically relevant therapeutic target. Our findings here 
support potential loss of regulation of Th2 chemokines in the context of type I IFN deficiency 
and this may have implications in asthma disease severity upon exposure to allergen and 
virus. Moreover, the result of this impaired IFN pathway in the context of RV infection 
appears to accelerate the development of type 2 inflammatory responses in the airways. 
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Chapter 5: Results: Effects of recombinant IFNβ 
treatment in a model of RV and allergen interactions 
in Balb/c mice 
 
5.1. Introduction  
In-line with the findings of type I and III IFN deficiency in asthmatics, a potential treatment 
strategy is to restore the anti-viral defence mechanisms of innate IFN signalling. The 
intention to boost anti-viral immunity in the airways would ideally target the increased 
susceptibility to respiratory viral infections in asthma. One approach currently under 
investigation is inhaled IFNβ therapy for the treatment of virus-induced asthma 
exacerbations. A phase II clinical trial recently assessed the effects of administration of 
inhaled IFNβ during the onset of naturally-occurring colds in asthmatics. This study found 
limited clinical benefits of IFNβ therapy in the general patient cohort; however, stratification 
of patient subsets by asthma severity found significant improvements in symptom control in 
the ‘difficult-to-treat’ patient subpopulation (Djukanovic et al., 2014). This evidence supports 
the potential to reduce the burden of asthma exacerbations in certain asthma patient 
subsets. This also aligns with the proposal that IFN deficiency in asthma is related to 
disease severity, where airway cells from patients with mild asthma do not exhibit impaired 
innate IFN production (Lopez-Souza et al., 2009, Sykes et al., 2014). Together, this indicates 
a target patient population for IFNβ therapy in which to deliver clinically beneficial outcomes 
for virus-induced asthma exacerbations.  
 
The proposal to directly restore type I IFN to the airways is supported by findings that type I 
IFN receptor signalling and downstream intracellular pathways are still intact and functional 
in asthmatic lung cells that have impaired IFN production (Wark et al., 2005, Sykes et al., 
2012). Indeed exogenous IFNβ stimulation induced expression of anti-viral ISGs in primary 
bronchial epithelial cells from both healthy and asthmatic donors, which was associated with 
reduced RV replication (Cakebread et al., 2011). Furthermore, Djukanovic et al found 
inhaled IFNβ treatment increased mRNA expression of ISGs MxA and OAS, compared with 
placebo controls, demonstrating the capacity to boost IFN-inducible anti-viral pathways in 
vivo (Djukanovic et al., 2014). Whether the ability of inhaled IFNβ to improve symptom 
control during a cold is directly attributed to this enhanced anti-viral capacity is unknown.  
 
Another component of asthma exacerbations to consider is the ability of RV infection to 
augment type 2 inflammation specifically in atopic asthmatics (Message et al., 2008, 
Jackson et al., 2014). Therefore, it is important to understand whether novel therapeutic 
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approaches to acute exacerbations can impact on this apparent pathological feature. It is 
also of interest to understand whether the clinical benefits of IFNβ therapy are due to its 
impact on exacerbated type 2 responses during asthma exacerbations. Interestingly, 
administration of IFNα has been shown to suppress OVA-induced eosinophil infiltration and 
IL-5 and IL-13 production in mice (Xirakia et al., 2010). However, there is limited evidence 
directly addressing the therapeutic indication of IFNβ therapy in the pathogenesis of type 2 
allergic airways inflammation during RV infection in vivo. A recent publication described a 
model of RV and house dust mite allergen interactions in TLR7 deficient mice, whereby 
administration of exogenous innate IFN suppressed eosinophil responses during RV 
infection (Hatchwell et al., 2015).  
 
It has been demonstrated in the previous two chapters that the lack of type I IFN signalling 
results in enhanced features of type 2 inflammation. Our model of RV and allergen 
interactions in Balb/C mice found RV infection augments allergen-induced AHR to 
methacholine, as well as features of the inflammatory profiles induced by either RV or 
allergen stimulus alone. In this chapter, we aimed to investigate the interactions between 
type I IFN signalling and the development of allergic airways inflammation during RV 
infection by administration of recombinant IFNβ intranasally, mimicking inhaled IFNβ 
therapy. Since the primary aim was to address the mechanisms of RV-induced responses in 
the context of allergic airways inflammation, IFNβ was be administered during the time of 
infection. However, it was also of interest to observe the effects of IFNβ in mice exposed to 
allergen in the absence of virus to gain insights into the therapeutic potential of inhaled IFNβ 
in allergic airways disease. Vehicle PBS was administered to corresponding control 
treatment groups and lung responses were assessed 1 and 4 days p.i.  
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5.2. Hypotheses 
Recombinant IFNβ treatment will:  
i) Enhance IFN-mediated anti-viral responses in the context of RV infection.  
ii) Suppress type 2 allergic airways inflammation in response to allergen sensitisation 
and challenge. 
iii) Suppress type 2 allergic airways inflammation during RV infection in allergen-
sensitised and challenged mice.  
 
5.3. Aims 
To investigate the effects of IFNβ treatment in a mouse model of RV-induced exacerbation 
of allergic airways inflammation.  
i) To determine a dosing regimen for a model of RV-induced exacerbation of allergic 
airways inflammation by assessing the kinetics of a single dose of IFNβ treatment i.n. 
on IFN-inducible responses. 
ii) To examine the effect of IFNβ treatment on RV-induced lung responses.  
iii) To assess the effect of IFNβ treatment on OVA-induced type 2 allergic airways 
inflammation.   
iv) To investigate the effect of IFNβ treatment on RV infection in allergen-sensitised and 
challenged mice.  
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5.4. Results  
 
5.4.1. Determination of recombinant IFNβ dosing strategy 
Previous studies performed in-house determined an optimal dose of 104 units IFNβ to induce 
significant levels of IFN-inducible responses including ISG expression up to 8 hours post-
treatment (unpublished data). In the context of the studies in this thesis, it was important to 
understand the kinetics of a single dose of IFNβ to determine an appropriate dosing strategy 
that would boost IFN responses up to 24 hours of RV infection, during which peak innate 
anti-viral responses occur. Lung tissue mRNA expression of OAS and PKR were induced 
from 4 to 12 hours post-IFNβ treatment compared with vehicle controls, after which levels 
returned to baseline as seen from 16 hours onwards. Viperin mRNA expression was also 
increased at 4 hours post-treatment and levels reduced to vehicle baseline from 8 hours 
onwards. IFNβ mRNA was also measured in lung tissue, which was increased from 4 to 12 
hours following exogenous IFNβ treatment (figure 5.2). Type III IFNλ2 mRNA and IFNλ2/3 
protein in BAL was also measured but was undetectable following IFNβ treatment (data not 
shown). CXCL10, an IFN-inducible lymphocyte chemoattractant was measured in BAL fluid 
supernatants, but was only detectable at 4 hours p.i. (figure 5.3).  
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Figure 5.1. Timecourse of IFN-stimulated gene expression in lung tissue 4 to 48 hours 
post-IFNβ treatment. 
Wild-type Balb/c mice were treated with 104 units IFNβ or vehicle (PBS; 50µl) i.n. RNA was 
extracted from the right apical lung lobe harvested at the indicated time-points post-
treatment and cDNA synthesised. OAS (a), PKR (b) and viperin (c) mRNA copies were 
assessed by Taqman qPCR. Data represents mean ± SEM of 3 mice per group from one 
independent experiment. (Statistical analysis was performed by unpaired t-test at each 
timepoint; * rIFNβ versus vehicle) 
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Figure 5.2. Timecourse of IFNβ gene expression in lung tissue 4 to 48 hours post-IFNβ 
treatment.  
Wild-type Balb/c mice were treated with 104 units IFNβ or 50µl PBS i.n. RNA was extracted 
from the right apical lung lobe harvested at the indicated time-points post-treatment and 
cDNA synthesised. Type I IFNβ mRNA levels were assessed by Taqman qPCR. Data 
represents mean ± SEM of 3 mice per group, from one independent experiment. (Statistical 
analysis was performed by unpaired t-test at each timepoint; * rIFNβ versus vehicle) 
 
 
 
Figure 5.3. Timecourse of IP-10 / CXCL10 production in BAL fluid 4 to 48 hours post-
IFNβ treatment.  
Wild-type Balb/c mice were treated with 104 units IFNβ or 50µl PBS i.n. Protein levels of IP-
10/CXCL10 were measured in BAL fluid supernatants collected from 4 to 48 hours post-
treatment by ELISA. Data represents mean ± SEM of 3 mice per group, from one 
independent experiment. (Statistical analysis was performed by unpaired t-test at each 
timepoint; * rIFNβ versus vehicle) 
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5.4.2. Effects of recombinant IFNβ treatment of RV-induced IFN responses 
A time course study of the effects of a single dose IFNβ treatment found its effects on IFN-
inducible responses to be relatively short-lived, where all markers analysed were diminished 
by 16 hours post-treatment. It was determined that a second dose of IFNβ was required to 
ensure that the induction of type I IFN signalling is maintained during the first 24 hours of RV 
infection. Figure 5.4 describes the dosing regimen adopted to investigate the effects of IFNβ 
treatment on RV and allergen interactions on pulmonary inflammation in allergen-sensitised 
mice.  
 
Figure 5.4. Dosing regimen of IFNβ treatment in a model of RV-induced exacerbation 
of allergic airways inflammation.  
Wild-type Balb/c mice were sensitised with 50µg OVA in 2mg alum i.p and challenged i.n. 
with either 10µg OVA or PBS (controls). Mice were then infected with RV1B or UV-
inactivated RV1B (controls) prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n 2 
and 10 hours post- RV infection. 
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5.4.2.1. Innate interferon production  
Type I IFNα and type III IFNλ2/3 protein production in the airways was measured in 
response to RV in the context of IFNβ treatment (figure 5.5). In vehicle-treated mice, type I 
IFNα protein was not detectable 1 day following RV-PBS treatment, but was significantly 
induced by RV-OVA (figure 5.5a). Similar patterns of IFNα induction were observed following 
administration of IFNβ, with no significant differences compared with vehicle treatment. 
Similar to IFNα, induction of IFNλ2/3 was only detected in response to RV-OVA in vehicle-
treated mice (figure 5.5b). Administration of IFNβ significantly enhanced IFNλ2/3 production 
in response to UV-OVA and RV-OVA compared with vehicle-treated controls.  
 
Figure 5.5. Effects of IFNβ treatment on RV-induced innate interferon production in 
BAL fluid 1 day p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B 
prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n. 2 and 10 hours post- RV 
infection. Protein levels of type I IFNα (a) and type III IFNλ2/3 (b) were measured in BAL 
fluid supernatants collected 1 day p.i. by ELISA. Data represents mean ± SEM of 4–6 mice 
per group, from one independent experiment. (# UV-PBS vs RV-PBS, UV-OVA or RV-OVA 
within vehicle or IFNβ-treated; ɸ RV-PBS vs RV-OVA within vehicle or IFNβ-treated; Ψ UV-
OVA vs RV-OVA within vehicle or IFNβ-treated and * vehicle vs IFNβ for indicated groups) 
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5.4.2.2. Interferon-stimulated gene expression 
To understand whether the current IFNβ dosing regimen is able to boost responses 
downstream of type I IFN receptor signalling, gene expression of ISGs in lung tissue were 
analysed 1 day p.i. RV-OVA significantly increased OAS mRNA compared with UV-PBS; 
however, the administration of IFNβ did not significantly alter OAS responses in any of the 
conditions tested (figure 5.6a). Significant levels of PKR expression were also detected 
following RV-OVA treatment (figure 5.6b). The administration of IFNβ significantly enhanced 
PKR expression in response to UV-PBS and RV-PBS. Surprisingly, IFNβ did not boost PKR 
responses in RV-OVA-treated mice. Furthermore, RV-OVA-treated mice had reduced PKR 
expression compared with RV-PBS in the context of IFNβ treatment. Viperin expression 
induced by RV-PBS and RV-OVA were not statistically significant in vehicle-treated mice 
(figure 5.6c). Administration of IFNβ profoundly exacerbated viperin expression in response 
to RV-PBS compared with vehicle controls. Similar to PKR expression, the administration of 
IFNβ had no effect on viperin expression following RV-OVA treatment.  
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Figure 5.6. Effects of IFNβ treatment on ISG expression in lung tissue 1 day p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B 
prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n. 2 and 10 hours post- RV 
infection. RNA was extracted from the right apical lung lobe harvested 1 day p.i. and PKR 
(a), viperin (b) and OAS (c) mRNA copies were assessed by Taqman qPCR. Data 
represents mean ± SEM of 4–6 mice per group, from one independent experiment. (# UV-
PBS vs RV-PBS, UV-OVA or RV-OVA within vehicle or IFNβ-treated; ɸ RV-PBS vs RV-OVA 
within vehicle or IFNβ-treated and * vehicle vs IFNβ for indicated groups) 
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 5.4.2.3. Rhinovirus viral load 
Considering the anti-viral roles of type I IFN signalling and downstream ISG functions, RV 
viral load in the lung tissue was measured 1 day (figure 5.7a) and 4 days p.i. (figure 5.7b) in 
the context of administration of IFNβ. Significant levels of RV viral RNA was detected in all 
RV-infected 1 day p.i. IFNβ treatment had no impact on viral load compared with vehicle 
controls. RV RNA was still detected in mice 4 days p.i. but was only found to be statistically 
significant in RV-PBS-infected mice treated with IFNβ 
 
 
Figure 5.7. Effects of IFNβ treatment on total RV viral load in lung tissue 1 and 5 days 
p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B 
prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n. 2 and 10 hours post- RV 
infection. RNA was purified from the right apical lung lobe and cDNA was synthesised by 
reverse transcription at the indicated time points. The level of RV RNA was measured by 
Taqman qPCR. Data represents mean ± SEM of 4–6 mice per group, from one independent 
experiment. (# UV-PBS vs RV-PBS, UV-OVA or RV-OVA within vehicle or IFNβ-treated) 
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5.4.3. Effects of recombinant IFNβ treatment on type 2 allergic airways 
inflammatory responses 
 
5.4.3.1. Airways hyperresponsiveness 
Clinical trial findings showed that inhaled IFNβ treatment during an upper respiratory tract 
infection resulted in significant improvements in morning peak flow compared with placebo in 
the difficult-to-treat asthmatic population (Djukanovic et al., 2014). In addition to assessing 
whether IFNβ would have any effects on RV-induced AHR in allergen-sensitised and 
challenged mice, it was also of interest to assess the effects of IFNβ on AHR induced by 
allergen in the absence of virus. Here, lung function was assessed by unrestrained whole 
body plethysmography as an index of AHR. Statistical analyses were performed in the 
context of all 8 treatment groups, consistent with those performed on other readouts. 
Relevant comparisons are presented separately in figures 5.8a to e. Figure 5.8a shows that 
in vehicle-treated mice, both UV-OVA and RV-OVA treatment significantly increased AHR in 
response to the top dose of methacholine (100mg/ml), compared with UV-PBS controls 
(p<0.01 and p<0.001, respectively). When responses were compared between vehicle and 
IFNβ treatment (figures 5.8b to e), RV-PBS-treated mice had increased AHR in response to 
100mg/ml methacholine (p<0.001). There were no significant differences between vehicle 
and IFNβ treatment among UV-PBS (figure 5.8f), UV-OVA (figure 5.8d) or RV-OVA-treated 
mice (figure 5.8c).  
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Figure 5.8. Effects of IFNβ treatment on AHR to methacholine 1 day p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B 
prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n. 2 and 10 hours post- RV 
infection. Penh was measured in response to 1 minute inhalation challenge with increasing 
doses of nebulised methacholine (3, 10, 30 and 100mg/ml MCh). Penh is expressed as an 
average over a 5 minute log period post-MCh challenge; vehicle-treated groups (a), IFNβ-
treated groups (b), vehicle vs IFNβ for RV-OVA groups (c), UV-OVA groups (d), RV-PBS 
groups (e) and UV-PBS groups (f). Data represents mean ± SEM of 4–6 mice per group, 
from one independent experiment. (Statistical analysis was performed in the context of all 8 
treatment groups by two-way ANOVA; Δ UV-PBS vs RV-PBS, Ω UV-PBS vs UV-OVA, # UV-
PBS vs RV-OVA, ɸ RV-PBS vs RV-OVA, Ψ UV-OVA vs RV-OVA, * vehicle vs IFNβ) 
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5.4.3.2. Pulmonary leukocyte infiltration  
A hallmark of allergic asthma is the accumulation of eosinophils in the airways and the 
majority of mouse models of allergic asthma mimic this feature. Interestingly, it has been 
shown that RV infection results in increased eosinophils in asthma compared with healthy 
controls. Furthermore, trends for increased neutrophil and lymphocyte infiltration were also 
demonstrated in asthma (Message et al., 2008). In addition to eosinophils, neutrophil and 
lymphocyte responses in the airways have also been shown to be modulated by the 
combination of RV and allergen in vivo (Bartlett et al., 2008). Figure 5.9a and b shows OVA 
sensitised and challenged mice had increased eosinophil accumulation 1 and 4 days post-
allergen challenge. RV-OVA-treated mice also exhibited significant levels of eosinophils 4 
days p.i. compared with both UV-PBS and RV-PBS. Administration of IFNβ had no effect on 
airway eosinophilia compared with vehicle treatment. Although the levels of neutrophilia in 
vehicle-treated mice were not found to be statistically significant 1 day p.i., there was a trend 
for increased neutrophil accumulation following RV-OVA treatment (figure 5.9c). 
Interestingly, administration of IFNβ resulted in significant accumulation of neutrophils in 
response to UV-OVA and RV-OVA. Furthermore, in the presence of IFNβ, UV-OVA-induced 
neutrophilia was significantly enhanced compared with vehicle-controls. The levels of 
neutrophils detected 4 days p.i. were not statistically significant (figure 5.9d). In vehicle-
treated mice, the levels of lymphocytes in the BAL were not found to be statistically 
significant 1 day p.i. (figure 5.9e). When mice were treated with IFNβ, UV-OVA and RV-
OVA-treated mice exhibited significant levels of lymphocytes in the airways. Consistent with 
previous findings in this model, BAL lymphocytes increase 4 days p.i., as seen in response 
to RV-OVA in both vehicle and IFNβ treatment groups (figure 5.9f).  
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Figure 5.9. Effects of IFNβ treatment on inflammatory leukocyte accumulation in BAL 
fluid 1 and 4 days p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B 
prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n. 2 and 10 hours post- RV 
infection. BAL fluid was collected and cytospins prepared 1 and 4 days p.i. and differential 
eosinophils (a and b), neutrophils (c and d) and lymphocytes (e and f) were enumerated. 
Data represents mean ± SEM of 4–6 mice per group, from one independent experiment. (# 
UV-PBS-Vehicle vs RV-PBS, UV-OVA or RV-OVA in both vehicle and IFNβ-treated; ɸ RV-
PBS vs RV-OVA within vehicle or IFNβ-treated; * vehicle vs IFNβ for indicated groups) 
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T-cell activation is a critical component in the development of allergic airways inflammation. 
Previous investigations showed that T cells constitute a major component of pulmonary 
lymphocyte responses during RV infection and allergen exposure in combination (Glanville 
et al., 2013b). Figure 5.10a and b show total CD3+ and CD4+ T lymphocytes in the BAL, 
respectively. Both allergen exposure alone and when in combination with RV infection 
resulted in the signficant accumulation of CD3+ and CD4+ T cells. Both UV-OVA and RV-
OVA induced significant levels of IFNγ Th1 cells in the BAL (figure 5.10c). Levels of Th1 
cells detected in the context of IFNβ treatment were not found to be statistically significant 
compared with vehicle controls. Th2 cells induced by UV-OVA and RV-OVA in the BAL in 
the context of IFNβ treatment were also not significantly different compared with vehicle 
controls (figures 5.10 d to f).  
 
Figure 5.11a and b show total CD3+ and CD4+ T lymphocytes in the lung tissue, 
respectively. The total numbers of T cells induced by RV and/or allergen were not found to 
statistically significant in the lung tissue, although UV-OVA and RV-OVA-treated mice had 
significant CD4+ T cells in the context of IFNβ treatment compared with UV-PBS controls 
(figure 5.11b). Analysis of Th1 cells by production of IFNγ  found significant induction in 
response to UV-OVA and RV-OVA, with no differences between vehicle and IFNβ treatment 
(figure 5.11c). In vehicle-treated mice, only RV-OVA induced significant levels of Th2 cells, 
defined by surface expression of T1ST2 (figure 5.11d), production of IL-5 (figure 5.11e) or 
IL-13 (figure 5.11f). Although significant numbers of Th2 cells were induced by both UV-OVA 
and RV-OVA in the context of IFNβ treatment, there were no significant differences when 
compared with vehicle controls.  
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Figure 5.10. Effects of IFNβ treatment on T-cell responses in BAL fluid 4 days p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B 
prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n. 2 and 10 hours post- RV 
infection. BAL fluid was collected and processed 4 days p.i. BAL cells were stimulated with 
PMA and ionomycin in the presence of monensin for 4 hours to induce intracellular cytokine 
production. BAL cells were stained for surface marker expression of CD3+ T cells (a), CD3+ 
CD4+ T cells (b), then differentiated into T cell subsets by IFNγ+ Th1 cells (c), T1ST2+ Th2 
cells (d), IL-5+ Th2 cells (e) and IL-13+ Th2 cells (f). Data represents mean ± SEM of 4–6 
mice per group, from one independent experiment. (# UV-PBS-Vehicle vs RV-PBS, UV-OVA 
or RV-OVA in vehicle and rIFNβ-treated; ɸ RV-PBS vs RV-OVA within vehicle or IFNβ-
treated) 
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Figure 5.11. Effects of IFNβ treatment on T-cell responses in lung tissue 4 days p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B 
prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n. 2 and 10 hours post- RV 
infection. The left lung lobe was harvested and processed 4 days p.i. Lung cell suspensions 
were stimulated with PMA and ionomycin in the presence of monensin for 4 hours to induce 
intracellular cytokine production. Lung cells were stained for surface marker expression of 
CD3+ T cells (a), CD3+ and CD4+ T cells (b), then differentiated into T cell subsets by IFNγ+ 
Th1 cells (c), T1ST2+ Th2 cells (d), IL-5+ Th2 cells (e) and IL-13+ Th2 cells (f). Data 
represents mean ± SEM of 4–6 mice per group, from one independent experiment. (# UV-
PBS-Vehicle vs RV-PBS, UV-OVA or RV-OVA in vehicle and rIFNβ-treated; ɸ RV-PBS vs 
RV-OVA within vehicle or IFNβ-treated) 
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5.4.3.3. Type 2 chemokines  
Previous chapters demonstrated enhanced CCL24 responses in the absence of type I IFN 
signalling. Although we observed no effect of IFNβ therapy on eosinophil and Th2 cell 
accumulation in this chapter, it was important to assess whether treatment had any impact 
on eosinophil chemokine production. The combination of RV and OVA induced significant 
production of CCL11 1 day p.i. and the addition of IFNβ resulted in significant enhancement 
of this response (figure 5.12a). Again, CCL11 was not detectable 4 days p.i. CCL24 was 
produced in response to UV-OVA and RV-OVA 1 day p.i., with no significant differences 
between vehicle and IFNβ treatment groups (figure 5.12b). Levels of CCL24 induced by UV-
OVA and RV-OVA 4 days p.i. were not found to be statistically significant compared with UV-
PBS controls.  
 
 
 
 
Chapter 5: Results 
165 
 
 
Figure 5.12. Effects of IFNβ treatment on eosinophil chemokine production in BAL 
fluid 1 day p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B 
prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n. 2 and 10 hours post- RV 
infection. Protein levels of eosinophil associated chemokines eotaxin-1/CCL11 (a) and 
eotaxin-2/CCL24 (b) were measured in BAL fluid supernatants collected 1 day p.i. by ELISA. 
Data represents mean ± SEM of 4–6 mice per group, from one independent experiment. (# 
UV-PBS vs RV-PBS, UV-OVA or RV-OVA within vehicle or IFNβ-treated; ɸ RV-PBS vs RV-
OVA within vehicle or IFNβ-treated; Ψ UV-OVA vs RV-OVA within vehicle or IFNβ-treated; * 
vehicle vs IFNβ for indicated groups) 
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Studies conducted in both IFNAR1KO mice and using anti-IFNAR1 antibody treatment 
demonstrated profound effects on the modulation of Th2 chemokine production in the 
context of allergen and RV exposure. OVA-sensitised and challenged mice produced 
significant levels of CCL17 and CCL22 1 day p.i. (figure 5.13a and c). During this earlier time 
point, addition of RV had no significant effect on Th2 chemokine production, nor did the 
administration of IFNβ. However, by day 4, UV-OVA-treated mice maintained significant 
levels of CCL17, which was significantly suppressed by IFNβ treatment (figure 5.13b). Both 
UV-OVA and RV-OVA-treated mice maintained significant CCL22 levels 4 days p.i., IFNβ 
treatment had no significant effects on this, although there was a non-significant trend for 
suppression of CCL22 in UV-OVA treated mice (figure 5.13d).  
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Figure 5.13. Effects of IFNβ treatment on Th2 cell chemokine production in BAL fluid 1 
and 4 days p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B 
prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n. 2 and 10 hours post- RV 
infection. Protein levels of Th2-cell associated chemokines TARC/CCL17 (a) and (b) and 
MDC/CCL22 (c) and (d) were measured in BAL fluid supernatants collected at both 
timepoints p.i. by ELISA. Data represents mean ± SEM of 4–6 mice per group, from one 
independent experiment. (# UV-PBS vs RV-PBS, UV-OVA or RV-OVA within vehicle or 
IFNβ-treated; ɸ RV-PBS vs RV-OVA within vehicle or IFNβ-treated; * vehicle vs IFNβ for 
indicated groups) 
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5.4.3.4. Type 2 cytokines  
Previous chapters have shown significant induction of type 2 cytokines following allergen 
exposure in both the absence and presence of RV infection. Although anti-IFNAR1 had no 
effect on type 2 cytokine production, IFNAR1KO mice showed enhanced IL-5 production 
compared with wild-type mice in response to allergen exposure. The effect of IFNβ therapy 
on type 2 cytokine production was investigated 1 day p.i. (figures 5.14a–c). UV-OVA resulted 
in significant IL-4, IL-5 and IL-13 production 1 day p.i.; however, administration of IFNβ did 
not affect this. RV-OVA also induced significant production of IL-4, which was not affected by 
IFNβ treatment.  
 
Figure 5.14. Effects of IFNβ treatment on type 2 cytokine production in BAL fluid 1 day 
p.i. 
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B 
prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n. 2 and 10 hours post- RV 
infection. Protein levels of Th2-cell associated cytokines IL-4 (a), IL-5 (b) and IL-13 (c) were 
measured in BAL fluid supernatants collected 1 day p.i. by ELISA. Data represents mean ± 
SEM of 4–6 mice per group, from one independent experiment. (# UV-PBS vs RV-PBS, UV-
OVA or RV-OVA within vehicle or IFNβ-treated; ɸ RV-PBS vs RV-OVA within vehicle or 
IFNβ-treated) 
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5.4.3.5. Mucins 
Increased mucus secretion in the airways is a key feature of asthma and found to occur 
during RV infection (Hewson et al., 2010). It has previously been shown that allergen 
exposure and RV infection increases the abundance of type I and type II mucin proteins, 
MUC5AC and MUC5B, respectively (Bartlett et al., 2008). Firstly, the effects of IFNβ on 
mucin gene expression in the lung tissue were assessed at both time points p.i. (figure 5.15). 
Allergen sensitised and challenged mice had increased MUC5AC expression, which was 
significantly exacerbated by RV infection 4 days p.i. (figure 5.15b). MUC5B was significantly 
induced by both UV-OVA and RV-OVA 4 days p.i. (figure 5.15d). The administration of IFNβ 
significantly increased both MUC5AC and MUC5B mRNA expression in UV-OVA-treated 
mice 4 days p.i., but had no significant impact under other conditions. Although IFNβ 
appears to modulate allergen-induced mucin gene expression, protein analysis of MUC5AC 
in the BAL found that all mice that were challenged with OVA had significant MUC5AC 
protein abundance, with no differences following RV infection or IFNβ treatment (figure 
5.16).  
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Figure 5.15. Effects of IFNβ treatment on mucin gene expression in lung tissue 1 and 
4 days p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B 
prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n. 2 and 10 hours post- RV 
infection. RNA was extracted from the apical lung lobe harvested at both time points p.i. and 
MUC5AC (a and b) and MUC5B (c and d) mRNA copies were assessed by Taqman qPCR. 
Data represents mean ± SEM of 4–6 mice per group, from one independent experiment. (# 
UV-PBS vs RV-PBS, UV-OVA or RV-OVA within vehicle or IFNβ-treated; ɸ RV-PBS vs RV-
OVA within vehicle or IFNβ-treated; Ψ UV-OVA vs RV-OVA within vehicle or IFNβ-treated; * 
vehicle vs IFNβ for indicated groups)    
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Figure 5.16. Effects of IFNβ treatment on MUC5AC production in BAL fluid 4 days p.i.  
Wild-type Balb/c mice were sensitised and challenged with OVA and infected with RV1B 
prior to treatment with 104 units IFNβ or vehicle PBS (50µl) i.n. 2 and 10 hours post- RV 
infection. MUC5AC protein levels were measured in BAL fluid supernatants collected 4 days 
p.i. by ELISA. Data represents mean ± SEM of 4–6 mice per group, from one independent 
experiment. (# UV-PBS vs RV-PBS, UV-OVA or RV-OVA within vehicle or IFNβ-treated) 
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5.5. Discussion  
This chapter sought to increase our understanding of the potential mechanisms of IFNβ 
therapy during RV infection in the context of allergic airways inflammation. In addition to 
assessing the direct interaction of type I IFN on anti-viral immune responses, this was an 
opportunity to explore whether IFNβ therapy has the potential to modulate type 2 responses 
that are considered to play pathological roles in RV-induced asthma exacerbations. We 
established an IFNβ dosing strategy that enhanced aspects of innate IFN signalling for up to 
24 hours, including upregulation of IFNΛ2/3, PKR and viperin expression. Despite boosting 
anti-viral pathways, IFNβ treatment had limited effects on virus-induced airways 
inflammation. In the context of allergic airways inflammation, administration of IFNβ 
suppressed CCL17 production 4 days post- allergen challenge, but increased CCL11 
production and gene expression of MUC5AC and MUC5B.  
 
5.5.1 Effects of recombinant IFNβ on IFN-induced pathways  
During initial optimisation studies, it was found that the effects of a single dose of IFNβ on 
downstream anti-viral pathways were short lived. When progressing into the model of RV 
and allergen interactions, we wanted to ensure that IFNβ signalling was optimal during the 
first 24 hours of RV infection to deliver a physiological effect on virus- and potentially 
allergen-driven responses. The final dosing regimen employed in this model resulted in 
increased type III IFNλ production and anti-viral ISG expression that were detectable 24 
hours p.i. In line with previous chapters, alterations in ISG expression did not impact on lung 
viral load in this model, further demonstrating the limitations of addressing mechanisms of 
RV replication in this model. Nevertheless, administration of IFNβ upregulated pulmonary 
ISG expression, in line with increased ISG expression in induced sputum of patients 
receiving inhaled IFNβ therapy during phase 2 clinical trials (Djukanovic et al., 2014).  
 
Earlier optimisation studies demonstrated exogenous IFNβ-induced IFNβ gene expression, 
supporting the positive feedback mechanism of IFNAR1 signalling in vivo. However, 
considering this mechanism of type I IFN signalling, administration of IFNβ failed to enhance 
IFNα production. This was surprising especially considering previous findings by Bartlett et 
al demonstrating abrogation of IFNα expression in IFNAR1-/- mice, indicating RV-induced 
IFNα induction is IFNAR1-dependent (Bartlett et al., 2012). The lack of effect on IFNα may 
indicate the limited efficacy of intranasal dosing of IFNβ. It is possible that recombinant IFNβ 
may fail to access IFNα-producing cell types in the lungs, for example DCs located in the 
lung parenchyma. Therefore, the effects of delivering recombinant IFNβ intranasally may be 
limited to its mechanism of action on superficial cell layers of the airways. At present, our 
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analyses of BAL and lung samples do not ascertain if the effects of intranasal IFNβ are 
restricted to airway lining cells. However, since asthmatic bronchial epithelial cells exhibit 
impaired type I IFN responses (Wark et al., 2005), the administration of IFNβ via inhalation 
may be adequate to address this deficiency. Furthermore, inhaled IFNβ treatment in 
asthmatics was found to induce IFN responses systemically, demonstrated by an increase in 
CXCL10 expression in peripheral blood (Djukanovic et al., 2014).  
 
In most cases, IFNβ treatment enhanced virus-induced ISG expression in RV-PBS groups, 
however administration of IFNβ did not enhance ISG responses in RV-OVA treated groups, 
indicating a potential lack of efficacy in this context. It is therefore unsurprising to find a lack 
of effect of exogenous IFNβ on outcomes associated with type 2 immunity in RV-OVA 
treated mice. It was theorised that this apparent limited efficacy could be due to increased 
abundance of airway mucus following allergen exposure, which could lead to trapping of 
recombinant IFNβ protein, resulting in reduced access to airway cells. Unfortunately, there 
was insufficient BAL sample to assess mucin protein abundance closer to the time of IFNβ 
administration. Although mucin genes were measured 1 day p.i., which found increased 
MUC5B and MUC5AC expression in allergen-exposed mice.   
 
Despite a failure to boost ISG expression in the lungs of RV-OVA treated mice, IFNβ 
treatment did enhance levels of IFNλ2/3 under all conditions. Interestingly, type III IFN was 
shown to suppress OVA-induced allergic airways inflammation, including type 2 cytokines 
and eosinophils (Koltsida et al., 2011). However, the increase in IFNλ2/3 in our model was 
not associated with similar reduction of type 2 responses. This could be due to differences in 
the timing of IFNλ2/3 induction, which in our model occurred after three allergen challenges 
and RV infection, whereas others induced IFNλ2/3 prior to allergen challenge (Koltsida et al., 
2011). Similarly, in published studies showing an inhibitory role for type I IFN in allergic 
inflammation, recombinant IFNα was administered prior to allergen challenge, and therefore 
before the development of allergic lung responses (Nakajima et al., 1994, Xirakia et al., 
2010). Hence, the timing of recombinant IFNβ administration after three allergen challenges 
in our model may be insufficient to impact on the cascade of ongoing allergic inflammatory 
events at this stage.  
 
5.5.2. Effects of recombinant IFNβ on allergen- and RV-induced responses 
Although IFNβ treatment showed a lack of effect on the majority of allergic responses, it did 
reduce CCL17 production in UV-OVA treated mice 4 days p.i. to levels comparable to those 
exhibited by RV-OVA treated mice, whereby the presence of virus appears to reduce CCL17 
expression. Considering the similarity in kinetics of CCL17 production between IFNβ 
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treatment and virus infection, it is reasonable to suggest that this effect of RV infection is a 
function of virus-induced type I IFN signalling. These observations certainly align with those 
found in previous chapters, in which we saw absence or blockade of type I IFN signalling 
caused increased CCL17 production, further supporting a role for type I IFN signalling in the 
regulation of Th2 chemokine expression.  
 
IFNβ treatment significantly increased airway neutrophil accumulation in UV-OVA treated 
mice. In the previous chapter, we showed that blockade of IFNAR1 signalling inhibits KC 
expression, which suggests a role for type I IFN in the regulation of neutrophil responses. 
Although KC was not measured in this present study, it is plausible to support a pro-
inflammatory role for type I IFN signalling, especially when taken together with findings that 
absence of IFNAR1 signalling results in impaired RSV-induced pro-inflammatory mediator 
expression (Goritzka et al., 2014). Furthermore, IFNβ treatment exacerbated CCL11 
production in RV-OVA treated mice. Although this did not translate to an increase in 
eosinophil accumulation, it does suggest that IFNβ therapy may not serve entirely beneficial 
outcomes on airways inflammatory responses. In addition, IFNβ treatment resulted in 
increased mucin gene expression in UV-OVA treated mice, which may contribute to airways 
obstruction. Therefore, use of IFNβ therapy in patients should be carefully considered where 
its therapeutic benefits outweigh its potential detrimental effects. Indeed this was partly 
demonstrated in recent clinical trial findings whereby IFNβ therapy only improved disease 
outcomes in patients who suffered clinically significant asthma exacerbations during a cold. 
In contrast, in patients with mild disease, IFNβ treatment resulted in a slight worsening of 
asthma symptoms, which was not found to be statistically significant but raised as a potential 
consideration by the authors (Djukanovic et al., 2014).  
 
Although IFNβ treatment had no effects on AHR in UV-OVA and RV-OVA treated mice, it 
was found to increase Penh in response to 100mg/ml MCh in RV-PBS treated mice. As 
discussed in the previous chapter, Penh responses to such a high dose of MCh may not be 
specific to airway pathology; therefore, this observation should be interpreted with caution. 
Future analysis of lung function responses by more direct methods would verify the validity 
of the observations made utilising unrestrained whole body plethysmography. 
 
5.5.3. Model of virus and allergen interactions as a pre-clinical model 
The therapeutic scope of IFNβ therapy in virus-induced asthma exacerbations is supported 
by findings that some asthmatics have deficient type I IFN responses. Based on the 
hypothesis that these asthmatics have deficient anti-viral responses, and therefore present 
an increased susceptibility to respiratory viral infection, IFNβ therapy primarily serves to 
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restore anti-viral defences (Djukanovic et al., 2014). Hence the optimal pre-clinical model to 
study virus-induced asthma exacerbations in this patient subset would ideally mimic 
impaired innate IFN production. However, Balb/C mice are IFN-competent, as demonstrated 
by the significant induction of both type I and III IFNs during RV infection in vehicle controls. 
Furthermore, the addition of exogenous IFNβ may not potentiate endogenous IFN 
responses further if a maximal biological effect has been induced. Therefore, the model used 
in this chapter fails to sufficiently model IFN-deficient asthmatics who may be more likely to 
receive IFNβ therapy to manage asthma exacerbations. Similarly, Djukanovic et al showed a 
lack of effect of inhaled IFNβ on asthma symptoms in mild asthmatic patients (Djukanovic et 
al., 2014), which when taken together with findings that mild asthmatics are unlikely to 
exhibit IFN deficiency (Sykes et al., 2014), demonstrates the redundancy in the use of IFNβ 
in an IFN-competent system. These findings further support the use of IFNβ therapy in 
patients who exhibit IFN deficiency, thus capitalising on the potential to boost anti-viral 
responses and deliver clinically beneficial outcomes. Recently, TLR7 deficient mice, which 
have impaired innate IFN responses, have been used to model RV and house dust mite 
allergen interactions. Interestingly, treatment with exogenous type I and III IFNs inhibited 
RV-induced exacerbation of type 2 inflammation in TLR7 deficient mice (Hatchwell et al., 
2015). Therefore, the use of TLR7 deficient mice may serve as a more appropriate surrogate 
model for investigating the therapeutic efficacy of treatment strategies to restore innate IFN 
responses in RV-induced asthma exacerbations in vivo.  
 
In this chapter, the use of the Balb/C model of RV and allergen interactions found that RV 
infection did not exacerbate OVA-induced AHR, unlike airway responses observed in the 
previous chapter. This indicates a lack of consistency in this model, which is likely attributed 
to the batch variations of RV1B preparations utilised between experiments. Under these 
circumstances, repeat experiments would be carried out to ensure the biological validity of 
current observations. However, we saw little impact of IFNβ treatment on type 2 
inflammation in this experiment, in addition to the potential redundancy in the administration 
IFNβ in this particular experimental system. As a result, it was considered that further repeat 
investigations were not warranted, especially considering the time constraints of this thesis.  
 
The ultimate aim of this chapter was to address the mechanism of inducing type I IFN 
signalling on airway inflammatory responses resulting from virus and allergen interactions. 
However, the direct dosing of recombinant IFNβ protein to the airways did not induce type I 
IFN signalling sufficiently to directly address its potential mechanistic role in the context of 
RV-OVA treatment. This is supported by the lack of effect on IFN responses in RV-OVA 
treated mice. In addition, IFNβ failed to increase IFNα production under all treatment 
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conditions in our experimental model, indicating a lack of effect on IFNα-expressing cells in 
the lungs. The current ‘therapeutic’ approach in which IFNβ was dosed at the time of RV 
infection was primarily to assess its effect in the context of a viral exacerbation. However, 
the specific lack of effect of recombinant protein in this context may warrant reconsidering 
the timing of IFNβ administration to prior to RV infection in future. Furthermore, alternative 
methods to induce type I IFN signalling in the lungs may prove more effective, for example 
adenoviral vectors expressing IFNβ, which may also prolong the induction of type I IFN 
signalling to elicit a physiologically significant effect.  
 
5.5.4. Summary  
Aside from exploration of multiple limitations of the experimental system utilised to address 
the effects of inhaled IFNβ treatment, IFNβ was found to inhibit CCL17 production in the 
context of UV-OVA treatment. This supports findings throughout this thesis indicating a role 
for type I IFN in the regulation of Th2 cell chemokine expression. Moreover, the observed 
impact of IFNβ on CCL17 in the absence of virus in this chapter further supports the 
therapeutic potential of restoring type I IFN signalling in allergic airways disease to control 
ongoing type 2 pathology.   
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Chapter 6: Results: Type I IFN-modulation of Th2 
chemokine production in vitro 
 
6.1. Introduction 
Inhaled IFNβ treatment as a strategy to restore anti-viral defences during virus-induced 
asthma exacerbations has potential benefits in improvement of clinical outcomes, at least in 
certain patient subsets (Djukanovic et al., 2014). The mechanism by which inhaled IFNβ 
improves asthma control during a respiratory virus infection in moderate–severe asthmatics 
is unknown. The role of type 2 inflammatory responses in allergic lung pathology is well-
established and emerging clinical evidence indicates a role in the pathogenesis of virus-
induced asthma exacerbations. In support of this, the magnitude of type 2 responses has 
been associated with increased clinical disease severity during RV infection in asthma 
(Message et al., 2008, Jackson et al., 2014). Therefore, insights into the physiological 
mechanisms that serve to regulate and control type 2 immune responses may reveal 
potential therapeutic targets to control this aspect of disease.  
 
Using animal models, we have so far demonstrated a role for type I IFN signalling in the 
regulation of some type 2 inflammatory responses in vivo. Impaired type I IFN signalling 
resulted in augmented production of type 2 soluble mediators with known roles in the 
recruitment of inflammatory leukocytes involved in allergic airway pathology. This led us to 
postulate that type I IFN signalling acts to control overexpression of type 2 pathways both in 
the absence and presence of virus infection.  Considering impaired type I IFN responses in 
asthmatics, this role may have pathological implications not only in RV-induced asthma 
exacerbations, whereby virus infection leads to enhanced allergic airways inflammation, but 
also ongoing allergic airways inflammation. Therefore, IFNβ therapy may have therapeutic 
indications in the control of allergen-induced type 2 inflammatory responses in asthma.    
 
So far, this thesis has consistently demonstrated striking effects of modulating type I IFN 
signalling on Th2 chemokine expression in vivo. Considering this, we sought to investigate 
the molecular mechanism of type I IFN in the modulation of CCL17 and CCL22 production in 
vitro. It has been shown that CD11b+ myeloid cells produce Th2 chemokines during allergic 
airways inflammation in mice (Medoff et al., 2009).  As a result, we established a model of 
Th2 chemokine expression in a human myeloid monocytic cell line (THP1). THP1 monocytes 
were stimulated with the phorbol ester PMA to induce differentiation into macrophage-like 
cells, which will be referred to as ‘THP1-derived macrophages’ in this thesis. To stimulate 
the expression of Th2 chemokines, THP1-derived macrophages were stimulated with IL-4 
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and TNFα. This model was then used to investigate the effects of IFNβ under two separate 
conditions; either cells were co-treated with IFNβ at the same time as IL-4/TNFα stimulation 
(co-treatment) or cells were pre-treated with IFNβ for 24 hours prior to stimulation with IL-
4/TNFα (pre-treatment). Upon establishing a role for IFNβ in the modulation of Th2 
chemokine production in vitro, microarray analysis was performed on THP1-derived 
macrophages in order to identify other IL-4/TNFα-induced genes modulated by IFN and to 
investigate IFN-mediated mechanisms in the regulation of Th2 chemokine expression. 
Further to this, a hypothesis-driven approach was used to explore potential signalling 
pathways that could play a role in the negative regulation of Th2 chemokine induction.  
 
6.2. Hypothesis  
i) IFNβ will inhibit Th2 chemokine production in THP1-derived macrophages.  
ii) IFNβ will induce a negative regulator of IL-4/TNFα-dependent signal transduction, 
resulting in impaired Th2 chemokine expression.  
 
6.3. Aims  
To investigate the effects of IFNβ treatment in an in vitro model of Th2 chemokine 
expression.  
i) To establish Th2 chemokine induction in THP1-derived macrophages.  
ii) To determine the effects of IFNβ treatment on Th2 chemokine expression.  
iii) To identify an IFNβ-inducible negative regulator of Th2 chemokine induction.  
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6.4. Results   
 
6.4.1. Th2 chemokine expression in THP1-derived macrophages 
THP1-derived macrophages were used to investigate the mechanism of type I IFN-mediated 
regulation of Th2 chemokines. The ability of THP1-derived macrophages to produce Th2 
chemokines was first established by stimulating cells with IL-4. Separately, cells were also 
stimulated in the presence of 10ng/ml TNFα. CCL17 and CCL22 were produced following IL-
4-stimulation in a concentration-dependent manner (figure 6.1). The addition of TNFα 
caused trends for increased CCL17 production. From these concentration-response curves, 
a concentration of 3ng/ml IL-4 in the presence of 10ng/ml TNFα was determined as the 
submaximal concentration to progress with investigating the role of type I IFN signalling.  
 
Figure 6.1. Th2 chemokine production by THP1-derived macrophages.  
Macrophages were stimulated with IL-4 (1 to 100ng/ml) in the absence or presence of 
10ng/ml TNFα for 24 hours. Cell culture supernatants were harvested 24 hours later and 
CCL17 and CCL22 protein levels were measured by ELISA. Data represents mean ± SEM 
of 2 experimental replicates.  
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6.4.2. IFNβ treatment of THP1-derived macrophages  
To study the effect of type I IFN signalling on Th2 chemokine production, THP1-derived 
macrophages were treated with IFNβ under two separate conditions, depicted in figure 6.2. 
IL-4 and TNFα-stimulated THP-derived macrophages were co-treated with IFNβ at the same 
time, termed ‘co-treatment’, or pre-treated with IFNβ for 24 hours prior to IL-4 and TNFα 
stimulation, termed ‘pre-treatment’. Cell culture supernatants were harvested 24 hours after 
cells were stimulated with IL-4/TNFα.  
 
 
Figure 6.2. IFNβ treatment of THP1-derived macrophages.  
THP1-derived macrophages were generated by PMA (10nM) stimulation of the THP1 
monocyte cell line upon seeding on day 0. Cells were washed on day 1 and rested for a 
further 24 hours. Co-treatment conditions consisted of 24 hour stimulation with IL-4 (3ng/ml) 
and TNFα (10ng/ml) in the presence of IFNβ (3 to 100units/ml). Pre-treatment conditions 
consisted of 24 hour pre-treatment with IFNβ (3 to 100units/ml), followed by stimulation with 
IL-4 (3ng/ml) and TNFα (10ng/ml) for a further 24 hours.  
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In support of the activation type I IFN signalling in THP1-derived macrophages, CXCL10 was 
measured in cell culture supernatants following treatment with IFNβ for 24 hours as a 
positive control. IFNβ treatment induced CXCL10 production in a concentration-dependent 
manner (figure 6.3).  
 
Figure 6.3. Effects of IFNβ on CXCL10 production.  
THP1-derived macrophages were treated with IFNβ (3 to 100units/ml) for 24 hours and 
CXCL10 protein levels in cell culture supernatants were analysed by ELISA. Data represents 
mean ± SEM of 4 experimental replicates. *p<0.05 versus media.  
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Under the first conditions, termed ‘co-treatment’, cells were stimulated with IL-4 and TNFα in 
the presence of 3, 10, 30 or 100units/ml IFNβ. CCL17 and CCL22 protein levels in cell 
culture supernatants were assessed 24 hours later. The concentrations of CCL17 and 
CCL22 in cell culture supernatants are presented in figures 6.4a and 6.4c, respectively, 
which detected trends in IFNβ-mediated inhibition of CCL17 and CCL22. In order to control 
for the variation in magnitude of induction of Th2 chemokines between experimental 
replicates, data is also expressed as a percentage of IL-4/TNFα-induced CCL17 and CCL22 
production (100%) in figures 6.4c and 6.4d. These analyses found IFNβ co-treatment inhibits 
CCL17 and CCL22 production in a concentration-dependent manner.   
 
Figure 6.4. Effects of IFNβ co-treatment on Th2 chemokine production.  
THP1-derived macrophages were stimulated with IL-4 (3ng/ml) and TNFα (10ng/ml) and 
treated with IFNβ (3 to 100units/ml). Cell culture supernatants were harvested 24 hours later 
and protein levels of CCL17 and CCL22 were measured by ELISA, presented as 
concentration/ml (a and c) and expressed as percentage of IL-4/TNFα-induced CCL17 and 
CCL22 production (b and d). Data represents mean ± SEM of 4 experimental replicates. 
*p<0.05, **p<0.01, ***p<0.001 versus IL-4/TNFα-treated cells. 
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The effects of type I IFNs were assessed under additional conditions where cells were pre-
treated with 3, 10, 30 or 100units/ml IFNβ for 24 hours, then stimulated with IL-4+TNFα for a 
further 24 hours, termed ‘pre-treatment’. Under these conditions, IFNβ pre-treatment had no 
effects on CCL17 production (figure 6.5a and b); however, IFNβ caused concentration-
dependent suppression of CCL22 production (figure 6.5c and d). 
 
Figure 6.5. Effects of IFNβ pre-treatment on Th2 chemokine production.  
THP1-derived macrophages were pre-treated with IFNβ (3 to 100units/ml) for 24 hours 
before stimulation with IL-4 (3ng/ml) and TNFα (10ng/ml). Cell culture supernatants were 
harvested 24 hours later and protein levels of CCL17 and CCL22 were measured by ELISA, 
presented as concentration/ml (a and c) and expressed as percentage of IL-4/TNFα-induced 
CCL17 and CCL22 production (b and d). Data represents mean ± SEM of 4 experimental 
replicates. *p<0.05, **p<0.01, ***p<0.001 versus IL-4/TNFα-treated cells. 
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In addition to the Th2 cell chemokines, other soluble mediators associated with type 2 
inflammation including eotaxins and CCL13 were measured in the same experiments to 
investigate whether type I IFN modulates could have a broader effect on type 2 pathways in 
these cells. These studies failed to detect protein levels of the eotaxins CCL11, CCL24 and 
CCL26 in cell culture supernatants (data not shown). However, detectable protein levels of 
CCL13, a chemokine with reported roles in eosinophil chemotaxis, were demonstrated 
(White et al., 2000). In contrast to the effects on Th2 cell chemokines, IFNβ treatment under 
both conditions augmented IL-4/TNFα-induced CCL13 production in a concentration-
dependent manner.  
 
Figure 6.6. Effects of IFNβ treatment on CCL13 production.  
THP1-derived macrophages were stimulated with IL-4 (3ng/ml) and TNFα (10ng/ml) and 
either co-treated (a) or pre-treated with IFNβ (3 to 100unis/ml) for 24 hours. Cell culture 
supernatants were harvested 24 hours after IL-4/TNFα stimulation and CCL13 was 
measured by ELISA. Data represents mean ± SEM of 4 experimental replicates. *p<0.05, 
***p<0.001 versus IL-4/TNFα-treated cells. 
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6.4.3. Microarray analysis  
Microarray analysis was performed on cells treated under the conditions described in figure 
6.7 to reveal the full extent of IL-4/TNFα inducible genes in THP1-derived macrophages and 
to explore the potential transcription-dependent mechanisms of type I IFN signalling on the 
modulation of Th2 chemokine production. CCL17, CCL22 and CXCL10 were measured in 
cell culture supernatants as indications of IL-4/TNFα and IFNβ signalling, respectively. IL-
4/TNFα significantly induced CCL17 and CCL22 and IFNβ treatment significantly induced 
CXCL10 production. The effects of co-treatment and pre-treatment of cells with IFNβ on 
CCL17 and CCL22 corresponded to those found in earlier concentration-response studies, 
further establishing this regulatory role of type I IFN signalling (figure 6.7a and b).  
 
Cell lysates were prepared for microarray analysis following RNA extraction and purification, 
cDNA synthesis and labelling. With 6 different treatment conditions and 3 experimental 
replicates, a total of 18 microarray gene expression analyses were performed using Illumina 
HumanHT-12v4 Expression BeadChip arrays. Relevant comparisons are presented as 
volcano plots; genes towards the left are upregulated, towards the right are downregulated. 
Please note that only selected genes are highlighted in the volcano plots; therefore, the top 
10 most highly upregulated or downregulated genes are summarised in the following tables. 
Fold-change of upregulated genes are denoted as a negative value as this value is related 
to the ‘control’, i.e. media (control) is ‘down’, and therefore negative, versus IL-4/TNFα 
upregulated genes. Full lists of all significantly modulated genes are presented in the 
appendix of this thesis.    
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Figure 6.7. Treatment conditions for microarray analysis of THP1-derived 
macrophages.  
THP1-derived macrophages were stimulated with IL-4 (3ng/ml) and TNFα (10ng/ml)  
(‘IL-4/TNFα’) or treated with IFNβ (100units/ml) alone (‘IFNβ’). Under co-treatment 
conditions, IL-4/TNFα-stimulated cells were co-treated with IFNβ (‘IFNβ+IL-4/TNFα’). Under 
pre-treatment conditions, IL-4/TNFα-stimulated cells were pre-treated with either IFNβ ‘IFNβ-
IL-4/TNFα’ or media ‘Media-IL-4/TNFα’ for 24 hours. Cell culture supernatants were 
harvested and protein levels of CCL17 (a), CCL22 (b) and CXCL10 (c) were measured by 
ELISA. Data represents mean ± SEM of 3 experimental replicates. *p<0.05, **p<0.01 as 
indicated.  
 
  
0
200
400
600
800
1000
M
D
C
 /
 C
C
L
2
2
 (
p
g
/m
l)
**
n.s
*
0
2
4
6
8
10
T
A
R
C
 /
 C
C
L
1
7
 (
p
g
/m
l)
**
p=0.08
0
5000
10000
15000
20000
25000
IP
-1
0
 /
 C
X
C
L
1
0
 (
p
g
/m
l)
*
** Media
IL-4/TNF
IFN+IL-4/TNF
IFN
Media-IL-4/TNF
IFN -IL-4/TNF
(a) (b)
(c)
Chapter 6: Results 
188 
 
6.4.3.1. IL-4/TNFα stimulated gene expression  
The levels of gene expression in IL-4/TNFα stimulated THP1-derived macrophages is 
displayed as a volcano plot (figure 6.8); the horizontal axis displays fold-change in gene 
expression between media control and IL-4/TNFα stimulation, the vertical axis displays the 
statistical significance of differentially expressed genes. A list of the top 10 most highly 
upregulated genes by IL-4/TNFα treatment alone is presented in table 6.1. A list of 
significantly upregulated genes following IL-4/TNFα stimulation was determined by a filter 
criteria set to a 2-fold increase in gene expression with a p value of less than 0.05. Genes 
encoding CCL22 and the DC adhesion molecule CD209 were among the most significantly 
upregulated genes in IL-4/TNFα-stimulated THP1-derived macrophages. Selected 
significantly upregulated genes with known roles in type 2 inflammatory pathways are also 
highlighted in the volcano plot in figure 6.8.  
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Table 6.1. List of 10 most highly upregulated genes following IL-4/TNFα 
stimulation in THP1-derived macrophages 
 
Gene Definition P-value Fold-Change 
CCL22 Homo sapiens chemokine (C-C motif) 
ligand 22 (CCL22), mRNA. 
0.00021683700 -6.00 
SLA Homo sapiens Src-like-adaptor (SLA), 
transcript variant 1, mRNA. 
0.00003261500 -5.28 
CD209 Homo sapiens CD209 molecule (CD209), 
mRNA. 
0.00000000003 -5.20 
FCRLA Homo sapiens Fc receptor-like A (FCRLA), 
mRNA. 
0.00017363700 -4.51 
MMP12 Homo sapiens matrix metallopeptidase 12 
(macrophage elastase) (MMP12), mRNA. 
0.00025764000 -4.49 
TGM2 Homo sapiens transglutaminase 2 (C 
polypeptide, protein-glutamine-gamma-
glutamyltransferase) (TGM2), mRNA.  
0.00000002042 -4.45 
ALDH1A2 Homo sapiens aldehyde dehydrogenase 1 
family, member A2 (ALDH1A2), transcript 
variant 2, mRNA. 
0.00000120245 -4.37 
FCRLB Homo sapiens Fc receptor-like B (FCRLB), 
mRNA. 
0.00331551000 -4.01 
SERPINE2 Homo sapiens serpin peptidase inhibitor, 
clade E (nexin, plasminogen activator 
inhibitor type I), mRNA 
0.00039758500 -3.53 
FCGR2C Homo sapiens Fc fragment of IgG, low 
affinity IIc, receptor for (CD32) (FCGR2C), 
mRNA. 
0.00057453800 -3.31 
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Figure 6.8. Volcano plot of differentially expressed genes in IL-4/TNFα stimulated 
THP1-derived macrophages.  
Horizontal axis depicts fold-change of differentially expressed genes; vertical axis depicts 
statistical significance of IL-4/TNFα modulated gene expression compared with media 
control. Only select genes are labelled, please refer to gene tables in the appendix for the 
full list of genes. 
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6.4.3.2. IFNβ-induced gene expression  
The level of gene expression in IFNβ-treated THP1-derived macrophages compared with 
media control is displayed as a volcano plot (figure 6.9). A list of the top 10 most highly 
upregulated genes by IFNβ treatment alone is presented in table 6.2. The primary aim of 
analysing IFNβ-induced genes was to provide an internal control for IFNβ signalling. Relative 
to genes induced by IL-4/TNFα stimulation, IFNβ induced a much greater magnitude of 
signature genes, for example the most highly upregulated gene CCL8 was increased by 
more than 20-fold. In addition, there were relatively more upregulated genes than those that 
were downregulated following IFNβ treatment; no downregulated genes exceeded a 4-fold 
change. As a result, a filter criteria of genes that were upregulated 4-fold and above with a p 
value of less than 0.05 are described in the volcano plot. Among the significantly 
upregulated IFNβ-induced genes were ISG20, ISG15, IFITM1 and CXCL10.  
 
Table 6.2. List of 10 most highly upregulated genes following IFNβ 
stimulation in THP1-derived macrophages 
  
Gene Definition P-value Fold-Change 
CCL8 
Homo sapiens chemokine (C-C motif) ligand 8 
(CCL8), mRNA. 
0.00012077 -21.67 
RSAD2 
Homo sapiens radical S-adenosyl methionine 
domain containing 2 (RSAD2), mRNA. 
0.00002884 -19.45 
ISG20 
Homo sapiens interferon stimulated 
exonuclease gene 20kDa (ISG20), mRNA. 
0.00000171 -17.61 
CXCL10 
Homo sapiens chemokine (C-X-C motif) ligand 
10 (CXCL10), mRNA. 
0.00350387 -14.95 
ISG15 
Homo sapiens ISG15 ubiquitin-like modifier 
(ISG15), mRNA. 
0.00000197 -10.07 
IFI44L 
Homo sapiens interferon-induced protein 44-
like (IFI44L), mRNA. 
0.00041769 -8.93 
IFI27 
Homo sapiens interferon, alpha-inducible 
protein 27 (IFI27), transcript variant 2, mRNA 
0.00003187 -8.84 
HERC5 
Homo sapiens hect domain and RLD 5 
(HERC5), mRNA. 
0.00006691 -8.61 
IFIT1 
Homo sapiens interferon-induced protein with 
tetratricopeptide repeats 1 (IFIT1), mRNA. 
0.00007586 -7.62 
IFITM1 
Homo sapiens interferon induced 
transmembrane protein 1 (9-27) (IFITM1), 
mRNA. 
0.00000013 -7.26 
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Figure 6.9. Volcano plot of differentially expressed genes in IFNβ treated THP1-
derived macrophages.  
Horizontal axis depicts fold-change of differentially expressed genes; vertical axis depicts 
statistical significance of IL-4/TNFα modulated gene expression. Only select genes are 
labelled, please refer to gene tables in the appendix for the full list of genes.  
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6.4.3.3. IFNβ co-treatment on IL-4/TNFα-induced gene expression  
Gene expression levels in IL-4/TNFα and IFNβ co-treated THP1-derived macrophages were 
compared with stimulation with IL-4/TNFα alone and displayed as a volcano plot (figure 
6.10). The top 10 most highly upregulated genes under IFNβ co-treatment conditions 
compared with IL-4/TNFα stimulation alone are presented in table 6.3. Due to the presence 
of IFNβ, a high ISG signature was detected, consistent with the gene expression profile 
induced by IFNβ treatment alone previously. One of the concerns of this high ISG signature 
was the risk of masking genes that may have a small but statistically significant fold-change 
that could play a role in the regulation of IL-4/TNFα signalling. As a result, a filter criteria was 
set to 1.5 fold-change to capture changes in gene expression that may be small in 
magnitude but physiologically relevant. In addition the typical ISG signature, a number of 
genes involved in the proteasome degradation pathway were induced by IFNβ including: 
ISG15, a ubiquitin-like molecule; HERC5, an E3 ubiquitin ligase; UBA7, a ubiquitin-activating 
enzyme; UBE2L6, a ubiquitin-conjugating enzyme; PSMB8, a proteasome subunit.  
  
Chapter 6: Results 
194 
 
Table 6.3. List of 10 most upregulated genes following IFNβ co -treatment 
compared with IL-4/TNFα stimulation 
 
Gene Definition P-value Fold-Change 
CCL8 
Homo sapiens chemokine (C-C motif) 
ligand 8 (CCL8), mRNA. 
0.000185492 -18.72 
ISG15 
Homo sapiens ISG15 ubiquitin-like modifier 
(ISG15), mRNA. 
0.000000453 -14.20 
RSAD2 
Homo sapiens radical S-adenosyl 
methionine domain containing 2 (RSAD2), 
mRNA. 
0.000095289 -13.59 
ISG20 
Homo sapiens interferon stimulated 
exonuclease gene 20kDa (ISG20), mRNA. 
0.000005159 -13.15 
IFIT1 
Homo sapiens interferon-induced protein 
with tetratricopeptide repeats 1 (IFIT1), 
mRNA. 
0.000015132 -11.11 
HERC5 
Homo sapiens hect domain and RLD 5 
(HERC5), mRNA. 
0.000058755 -8.88 
IFI27 
Homo sapiens interferon, alpha-inducible 
protein 27 (IFI27), transcript variant 2, 
mRNA. 
0.000048877 -8.02 
IFI44 
Homo sapiens interferon-induced protein 
44 (IFI44), mRNA. 
0.000106639 -7.29 
EPSTI1 
Homo sapiens epithelial stromal interaction 
1 (breast) (EPSTI1), transcript variant 2, 
mRNA. 
0.000050752 -6.93 
CASP1 
Homo sapiens caspase 1, apoptosis-
related cysteine peptidase (interleukin 1, 
beta, convertase) (CASP1), mRNA.  
0.000000446 -6.66 
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Table 6.4. List of 10 most down-regulated genes following IFNβ co-treatment 
compared with IL-4/TNFα stimulation 
 
Gene Definition P-value Fold-Change 
ALDH1A2 
Homo sapiens aldehyde 
dehydrogenase 1 family, member A2 
(ALDH1A2), transcript variant 2, mRNA.  
0.000033797 2.88 
TNFRSF10D 
Homo sapiens tumor necrosis factor 
receptor superfamily, member 10d, 
decoy with truncated death domain 
(TNFRSF10D), mRNA. 
0.000002499 2.87 
C5orf13 
Homo sapiens chromosome 5 open 
reading frame 13 (C5orf13), mRNA. 
0.000005072 2.67 
AQP9 
Homo sapiens aquaporin 9 (AQP9), 
mRNA. 
0.000006259 2.65 
MMD 
Homo sapiens monocyte to 
macrophage differentiation-associated 
(MMD), mRNA. 
0.000000514 2.53 
LOC100129667 
PREDICTED: Homo sapiens 
misc_RNA (LOC100129667), 
miscRNA. 
0.000032736 2.43 
LOC100133632 
PREDICTED: Homo sapiens 
hypothetical protein LOC100133632 
(LOC100133632), mRNA. 
0.000012178 2.40 
UBE4B 
Homo sapiens ubiquitination factor E4B 
(UFD2 homolog, yeast) (UBE4B), 
mRNA. 
0.000015071 2.28 
RHOQ 
Homo sapiens ras homolog gene 
family, member Q (RHOQ), mRNA. 
0.000023316 2.18 
PRKCA 
Homo sapiens protein kinase C, alpha 
(PRKCA), mRNA. 
0.000014647 2.10 
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Figure 6.10. Volcano plot of differentially expressed genes by IL-4/TNFα stimulation 
and IFNβ co-treatment in THP1-derived macrophages. 
Horizontal axis depicts fold-change of differentially expressed genes. Vertical axis depicts 
statistical significance of IL-4/TNFα modulated gene expression. Only select genes are 
labelled, please refer to gene tables in the appendix for the full list of genes. 
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6.4.3.4. IFNβ pre-treatment on IL-4/TNFα-induced gene expression  
The level of gene expression in IL-4/TNFα stimulated THP1-derived macrophages that were 
pre-treated with IFNβ is displayed as a volcano plot (figue 6.11). The top 10 most highly 
upregulated genes under IFNβ pre-treatment conditions compared with IL-4/TNFα 
stimulation alone are presented in table 6.4. It was apparent that the majority of upregulated 
genes retained a high ISG signature in IFNβ pre-treated cells, similar to that demonstrated 
by IFNβ treatment alone, with CCL8 and ISG15 among the most highly upregulated genes. 
In an attempt to capture a more in depth picture of genes modulated by IFNβ that could 
negatively regulate Th2 chemokine production, a criteria of 1.5 fold-change with a p value 
less than 0.05 was used in this analysis. IFNβ-pre-treated cells exhibited significantly 
increased expression of PTPN6, which encodes the protein tyrosine phosphatase SHP-1 
with indicated roles in the negative regulation of cytokine signalling (Haque et al., 1998).    
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Table 6.5. List of 10 most upregulated genes following IFNβ pre -treatment 
compared with IL-4/TNFα stimulation 
 
Gene Definition P-value Fold-Change 
IFI27 
Homo sapiens interferon, alpha-inducible 
protein 27 (IFI27), transcript variant 2, 
mRNA 
0.000009857 -11.69 
ISG15 
Homo sapiens ISG15 ubiquitin-like modifier 
(ISG15), mRNA. 
0.000002250 -9.78 
IFITM3 
Homo sapiens interferon induced 
transmembrane protein 3 (1-8U) (IFITM3), 
mRNA. 
0.000026218 -5.28 
IFITM1 
Homo sapiens interferon induced 
transmembrane protein 1 (9-27) (IFITM1), 
mRNA. 
0.000002847 -4.43 
IFITM2 
Homo sapiens interferon induced 
transmembrane protein 2 (1-8D) (IFITM2), 
mRNA. 
0.000007622 -3.81 
TXNIP 
Homo sapiens thioredoxin interacting 
protein (TXNIP), mRNA. 
0.000008969 -3.61 
GCA 
Homo sapiens grancalcin, EF-hand calcium 
binding protein (GCA), mRNA. 
0.000004784 -2.62 
IRF9 
Homo sapiens interferon regulatory factor 9 
(IRF9), mRNA. 
0.000016925 -2.37 
LOC144383 
PREDICTED: Homo sapiens similar to 
Interferon-induced transmembrane protein 3 
0.000037699 -2.17 
H1F0 
Homo sapiens H1 histone family, member 0 
(H1F0), mRNA. 
0.000007698 -1.71 
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Table 6.6. List of 10 most downregulated genes following IFNβ pre -treatment 
compared with IL-4/TNFα stimulation 
  
Gene Definition P-value Fold-Change 
QPCT 
Homo sapiens glutaminyl-peptide 
cyclotransferase (QPCT), mRNA. 
0.000006416 2.16 
FAP 
Homo sapiens fibroblast activation protein, 
alpha (FAP), mRNA. 
0.000004503 2.08 
MMD 
Homo sapiens monocyte to macrophage 
differentiation-associated (MMD), mRNA. 
0.000009940 2.01 
PRKCA 
Homo sapiens protein kinase C, alpha 
(PRKCA), mRNA. 
0.000041856 1.95 
CPE 
Homo sapiens carboxypeptidase E (CPE), 
mRNA. 
0.000012165 1.93 
DIRAS2 
Homo sapiens DIRAS family, GTP-binding 
RAS-like 2 (DIRAS2), mRNA. 
0.000040028 1.92 
USP53 
Homo sapiens ubiquitin specific peptidase 53 
(USP53), mRNA. 
0.000039938 1.89 
TFRC 
Homo sapiens transferrin receptor (p90, CD71) 
(TFRC), mRNA. 
0.000038310 1.84 
ITGA6 
Homo sapiens integrin, alpha 6 (ITGA6), 
mRNA. 
0.000047755 1.82 
KAL1 
Homo sapiens Kallmann syndrome 1 
sequence (KAL1), mRNA. 
0.000004494 1.73 
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Figure 6.11. Volcano plot of differentially expressed genes by IL-4/TNFα stimulation of 
IFNβ pre-treated THP1-derived macrophages.  
Horizontal axis depicts fold-change of differentially expressed genes; vertical axis depicts 
statistical significance of IL-4/TNFα modulated gene expression. Only select genes are 
labelled, please refer to gene tables in the appendix for the full list of genes. 
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6.4.3.5. Effects of IFNβ treatment on the most highly upregulated IL-4/TNFα-induced 
genes 
In addition to identifying the regulatory mechanism of type I IFN signalling on Th2 
chemokines, the wider impact of type I IFN signalling was explored by assessing its effects 
on genes that significantly upregulated by IL-4/TNFα stimulation. Figure 6.12 depicts the 
relative expression of the top 10 most highly upregulated genes by IL-4/TNFα and additional 
significantly induced type 2 associated genes (CYSLT1 and CCL26) in the absence and 
presence of IFNβ co-treatment or pre-treatment. Co-treatment with IFNβ significantly 
enhanced IL-4/TNFα-induced CYSLT1 expression (figure 6.12k), which encodes the 
cysteinyl leukotriene receptor-1 (p=0.000138; –2.05-fold change). However, the effects of 
IFNβ co-treatment or pre-treatment on all other IL-4/TNFα-induced genes presented in figure 
6.12 were not found to be statistically significant. The pattern of CCL22 gene expression 
(figure 6.12a) detected by the microarray under each condition did confirm previous protein 
analysis, validating the microarray. IFNβ significantly downregulated ALDH1A2 (figure 
6.12g) which encodes the enzyme aldehyde dehydrogenase 1 family member 2 that 
converts retinaldehyde to retinoic acid in DCs (Coombes et al., 2007) (p=0.000033797; 2.88 
fold change). The presence of IFNβ in THP1 cultures also appeared to have a suppressive 
effect on additional genes: SLA (figure 6.12b), which encodes Src-like adaptor protein 
(SLAP) with proposed roles in the negative regulation of T-cell activation (Sosinowski et al., 
2000); CCL26, encodes the eosinophil chemokine CCL26/ eotaxin-3. IFNβ treatment also 
downregulated IL-4/TNFα-induced MMP12 expression, which encodes matrix 
metalloproteinase 12 (macrophage elastase).  
 
  
Chapter 6: Results 
202 
 
 
Figure 6.12. The relative expression of significantly upregulated IL-4/TNFα-induced 
genes under all treatment conditions.  
The relative expression of the top 10 most highly upregulated IL-4/TNFα-induced genes in 
THP1-derived macrophages and select genes with known type 2 inflammatory functions 
(CYSLT1 and CCL26) were assessed to explore the effects of treatment with IFNβ.   
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6.4.4. Identification of potential IFNβ-induced negative regulators of IL-4/TNF 
signalling: proteasome-mediated pathways 
A hypothesis-driven approach was used to dissect data generated from microarray analysis 
of THP1-derived macrophages, where focus was directed at identifying genes that could 
have roles in the negative regulation of Th2 chemokine production. A common endogenous 
regulatory pathway involves the ubiquitination and targeted proteasomal degradation of 
cellular proteins. Such processes have been implicated in the regulation of immune 
responses (Liu et al., 2005). A number of molecules involved in protein ubiquitination and 
proteasome function were identified in cells treated with IFNβ. As a result, it was 
hypothesised that IFNβ activated proteasomal degradation pathways that resulted in the 
degradation of signalling components involved in Th2 chemokine expression, thereby 
leading to impaired Th2 chemokine production. In order to demonstrate a role for the 
proteasome in IFN-mediated inhibition of CCL17 and CCL22, the effects of a proteasome 
inhibitor MG132 (2.5 to 10µM) was assessed. The treatment of cells with MG132 caused 
dose-dependent trends for increased CCL17 production in both the absence and presence 
of IFNβ. In contrast, all concentrations of MG132 tested completely abolished CCL22 
production under all stimulatory conditions.   
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Figure 6.13. Effects of MG132 on Th2 chemokine production.  
THP1-derived macrophages were treated with MG132 (2.5 to 10µM) for 90 minutes, prior to 
co-treatment with IFNβ (100units/ml) and IL-4 (3ng/ml) and TNFα (10ng/ml) in the presence 
of MG132. Under pre-treatment conditions, cells were treated with IFNβ (100units/ml) for 24 
hours, then treated with MG132 for 90 minutes prior to stimulation with IL-4/TNFα in the 
presence of MG132. Cell culture supernatants were harvested 24 hours after IL-4/TNFα 
stimulations and protein levels of CCL17 and CCL22 were measured by ELISA. Data 
represents mean ± SEM of 3 experimental replicates.   
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6.4.5. Identification of potential IFNβ-induced negative regulators of IL-4/TNF 
signalling: PTPN6 
Upon examining the list of genes altered by IFNβ that could have potential roles in the 
suppression of Th2 chemokine production, PTPN6 was upregulated in cells pre-treated with 
IFNβ. PTPN6 encodes SHP1, a member of the protein tyrosine phosphatase (PTP) family. 
PTPs are enzymes that remove phosphates from phosphorylated tyrosine residues in 
proteins, thereby controlling signal transduction. In particular, SHP1 has been identified as a 
negative regulator of type 2 signalling, in which SHP1 deficient mice demonstrate 
spontaneous type 2 airways inflammation analogous to models of allergen-induced lung 
inflammation (Oh et al., 2009). Furthermore, SHP1 has been shown to inhibit IL-4-mediated 
STAT6 activation, resulting in reduced IL-4-responsive gene transcription (Haque et al., 
1998).  It was therefore hypothesised that the inhibition of Th2 chemokine production by 
IFNβ could be mediated through SHP1. As a result, mRNA expression of PTPN6 was 
confirmed by Taqman qPCR (figure 6.14), which demonstrated comparable fold change in 
PTPN6 upregulation to results from microarray analysis in cells pre-treated with IFNβ.  
 
Figure 6.14. Effects of IFNβ on PTPN6 gene expression.  
THP1-derived macrophages were treated with IL-4 (3ng/ml) and TNFα (10ng/ml) either 
alone or co-treated with IFNβ (100units/ml). In separate conditions, cells were pre-treated 
with IFNβ for 24 hours prior to stimulation with IL-4/TNFα. Cell lysates were harvested 24 
hours after IL-4/TNFα stimulation and RNA was purified and cDNA synthesised by reverse 
transcription. The level of PTPN6 RNA was analysed by Taqman qPCR. Data represents 
mean ± SEM of 4 experimental replicates. 
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In generating our hypotheses of how IFNβ inhibits Th2 chemokine production induced by IL-
4 and TNFα, it was reasoned that induction of CCL17 and CCL22 was STAT6-dependent, 
especially considering the involvement of IL-4 in the stimulatory conditions. IL-4 signals 
through the IL-4Rα activating Janus kinases (JAK), specifically JAK-1 and JAK-3, leading to 
signal transducer and activator of transcription-6 (STAT6) phosphorylation at its tyrosine 641 
residue (Y641) (Takeda et al., 1996). STAT6-P(Y641) forms homodimers which translocate 
to the nucleus and bind to STAT6-responsive promoters to elicit gene transcription (Takeda 
et al., 1996, Kotanides and Reich, 1996). Furthermore, multiple studies have demonstrated 
STAT6-dependent regulation of CCL17 and CCL22 (Medoff et al., 2009, Liu et al., 2007, 
Fulkerson et al., 2004, Liddiard et al., 2006, Wirnsberger et al., 2006). 
 
SHP1 has been indicated in the regulation of IL-4-dependent signal transduction through 
dephosphorylation of STAT6 and downstream gene transcription (Haque et al., 1998, 
Hanson et al., 2003). Taken together with the observed upregulation of PTPN6 gene 
expression, it was hypothesised that IFNβ induced SHP1 suppresses STAT6 signalling, 
leading to reduced CCL17 and CCL22 expression. In order to explore to this hypothesis, 
analysis of STAT6 activation in THP1-derived macrophages was performed by western blot 
(figure 6.15). Cells were also assessed for total STAT6 protein abundance, analysed on a 
separate gel. The abundance of STAT6-P(Y641) was quantified by densitometry, expressed 
relative to β-actin in the same gel (figure 6.15b). STAT6 activation was analysed up to for 4 
hours of IL-4/TNFα stimulation, which demonstrated rapidly increased STAT6-P(Y641) from 
10 minutes post-stimulation.   
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(a) 
 
 
(b)  
 
Figure 6.15. Timecourse of IL-4 and TNFα-induced STAT6 activation.  
THP1-derived macrophages were stimulated with IL-4 (3ng/ml) and TNFα (10ng/ml) for up to 
4 hours. Cells were lysed and protein extracted in the presence of protease and 
phosphatase inhibitors. Protein extracts were analysed by western blot for Y641-
phosphorylated STAT6, total STAT6 and β-actin control. Western blots (a) of one single 
experiment, representative of 3 experimental replicates. Densitometry data (b) represents 
mean ± SEM of 3 experimental replicates.  
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Following confirmation of STAT6 activation in IL-4 and TNFα stimulated THP1-derived 
macrophages, it was then relevant to assess whether IFNβ modulates STAT6 activation. 
STAT6 phosphorylation was assessed at two timepoints: 30 (figure 6.16a) and 60 (figure 
6.16b) minutes post-IL-4 and TNFα stimulation. Although IL-4 and TNFα stimulation 
increased STAT6-P(Y641), IFNβ treatment under either co-treatment or pre-treatment 
conditions had no effects on STAT6 activation.  
 
Figure 6.16. Effects of IFNβ on STAT6 activation.  
THP1-derived macrophages were stimulated with IL-4 (3ng/ml) and TNFα (10ng/ml) for 30 
(a) or 60 (b) minutes. Macrophages were also either co-treated or pre-treated with IFNβ 
(100units/ml). Cells were lysed and protein extracted in the presence of protease and 
phosphatase inhibitors. Protein extracts were analysed by western blot for Y641-
phosphorylated STAT6 and β-actin control. Densitometry data represents mean ± SEM of 3 
experimental replicates.  
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In addition to the lack of effect of IFNβ on STAT6 activation, it was also found that IFNβ had 
no effect on the abundance of total STAT6 protein at either timepoints (figure 6.17 and 6.18). 
Although no changes to STAT6 were found in these studies, it does not rule out a role for 
SHP1 in the negative regulation of other signalling pathway components involved in Th2 
chemokine induction. In order to further assess the involvement of SHP1 as an IFNβ-
inducible negative regulator of Th2 chemokine expression, protein abundance of SHP1 was 
also analysed. Despite the upregulation of PTPN6 gene expression in IFNβ pre-treated 
THP1-derived macrophages, there were no corresponding changes to SHP1 protein under 
the treatment conditions tested at either timepoint in these studies. However, it has been 
found that SHP1 protein contains two tyrosine phosphorylation sites in its C-terminal tail, 
which have been implicated in the increased phosphatase activity of SHP1 (Zhang et al., 
2003). Although, there was no change in total SHP1 abundance, it was reasoned that its 
phosphorylation, and therefore phosphatase activity on other proteins, could be altered 
under IFNβ treatment. As a result, Y536- and Y564-phosphorylated SHP1 proteins were 
analysed at both timepoints, which found no changes in their abundance under these 
conditions (figure 6.17 and 6.18).  
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Figure 6.17. Effects of IFNβ on STAT6 activation and SHP1 30 minutes post-IL-4 and 
TNFα stimulation.  
THP1-derived macrophages were stimulated with IL-4 (3ng/ml) and TNFα (10ng/ml) for 30 
minutes. Macrophages were also either co-treated or pre-treated with IFNβ (100units/ml). 
Cells were lysed and protein extracted in the presence of protease and phosphatase 
inhibitors. Protein extracts were analysed by western blot for: Y641-phosphorylated STAT6; 
β-actin; total STAT6; total SHP1; Y536-phosphorylated SHP1; Y564-phosphorylated SHP1; 
β-actin. Western blots of one single experiment, representative of 3 experimental replicates.  
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Figure 6.18. Effects of IFNβ on STAT6 activation and SHP1 60 minutes post-IL-4 and 
TNFα stimulation.  
THP1-derived macrophages were stimulated with IL-4 (3ng/ml) and TNFα (10ng/ml) for 60 
minutes. Macrophages were also either co-treated or pre-treated with IFNβ (100units/ml). 
Cells were lysed and protein extracted in the presence of protease and phosphatase 
inhibitors. Protein extracts were analysed by western blot for: Y641-phosphorylated STAT6; 
β-actin; total STAT6; total SHP1; Y536-phosphorylated SHP1; Y564-phosphorylated SHP1; 
β-actin. Western blots of one single experiment, representative of 3 experimental replicates. 
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6.4.5.2. Effect of protein tyrosine phosphatase inhibitors 
In line with investigating the functional involvement of SHP1 in IFNβ-mediated negative 
regulation of Th2 chemokine expression, the effects of PTP inhibitors were examined. 
Sodium orthovanadate (SOV) is a broad spectrum PTP inhibitor, which has been shown to 
augment cytokine responses by preventing dephosphorylation of proteins and termination of 
signalling cascades. Thus it was hypothesised that SOV would augment IL-4/TNFα-induced 
CCL17 and CCL22 production. Additionally, if IFNβ-mediated SHP1 was involved in the 
suppression of CCL17 and CCL22 expression, the presence of SOV would reverse the 
inhibitory effects of IFNβ. Macrophages were treated with SOV for 90 minutes prior to 
stimulation with IL-4/TNFα for 24 hours in the presence of 3 to 30µM SOV (figure 6.19). In 
vehicle treated controls, addition of IFNβ co-treatment reduced CCL17 (figure 6.19a) and 
CCL22 (figure 6.19c) induction compared with IL-4/TNFα treatment alone. The presence of 
SOV had little effect on CCL17 and CCL22 production in the context of IFNβ co-treatment. 
However, 3µM SOV appeared to increase CCL22 induction in the presence of IFNβ, which 
appeared to be caused by a single outlier and not attributed the effects of SOV specifically. 
This was supported by the lack of concentration-dependent effect of SOV in these 
conditions. Under IFNβ pre-treatment conditions, IFNβ caused trends for reduced CCL22 
(figure 6.19d) but not CCL17 (figure 6.19b), consistent with previous data. The higher 
concentrations of SOV (10 and 30µM) appeared to reverse the inhibitory effects of IFNβ pre-
treatment on CCL22 production (figure 6.19d). Additional experimental replicates are 
required to understand if this effect is biologically relevant and significant.  
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Figure 6.19. Effects of sodium orthovanadate on Th2 chemokine production.  
THP1-derived macrophages were treated with IL-4 (3ng/ml) and TNFα (10ng/ml) or either 
co-treated or pre-treated with IFNβ (100units/ml), in the presence of sodium orthovanadate 
(3 to 30µM). Cell culture supernatants were harvested and protein levels of CCL17 (a and b) 
and CCL22 (c and d) were measured by ELISA. Data represents mean ± SEM of percentage 
of CCL17 or CCL22 production induced by IL-4/TNFα under vehicle conditions; N=2.   
 
PTPs are involved in many signal transduction pathways and their activity may positively or 
negatively regulate signalling cascades depending on the intracellular context. It was 
considered that due to the non-specific PTP inhibitory activity of SOV, a specific SHP1 
inhibitor would provide more informative conclusions. As a result, sodium stibogluconate 
(SSG) was tested. SSG is reported to inhibit SHP1 at a 10-fold lower concentration than that 
required to inhibit other PTPs SHP2 and PTPB1 (Pathak and Yi, 2001). SSG was tested at 
concentrations between 10 and 100µM based on other studies that found a concentration 
equivalent to 10µM SSG inhibited SHP1 (Pathak and Yi, 2001). SSG treatment had no 
effects on the suppression of CCL17 by IFNβ co-treatment (figure 6.20a); however, high 
concentrations of SSG appeared to enhance CCL17 production in the presence of IFNβ 
(figure 6.20b). SSG treatment had little or no effect on CCL22 production under either IFNβ 
co-treatment or pre-treatment conditions (figure 6.20c and d).  
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Figure 6.20. Effects of sodium stibogluconate on Th2 chemokine production.  
THP1-derived macrophages were treated with IL-4 (3ng/ml) and TNFα (10ng/ml) or either 
co-treated or pre-treated with IFNβ (100units/ml), in the presence of sodium stibogluconate 
(10 to 100µM). Cell culture supernatants were harvested and protein levels of CCL17 (a and 
b) and CCL22 (c and d) were measured by ELISA. Data represents mean ± SEM of 
percentage of CCL17 or CCL22 production induced by IL-4/TNFα under vehicle conditions; 
N=2.   
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In addition to the use of small molecule inhibitors of PTPs in order to functionally assess the 
role of SHP1 on Th2 chemokine production, a small interfering RNA (siRNA) approach was 
used to block the effects of SHP1 specifically. In order to optimise conditions for siRNA 
transfection and subsequent knockdown of SHP1 protein, a timecourse of SHP1 protein 
abundance was assessed for up to 72 hours post-PTPN6 siRNA transfection of naïve THP1-
derived macrophages (figure 6.21). Assessment of mRNA expression found that PTPN6 
siRNA transfection caused approximately 50% knockdown of PTPN6 mRNA compared with 
control siRNA transfection (figure 6.21a). However, non-transfected cells exhibited a level of 
PTPN6 mRNA ‘knockdown’ that was similar to the effects of PTPN6-specific siRNA. Despite 
observing knockdown of PTPN6 mRNA, it was important to assess the effects of siRNA on 
SHP1 protein abundance. A small reduction of SHP1 protein abundance was observed 72 
hours post-transfection but not at earlier timepoints (figure 6.21b). Such a delayed effect in 
SHP1 protein knockdown was unexpected. In order to pursue the functional effect of SHP1 
knockdown by siRNA, the experimental paradigm described in figure 6.2 would have to be 
re-optimised to commence at this 72-hour post-transfection timepoint when SHP1 protein 
knockdown is apparent. However, the functional capabilities of THP1-derived macrophages 
in this system have not been assessed beyond this timepoint; therefore, it was not 
considered feasible to pursue this in the given time constraints of this PhD thesis.  
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(a) 
 
 
(b) 
 
 
Figure 6.21. Effects of SHP1 siRNA transfection on SHP1/PTPN6 expression.  
THP1-derived macrophages were transfected with SHP1 siRNA, control siRNA or were left 
untransfected (non-transfected). PTPN6 mRNA expression was assessed by Taqman qPCR 
and the percentage knockdown relative to control siRNA was analysed (a), representative of 
one experiment. Protein abundance of SHP1 and β-actin control was assessed by western 
blot 24, 48 or 72 hours post-transfection, representative of two experimental replicates (b).  
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6.5. Discussion  
Earlier in this thesis, we demonstrated profound effects of modulating type I IFN signalling 
on Th2 chemokine production in vivo. Proceeding from this finding, we established a THP1-
derived macrophage model in an attempt to understand the mechanisms of Th2 chemokine 
regulation by type I IFN. The role of type I IFN in the negative regulation of Th2 chemokines 
was translated into this in vitro model, in which the presence of IFNβ inhibited CCL17 and 
CCL22 production in a concentration-dependent manner. In other conditions, IFNβ pre-
treatment of THP1-derived macrophages inhibited CCL22 production.  
 
It was hypothesised that the regulatory mechanism of type I IFN may involve a signalling 
molecule that directly suppressed the stimulatory pathway that leads to Th2 chemokine 
expression. Microarray analysis was utilised to explore potential regulatory mechanisms of 
type I IFN in the regulation IL-4/TNFα signalling on a transcriptional level. Our microarray 
analysis confirmed the upregulation of CCL22 mRNA in IL-4/TNFα-stimulated cells, as well 
as modulation of CCL22 gene expression by IFNβ, strengthening this demonstrated role for 
type I IFN signalling throughout this thesis. However, these arrays failed to detect any 
significant signal in CCL17 mRNA expression; this could be due to rapid degradation of 
CCL17 mRNA following protein translation. Ideally, mRNA expression should be confirmed 
by qPCR analysis, but we failed to achieve this during the time frame of this thesis. 
However, it was considered the data obtained to be sufficient to continue pursuing our 
research question.  
 
6.5.1. Regulation of Th2 chemokines  
The experiments in this chapter were designed to examine the mechanisms of Th2 
chemokine regulation by type I IFNβ. Expression of CCL22 by THP1-derived macrophages 
has been demonstrated (Hung et al., 2008), which supported our initial investigations 
utilising this cell type. Following stimulation with IL-4 and TNFα, we detected CCL17 protein 
in addition to CCL22 in cell culture supernatants. Although the concentrations of CCL17 
detected were relatively lower than those of CCL22, the level of induction of CCL17 was 
found to be statistically significant. Upon examining the role of type I IFN signalling on Th2 
chemokine production, we found that co-treatment of cells with IFNβ inhibited CCL17 and 
CCL22 production, whereas IFNβ pre-treatment only inhibited CCL22 production. These 
findings demonstrate a direct role for type I IFN signalling in the negative regulation of Th2 
chemokine production, supporting results demonstrated in mice in vivo in the previous 
chapters of this thesis. However, it also indicates that IFNβ may regulate CCL17 and CCL22 
by different mechanisms due to the lack of effect of IFNβ pre-treatment on CCL17 
expression. A disparity between the regulation of CCL17 and CCL22 was also apparent 
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during experiments using the proteasome inhibitor MG132, where MG132 had profoundly 
different effects on the two chemokines.  
 
6.5.2. Role of the proteasome   
A collection of genes were upregulated in cells treated with IFNβ that have known roles in 
proteosomal degradation pathways including ISG15, HERC5, UBA7 and UBE2L6 (Bedford 
et al., 2011). It was hypothesised that the inhibitory effect of IFNβ was dependent on the 
proteasome, potentially by targeting components of the signalling pathway that leads to 
CCL17 and CCL22 induction for proteosomal degradation. To explore the involvement of the 
proteasome in the IFNβ-mediated negative regulation of Th2 chemokine production, the 
effect of a proteasome inhibitor MG132 was investigated. The inhibitory action of IFNβ co-
treatment on CCL17 production was maintained in the presence of MG132, indicating the 
proteasome does not play a role in the effect of type I IFN on CCL17 expression. However, 
the presence of MG132 resulted in the complete abrogation of CCL22 production under all 
conditions, suggesting that the signalling pathway leading to CCL22 production is 
proteasome-dependent. A proteasome-dependent mechanism of signal transduction has 
been identified for NFκB signalling, in which IKBα is targeted for degradation to allow for 
p65-dependent gene transcription (Bowie and Unterholzner, 2008). Furthermore, NFκB-
dependent induction of CCL22 has been identified (Berin et al., 2001). Therefore, the 
demonstrated inhibition of IL-4/TNFα-induced CCL22 in the presence of MG132 suggests 
CCL22 expression in our THP1 model requires NFκB-mediated gene transcription. 
Considering CCL17 and CCL22 production may be dependent on different mechanisms, it is 
possible that the inhibitory effects of IFNβ utilises different regulatory mechanisms also.  
 
6.5.3. Role of PTPN6 
A result from the array identified PTPN6, which encodes the protein tyrosine phosphatase 
SHP1 with proposed roles in the negative regulation of IL-4 and IL-13 cytokine signalling 
(Haque et al., 1998). Furthermore, a role for SHP1 in the regulation of type 2 inflammation in 
vivo has been demonstrated. In particular, SHP1 deficient mice spontaneously develop lung 
inflammation that is characteristic of type 2 allergic airways inflammation and AHR to 
methacholine (Oh et al., 2009). A functional role for SHP1 in IL-4-STAT6 signalling has been 
demonstrated in vitro, where SOV treatment of murine lymphocytes ex vivo augmented  
IL-4-induced phosphorylated STAT6 (Huang and Paul, 2000). As IL-4 is used to stimulate 
Th2 chemokine production, albeit in the presence of TNFα, we considered whether SHP1-
mediated regulation of STAT6 was involved in the negative regulation of Th2 chemokine 
expression. Therefore, it was theorised that if IFNβ-induced SHP1 was responsible for the 
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suppression of IL-4-induced Th2 chemokine induction, inhibition of SHP1 function would 
reverse the effects of IFNβ. Unfortunately, our studies utilising protein tyrosine phosphatase 
inhibitors did not alter Th2 chemokine production by THP1 macrophages, indicating SHP1 
activity is not involved in the regulation of Th2 chemokine induction. However, a limitation to 
these experiments was a lack of a direct positive control to indicate the function of these 
inhibitors. A potential method to assess the functionality of PTP inhibitors could be to 
measure STAT6 phosphorlyation. However, this was not considered practical during our 
experiments as chemokine production was measured 24 hours post-stimulation, whereas 
STAT6 activation occurs much earlier (detected from 15 minutes post-stimulation). 
Furthermore, it was also considered that the inhibitors tested were not specific to SHP1, 
which could potentially affect multiple signalling pathways. Consequently, a siRNA approach 
was tested, which unfortunately did not knockdown SHP1 protein abundance sufficiently to 
warrant further investigation in the given time constraints.  
 
Alternatively, it is possible that STAT6 activity is not involved in the regulation of Th2 
chemokine induction in this system, especially considering the abundance of  
IL-4/TNFα-induced STAT6-P(Y641) protein was not altered in the presence of IFNβ  
co-treatment or pre-treatment. However, it should also be considered that our analysis of 
STAT6 protein abundance did not assess the specific nuclear abundance of activated 
STAT6, which is ultimately required to drive STAT6-dependent gene transcription. However, 
our initial attempts made to separate cytosolic and nuclear fractions of THP1 macrophages 
to gain further understanding of STAT6 signalling in this system were unsuccessful. Specific 
inhibition of STAT6, potentially through the use of STAT6-specific siRNA, would verify 
whether CCL17 and CCL22 production are STAT6-dependent in this model, which may 
elucidate the potential mechanism of type I IFN signalling. It is also important to consider 
that CCL22 production could be dependent on NFκB signalling; therefore, the role of such 
mechanisms in this experimental system should be explored further.  
 
6.5.4. Effects of IFNβ on IL-4/TNFα-induced genes 
Further to determining the role of type I IFN on Th2 chemokine expression, our microarray 
analysis allowed the identification of the effects of type I IFN on other genes induced by IL-
4/TNFα stimulation. Among the list of most highly upregulated genes by IL-4/TNFα 
stimulation, IFNβ treatment reduced the expression of CCL26, which encodes human 
eotaxin-3. We observed similar results in previous chapters in mice, which demonstrated 
that impaired type I IFN signalling leads to exacerbation of other eotaxins (CCL11 and 
CCL24) and eosinophilic inflammation. Attempts were made to measure CCL26 in cell 
culture supernatants; however, it was found that the baseline signal in media-treated THP1 
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macrophages exceeded the maximum detection limit of the assay despite efforts to titrate 
samples to reduce the background signal. Nevertheless, these findings from the array 
continue to support the role for IFNβ in the regulation of some soluble mediators associated 
with type 2 inflammatory pathways.   
 
Despite a proposed suppressive role for type I IFN in type 2 inflammation throughout this 
thesis, results from both protein analysis and the microarray have highlighted the complexity 
of type I IFN signalling. Analysis of cell culture supernatants found that IFNβ co-treatment 
and pre-treatment significantly augmented CCL13 production. Considering the role of CCL13 
in eosinophil chemotaxis through the CCR3 receptor, this effect of IFNβ in vivo could cause 
increased eosinophilic inflammation (White et al., 2000). However, we found in earlier 
chapters that impairment of type I IFN signalling resulted in enhanced eosinophilia, 
suggesting IFN functions to negatively regulate eosinophilic inflammation.  
 
Our microarray analysis found that IFNβ co-treatment also significantly enhanced  
IL-4/TNFα-induced CYSLT1 expression in THP1-derived macrophages. CYSLT1 encodes 
the cysteinyl leukotriene receptor-1 (CysLT1) and was among the significantly upregulated 
genes following stimulation by IL-4/TNFα. The role of CysLT1 has been implicated in asthma; 
its expression on smooth muscle cells and activation leads to smooth muscle contraction, 
which may contribute to bronchoconstriction (Lynch et al., 1999). Montelukast is a CysLT1 
antagonist that is indicated for the treatment of asthma in some patients (Leff et al., 1998). 
Studies have reported a role for IFNγ in the upregulation of CysLT1 expression in peripheral 
blood cells and airway smooth muscle cells (Early et al., 2007, Amrani et al., 2001). In 
particular, IFNγ-induced CysLT1 expression on airway smooth muscle cells was functionally 
associated with increased responsiveness to its agonist leukotriene D4, measured by cell 
stiffness as a proxy for cell contractility (Amrani et al., 2001). Although our findings have not 
established the functional consequence of IFNβ-induced augmentation of CYSLT1 
expression in THP1-macrophages nor the physiological impact of this in vivo, the complexity 
of type I IFN signalling should be taken into consideration when in a therapeutic context.  
 
In addition, we also detected modulation of other IL-4/TNFα-induced genes in the presence 
of IFNβ treatment that may have potentially detrimental effects in the context of asthma 
pathology. IFNβ treatment enhanced IL-4/TNFα-induced MMP12 expression, which has 
been implicated in asthma due to its role in the degradation of extracellular matrix that could 
contribute to airways remodelling in asthma. Furthermore, studies in animal models showed 
inhibition of MMP12 suppressed the development of the early and late asthmatic responses 
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to allergen challenge (Mukhopadhyay et al., 2010). Therefore, IFNβ may promote MMP12 
production and contribute to mechanisms of airway pathology in asthma.  
 
One of the most highly upregulated genes following IL-4/TNFα stimulation was SLA, which 
SLAP. SLAP has been reported to function as a negative regulator of TCR signalling and T-
cell activation (Sosinowski et al., 2000); therefore, its induction by IL-4 may act as a 
physiological brake on T-cell activation, especially considering the role of IL-4 in Th2 cell 
differentiation. The reduced expression of SLA when cells were treated with IFNβ indicates 
type I IFN signalling may suppress this regulatory mechanism, which could result in 
increased T-cell activation. This may therefore be disadvantageous in the context of Th2 
cell-mediated allergic airways inflammation in asthma. However, it is uncertain whether the 
differential expression of SLA observed in THP1-macrophages in the presence of IFNβ 
translates to T cells.  
 
Another IL-4/TNFα-induced gene that was significantly modulated by IFNβ was ALDH1A2. 
ALDH1A2 expression is enriched in DCs and its role in the production of retinoic acid 
functions to promote DC-induced development of Foxp3+ regulatory T (Treg) cells to 
negatively regulate inflammatory responses (Coombes et al., 2007, Zhu et al., 2013). 
Retinoic acid was also found to specifically modulate the phenotype of existing inflammatory 
DCs to adopt a ‘regulatory’ function that promoted Treg cell development (Zhu et al., 2013). 
The observed effect of IFNβ in the suppression of IL-4/TNFα-induced ALDH1A2 could 
reduce retinoic acid production, which may result in reduced Treg cell responses that are 
considered protective in disease. Indeed Treg cells have been found to suppress the 
development of allergen-induced type 2 inflammation in mice (Saito et al., 2008). Therefore, 
inhaled IFNβ therapy may support DCs to retain a pro-inflammatory phenotype and limit the 
development of protective Treg cell responses in asthma.  
 
It is important to note that some of the effects of IFNβ on IL-4/TNFα-induced genes 
discussed here were not statistically significant in the context of the microarray; therefore, 
their interpretation should be supported by validation of these observations by Taqman 
qPCR before drawing firm conclusions. Further to this, the effects of IFNβ observed at the 
transcriptional level may not directly translate to the proposed protein functions described; 
therefore, protein analysis and functional studies should be conducted to address this. 
Moreover, whether the IFNβ-mediated modulation of these genes in a single cell type, 
particularly a cell line, translates to clinically relevant functional responses cannot be 
determined at this level and would require further investigations to establish potential 
contraindications of inhaled IFNβ therapy.  
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Type I IFNs may serve a protective pro-inflammatory role during infection to aid viral 
clearance, for example absence of IFN signalling during respiratory syncytial virus infection 
resulted in impaired pro-inflammatory cytokine production, which was associated with 
increased viral load and increased weight loss in mice (Goritzka et al., 2014). However, the 
induction of pro-inflammatory pathways by type I IFN in the context of inflammatory 
comorbidities, such as asthma, may contribute to further inflammation that could be 
detrimental and cause further pathology. Therefore, the therapeutic indication of inhaled IFN 
therapy in asthma should be considered in a context in which its benefits outweigh its 
potential contraindications. Findings from inhaled IFNβ therapy clinical trials showed that 
IFNβ treatment in patients with mild asthma (Steps 2–3) exhibited a mean increase in 
asthma symptoms, which although was not significantly different to placebo, was raised by 
the authors as a possible adverse response to IFNβ. Furthermore, these patients did not 
exhibit clinically significant increases in symptom scores after developing a cold, unlike 
patients with moderate-to-severe asthma who were found to benefit from inhaled IFNβ 
therapy (Djukanovic et al., 2014). As with any pharmacological intervention, the therapeutic 
potential of IFNβ should be considered amongst its risks and benefits, especially in light of 
the complexity of type I IFN signalling. The findings from the microarray analysis 
demonstrate potential new regulatory roles for type I IFN signalling in the context of IL-
4/TNFα-induced inflammatory pathways that could be relevant to asthma pathology.  
 
In addition to investigating the role of type I IFN signalling on IL-4/TNFα-induced gene 
expression, these microarray studies have also provided new data on genes that could be 
relevant to Th2-driven asthma pathology. In particular, we have identified a number of IL-
4/TNFα-induced genes expressed in THP1-derived macrophages with known roles in DC–T 
cell biology including CD209, SLA and ALDH1A2 that could have relevant functions in 
asthma immunopathology. However, the current stimulatory conditions do not elucidate 
whether these genes are specific to IL-4 or TNFα or both and future exploration of the 
potential role of these genes should address this. Interestingly, type I IFN has been reported 
to negatively regulate IL-4-induced CD209 expression in monocytes purified from human 
PBMCs and thereby limit DC activation and cross-talk with T cells (Relloso et al., 2002). The 
lack of effect of IFNβ treatment on CD209, assessed by microarray analysis, may indicate 
the potential limitations of using a cell line such as THP1 monocytes/macrophages; 
therefore, further investigations are required to support and validate the physiological 
relevance of the findings in this chapter.  
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6.5.5. Summary 
Despite failure to capture the specific regulatory mechanism of IFNβ in the given time frame 
of this thesis, the findings in this chapter have supported a regulatory role for type I IFN on 
Th2 chemokine induction beyond murine models. Furthermore, we have identified a number 
of additional genes that could be modulated by IFNβ, which may have implications in asthma 
pathology that raise potential contraindications to inhaled IFNβ therapy that warrant further 
investigations.    
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Chapter 7: Discussion and future work  
 
7.1. Discussion  
Asthma exacerbations are considered one of the greatest treatment challenges associated 
with asthma. The combined exposure to allergen and respiratory virus in asthma as a 
significant risk factor for the development of asthma exacerbations has been identified 
(Green et al., 2002, Murray et al., 2006). Increasing our understanding of the interactions 
between allergen- and virus-induced immunopathology may highlight opportunities to 
address this unmet medical need.  Several studies have revealed that asthmatic lung cells 
have deficient virus-induced IFN responses, which may contribute to the increased severity 
of respiratory viral infections in asthma (Wark et al., 2005, Contoli et al., 2006, Sykes et al., 
2012, Baraldo et al., 2012, Edwards et al., 2013a). Further to this, studies have identified 
IFN signalling as a negative regulator of Th2 cell activation and development of allergic 
airways inflammation (Xirakia et al., 2010, Koltsida et al., 2011). Therefore, deficient IFN 
responses in asthma may result in allergen-induced type 2 immunopathology and asthma 
symptoms that are exacerbated during RV infection.  
 
The mouse models used in this thesis have provided the opportunity to modulate type I IFN 
signalling in the context of allergen and RV interactions in vivo. We have shown that 
impaired type I IFN signalling, either through the use of IFNAR1-/- mice or an anti-IFNAR1 
blocking antibody, resulted in enhanced features of allergic airways inflammation both in the 
absence and presence of RV infection. Specifically, deficient type I IFN signalling 
augmented airway eosinophil accumulation and the production of eosinophil and Th2 cell 
chemoattractants. In particular, type I IFN signalling was consistently found to negatively 
regulate CCL17 and CCL22 production in response to allergen and RV and their 
combination in vivo. This effect of type I IFN signalling was further supported by an in vitro 
model of Th2 chemokine expression. To our knowledge, this is the first time type I IFN has 
been directly shown to regulate and suppress Th2 chemokine expression, especially in the 
context of combined exposure to allergen and RV.   
 
Chapter 7: Discussion and future work 
226 
 
 
Figure 7.1. Type I IFN signalling regulates type 2 inflammation in response to RV and 
allergen exposure. 
Impaired type I IFN signalling during RV and allergen exposure resulted in increased Th2 
chemokines CCL17 and CCL22, eosinophil mediators IL-5, CCL11 and CCL24, and 
eosinophilic inflammation. 
 
Although previous studies have identified a role for innate IFN signalling in the suppression 
of type 2 pathways, particularly T-cell responses, few studies have described such a role in 
the context of RV infection. Pritchard et al demonstrated type I IFN suppresses type 2 
cytokine expression by T cells in response to RV stimulation (Pritchard et al., 2012). 
However, the physiological relevance of direct stimulation of peripheral blood cells by RV is 
somewhat limited, especially considering the airway epithelium is the primary site of RV 
infection. The work carried out in this thesis aimed to directly address the role of type I IFN 
signalling on pulmonary allergen and RV-induced immunopathology. We realised both the 
strengths and limitations of using IFNAR1-/- mice on both systemic and local airway immune 
responses, which could affect interpretations of the mechanisms involved in type I IFN 
signalling. As a result, we additionally employed an anti-IFNAR1 blocking antibody to 
specifically examine the effects of immediate impaired IFN signalling in the airways, 
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supporting studies describing IFN deficiency in asthmatic lung cells. Our findings from both 
models demonstrated a causal effect of impaired type I IFN signalling on eosinophilic 
inflammation. Prior to the work conducted in this thesis, a similar effect of IFN signalling had 
been described in models of allergen-induced eosinophilic lung inflammation by others 
(Nakajima et al., 1994, Xirakia et al., 2010), but not in the context of RV infection. Our 
experiments were thus conducted to address this knowledge gap. We demonstrated 
enhanced features of allergen- and RV-induced type 2 inflammation, specifically following 
the direct impairment of type I IFN signalling. Recently, the use of TLR7 deficient mice, 
which exhibit impaired IFN responses, demonstrated similar findings during RV infection. It 
was also found that IFN treatment reverses RV-induced exacerbation of allergic airways 
inflammation in TLR7 deficient mice (Hatchwell et al., 2015). These findings utilising a 
different experimental model and allergen stimulus indirectly support our hypothesis.   
 
7.1.1. Limitations of mouse models of RV-induced airways disease  
There are a number of limitations associated with the experimental mouse models utilised in 
this thesis that may challenge the clinical relevance of our findings. Firstly, the use of a 
human viral pathogen instead of a mouse-adapted virus strain resulted in the use of 
relatively high RV titres in mice that are not considered comparable to infective doses in 
man. Despite the use of high RV1B titres, we saw limited effects of allergic airways 
inflammation and impaired IFN responses on viral load, indicating that mice are not 
sufficiently permissive to robust RV1B infection to assess differences in viral replication. As a 
result, we were not able to model the increased susceptibility to RV infection seen in 
asthmatic (Corne et al., 2002). The use of a mouse-adapted RV strain may prove more 
valuable for directly assessing viral replication in mice. This may also bypass the use of 
different RV1B preparations between experiments to improve inter-experimental variability, 
which was discussed in chapter 5.  
 
We were also limited to the use of a minor group RV strain due to the absence of human 
ICAM1 expression in wild-type mice, preventing the use of major group RV strains. 
Therefore, this may limit our interpretation of the inflammatory profile seen in mice in relation 
to that observed in human experimental infection studies, which utilise major group RV 
strains. However, we were still able to address our research questions in relation to type 2 
inflammatory responses in the context of RV infection independently of these limitations.  
 
Despite potential limitations of the viral stimulus used, we found that enhanced type 2 
inflammation appeared to be independent of viral load. Consistent with our findings, Duerr et 
al also found comparable viral load between IFNAR1-/- and wild-type mice infected with a 
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sub-lethal dose of influenza A virus, despite IFNAR1-/- mice exhibiting increased type 2 
immunopathology (Duerr et al., 2016). These findings suggest that enhanced type 2 
inflammation is not driven by virus and is likely an independent function of impaired IFN 
signalling, consistent with the overall premise that IFN signalling represents an important 
negative regulator of type 2 responses. This was supported by the effects of modulating IFN 
signalling on type 2 responses in the absence of viral stimulus; as seen in UV-OVA treated 
mice and in THP1 experiments.  
 
The use of OVA as an allergic stimulus and a systemic adjuvant-driven sensitisation protocol 
may not be considered a clinically relevant pathogenic mechanism. Other stimulation 
protocols, for example repeated inhaled exposure to house dust mite, may be considered 
more clinically relevant to the development of allergic airways inflammation in humans. 
Indeed Hatchwell et al recently deployed a model of house dust mite-induced allergic 
airways inflammation to investigate the effects of TLR7 deficiency and RV infection 
(Hatchwell et al., 2015). However, the model of RV and allergen interactions used in this 
thesis was adequate to address our key research questions. Firstly, we wanted to model the 
effects of RV infection in the context of established allergic airways inflammation; the OVA 
sensitisation and challenge protocol drives a robust type 2 inflammatory response for use as 
an appropriate platform. Secondly, we wanted to investigate the role of IFN signalling on 
type 2 immune mechanisms specifically; OVA provides a consistent type 2-driven 
inflammatory profile, whereas house dust mite for example may contain contaminants such 
as LPS that may contribute further complexity to our existing model.  
 
7.1.2. Limitations of THP1 experiments  
We were able to translate the regulatory effect of type I IFN signalling on Th2 chemokine 
expression to an in vitro model using THP1-derived macrophages. One limitation to the 
interpretation of these findings could be due to use of dual stimulation with IL-4 and TNFα; 
therefore, we cannot determine which specific cytokine pathway that leads to the expression 
of specific genes. This leads to difficulty in dissecting the regulatory mechanism of type I IFN 
and determination of the specific signalling pathway that IFN acts on to regulate IL-4/TNFα-
induced genes. Future studies to dissect the gene expression profile of IL-4 and TNFα 
should be conducted to further investigations into the regulatory mechanisms of type I IFN 
signalling.  
 
Furthermore, the clinical interpretations of the regulatory effects of type I IFN in these studies 
are limited by the use of a cell-line. Although, THP1 monocytes provided a practical and 
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appropriate platform for our exploratory mechanistic investigations. Translation of this model 
to human primary monocytes in the future would validate the current findings. 
 
7.2. Clinical implications 
At present, therapeutic strategies beyond steroids are limited in asthma exacerbations. 
Although some add-on biologic therapies have been shown to partially reduce the risk of 
exacerbations in some patients, there are no specific targeted treatments for virus-induced 
exacerbations (Soler et al., 2001, Pavord et al., 2012). The demonstrated relationship 
between impaired IFN responses and increased type 2 inflammation in this thesis supports 
the therapeutic potential of strategies to restore IFN signalling to control exacerbated type 2 
responses during asthma exacerbations. Therefore, inhaled IFN therapy may have the 
potential to target two pathological mechanisms that are considered to drive virus-induced 
asthma exacerbations; impaired anti-viral IFN responses and augmented type 2 
inflammation.  
 
The next challenge in the clinical development of inhaled IFNβ therapy is the identification of 
patients who are most likely to benefit from treatment. Considering limitations associated 
with the analysis of IFN responses in vivo, a practical biomarker will be required to define a 
target patient population who are most likely to benefit from treatment. It is postulated that 
only subsets of asthmatics exhibit IFN deficiency, which could be related to disease severity 
(Sykes et al., 2012, Sykes et al., 2014). This was supported by phase 2 clinical trials of 
inhaled IFNβ therapy, which found significant clinical improvements in moderate-to-severe 
asthmatics but not mild asthmatics (Djukanovic et al., 2014). Previous studies have also 
found an association between IFN deficiency and enhanced type 2 allergic responses 
(Baraldo et al., 2012, Sykes et al., 2012). The findings from this thesis have demonstrated 
that impairment of IFN signalling leads to enhanced type 2 inflammation in response to 
allergen exposure and RV infection. It is possible that patients with asthma who are most 
likely to benefit from inhaled IFNβ therapy are those with over-abundant type 2 inflammatory 
responses. Therefore, biomarkers that indicate enhanced type 2 immunopathology could be 
used to indicate patients likely to a) exhibit impaired IFN responses b) benefit from the 
potential suppression of type 2 inflammation as a result of IFN therapy. However, formal 
investigations are required in order to establish these relationships in asthma in vivo to 
support such clinical implications.  
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7.3. Future work 
Potential future work to address specific limitations in the experimental systems utilised has 
been discussed throughout this thesis. Here, we will discuss potential future work to address 
the key questions raised after review of the findings presented.  
 
7.3.1. Source of Th2 chemokines 
Type I IFN was consistently shown to regulate Th2 chemokine expression in vivo. At 
present, we do not know where IFNs target to regulate type 2 inflammatory responses 
amongst the complex immune pathways in this model. It was previously discussed that 
identification of the cellular sources of CCL17 and CCL22 would provide further insights in 
the mechanism of IFN signalling. Based on studies in similar models of OVA-induced allergic 
airways inflammation, we considered DCs as likely sources of Th2 chemokines. The use of 
CCL17- or CCL22-eGFP reporter mice could be used to identify which cell populations within 
the lungs express Th2 chemokines in vivo. Further to identification of cellular sources of Th2 
chemokines in mice, studies could be conducted in human cells ex vivo to translate our 
findings to a more clinically relevant context. This would indicate whether similar type I IFN-
mediated regulatory pathways exist in human cells and further support the therapeutic 
potential of restoring IFN-responses in asthma.  
 
7.3.2. CCR4-expressing cell populations  
It is also important to identify where Th2 chemokines act to understand the physiological and 
potential clinical impact of exacerbated Th2 chemokine responses. Assessment of CCR4-
expressing cell populations in the lungs and periphery, for example the lymph nodes, would 
aid this. In addition to Th2 cells, CCR4 is also expressed on Treg cells (Iellem et al., 2001). 
Since Treg cells have been found to be functionally protective in a model of allergic airways 
inflammation (Saito et al., 2008), increased Th2 chemokines in the absence of IFN could 
function in a protective regulatory capacity. Blockade of the CCR4 receptor in our model of 
RV and allergen interactions could increase understanding of the functional relevance of 
enhanced Th2 chemokines in the absence of type I IFN signalling.  
 
7.3.3. IgE responses  
The analyses conducted in this thesis focussed more specifically on acute inflammatory 
responses as this was considered more relevant to existing evidence from clinical 
experimental infection studies. Considering the reported counter-regulatory role of FcεRIα 
activation and type I IFN expression on pDCs (Gill et al., 2010), it would be valuable to 
assess IgE responses and FcεRIα expression in the absence of IFNAR1 signalling in our 
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models. This would provide further insights in the impact of IFN deficiency on the adaptive 
immune response following RV infection.  
 
7.3.4. Mouse model of IFN deficiency  
In addition to providing insights into mechanisms of disease, animal models of disease can 
be used as a tool to assess the efficacy of potential therapies. One of the key limitations to 
the models used in this thesis is that we impaired IFNAR1 signalling in order to model IFN 
deficiency. However, despite impaired expression of IFN in asthma, intact IFNAR1 signalling 
has been demonstrated, supporting the potential to restore IFN in a therapeutic context 
(Wark et al., 2005, Cakebread et al., 2011, Djukanovic et al., 2014). In chapter 5, we found 
administration of IFN had little impact in a model of allergen and RV interactions in wild-
type Balb/C mice.  It was considered that IFN treatment was redundant in an IFN-
competent system, as RV infection induced significant IFN expression and downstream 
responses that may not be surmountable by addition of IFNβ. Ideally, a mouse model that 
possesses impaired induction of IFNs but with intact downstream pathways would closely 
model IFN deficiency in asthma. Such a model would also be more appropriate for 
assessment of the potential broader efficacy of inhaled IFNβ, or other potential 
pharmacological candidates, on allergen- and virus-induced pathology. Indeed others have 
shown that TLR7 deficient mice constitute a potential surrogate model for IFN deficiency, 
whereby restoration of type I IFN reverses the enhanced type 2 immunopathology in these 
mice following RV and HDM stimulation (Hatchwell et al., 2015).  
 
7.3.5. Mechanism of IFN-regulation of type 2 pathways  
Our results support a regulatory role for type I IFN signalling in type 2 immunity in the 
context of allergen and virus stimulation, which has important implications in our 
understanding of the mechanisms of asthma exacerbations. However, we have yet to 
identify the mechanism that mediates IFN-induced suppression of Th2 chemokines. Our 
microarray analysis found that IFNβ had a much wider range of effects on IL-4/TNFα-
induced gene expression than mere suppression of Th2 chemokines. Indeed IFNβ treatment 
enhanced expression of specific genes that may have pathological roles in asthma. It would 
therefore be beneficial to identify a molecular mechanism that bypasses the wider and 
potentially detrimental effects of IFN. This would reveal a more specific therapeutic target in 
which to harness the mechanism that directly mediates the suppression of type 2 
inflammatory pathways. At present, add-on biologics anti-IgE and anti-IL-5 block specific 
type 2 immune pathways that are thought to be over-active in asthma. The mechanism 
responsible for the over-activation of type 2 immunity in asthma has not been established. 
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The findings from this thesis support the hypothesis that innate IFN signalling provides a 
physiological brake on type 2 immune responses. Therefore, targeting this regulatory 
mechanism in asthma provides a logical ‘restorative’ treatment strategy that guides 
endogenous immune regulation, rather than introducing exogenous brakes.  
 
7.4. Conclusions  
The experiments conducted in this thesis were the first demonstration of the direct effects of 
type I IFN signalling on immune responses to the combination of allergen exposure and RV 
infection. Impaired type I IFN signalling augmented eosinophilic airway inflammation and 
type 2 soluble mediators, including eotaxins and Th2 chemokines. Type I IFN signalling was 
also shown to directly suppress Th2 chemokine production in vivo and in vitro. These 
findings suggest that impaired type I IFN signalling in asthma may contribute to enhanced 
type 2 inflammation that is considered pathological in Th2-driven asthma and virus-induced 
asthma exacerbations.  
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Appendix  
 
Chapter 4 supplementary data: Isotype control optimisation  
The antibody selected to exogenously block type I IFN receptor signalling in vivo was a 
mouse IgG1 isotype; therefore, a selection of mouse IgG1 isotype control antibodies were 
tested in order to ensure there were minimal biological effects. Three different clones of 
mouse IgG1 control antibodies were assessed in the context of RV infection: MOPC21, 
MG145 and GIR208. To ensure treatment with immunoglobulin directly to the airways had 
no impact on infectivity of the lungs, RV viral load in the lung tissue was measured by qPCR. 
Assessment of RV viral load found no significant differences between RV-infected mice in 
the absence or presence of isotype control treatments (figure S4.1).  
 
 
Figure S4.1. Effects of mouse IgG1 isotype control antibodies on RV RNA viral load in 
lung tissue 1 day p.i.  
Mice were dosed with 30µg mouse IgG1 isotype control antibodies 2 hours prior to RV1B 
infection or PBS treatment. RNA was purified from the apical right lung lobe 1 day p.i. and 
RV RNA levels measured by qPCR. Data represents 3–5 mice per group.   
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Since airway inflammatory cell accumulation is a critical end point in these analyses, 
leukocyte responses were assessed 1 day p.i. in the presence of immunoglobulin treatment. 
RV infection caused trends for increased neutrophil infiltration (figure S4.2a). Treatment with 
any of the three IgG1 isotype control antibodies had no significant effects on RV-induced 
neutrophilia. Analysis of lymphocyte responses 1 day p.i. found trends for increased 
lymphocyte infiltration in RV-infected mice treated with MG145 and GIR208 immunoglobulins 
compared with PBS, although this was not statistically significant (figure S4.2b).  
 
Figure S4.2. Effects of mouse IgG1 isotype control antibodies on inflammatory 
leukocyte accumulation in the BAL 1 day p.i.  
Mice were dosed with 30µg mouse IgG1 isotype control antibodies 2 hours prior to RV1B 
infection or PBS treatment. BAL fluid was collected 1 day p.i. and cytospins prepared and 
stained to differentially numerate neutrophils (a) and lymphocytes (b). Data represents 3–5 
mice per group.  
 
Considering the trends for increased lymphocyte infiltration seen in figure 4.2, soluble 
mediators involved in the recruitment of lymphocytes following RV infection, CXCL10 (figure 
S4.3a) and CCL5 (figure S4.3b) were measured in the BAL. MG145 treatment resulted in 
non-significant trends for increased CXCL10 production compared with PBS control 
treatment, but significantly enhances RV-induced CCL5 production. Additional soluble 
mediators associated with RV infection were assessed, including IFNλ2/3, in which MG145 
treatment significantly increased IFNλ2/3 levels, similar patterns of responses to CCL5 
(figure S4.3c). IgG1 isotype control treatments did not affect RV-induced KC production 
(figure S4.3d).  
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Figure S4.3. Effects of mouse IgG1 isotype control antibodies on RV-induced cytokine 
and chemokine production in BAL fluid 1 day p.i.  
Mice were dosed with 30µg mouse IgG1 isotype control antibodies 2 hours prior to RV1B 
infection or PBS treatment. Protein levels of IFNλ2/3 (a), IP-10/CXCL10 (b), RANTES/CCL5 
(c) and KC/CXCL1 (d) were measured 1 day p.i. by ELISA. Data represents 3–5 mice per 
group.   
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Chapter 6 supplementary: Microarray gene lists  
 
Table S6.1. List of significantly upregulated genes following IL-4/TNFα 
stimulation in THP1-derived macrophages   
 
Gene Definition P-value Fold-Change 
CCL22 
Homo sapiens chemokine (C-C motif) 
ligand 22 (CCL22), mRNA. 
0.00021683700 -6.00 
SLA 
Homo sapiens Src-like-adaptor (SLA), 
transcript variant 1, mRNA. 
0.00003261500 -5.28 
CD209 
Homo sapiens CD209 molecule (CD209), 
mRNA. 
0.00000000003 -5.20 
FCRLA 
Homo sapiens Fc receptor-like A (FCRLA), 
mRNA. 
0.00017363700 -4.51 
MMP12 
Homo sapiens matrix metallopeptidase 12 
(macrophage elastase) (MMP12), mRNA. 
0.00025764000 -4.49 
TGM2 
Homo sapiens transglutaminase 2 (C 
polypeptide, protein-glutamine-gamma-
glutamyltransferase) (TGM2), mRNA.  
0.00000002042 -4.45 
ALDH1A2 
Homo sapiens aldehyde dehydrogenase 1 
family, member A2 (ALDH1A2), transcript 
variant 2, mRNA. 
0.00000120245 -4.37 
FCRLB 
Homo sapiens Fc receptor-like B (FCRLB), 
mRNA. 
0.00331551000 -4.01 
SERPINE2 
Homo sapiens serpin peptidase inhibitor, 
clade E (nexin, plasminogen activator 
inhibitor type I), mRNA 
0.00039758500 -3.53 
FCGR2C 
Homo sapiens Fc fragment of IgG, low 
affinity IIc, receptor for (CD32) (FCGR2C), 
mRNA. 
0.00057453800 -3.31 
SEPT3 
Homo sapiens septin 3 (SEPT3), transcript 
variant B, mRNA. 
0.00000069948 -3.08 
CCL26 
Homo sapiens chemokine (C-C motif) 
ligand 26 (CCL26), mRNA. 
0.00531321000 -3.05 
FCGR2A 
Homo sapiens Fc fragment of IgG, low 
affinity IIa, receptor (CD32) (FCGR2A), 
mRNA. 
0.00039649700 -2.99 
PMP22 
Homo sapiens peripheral myelin protein 22 
(PMP22), transcript variant 2, mRNA. 
0.00001277350 -2.98 
SPINT2 
Homo sapiens serine peptidase inhibitor, 
Kunitz type, 2 (SPINT2), mRNA. 
0.00002644660 -2.93 
OLR1 
Homo sapiens oxidized low density 
lipoprotein (lectin-like) receptor 1 (OLR1), 
mRNA. 
0.00004094600 -2.86 
AQP9 
Homo sapiens aquaporin 9 (AQP9), 
mRNA. 
0.00000293886 -2.85 
SLC5A3 
Homo sapiens solute carrier family 5 
(sodium/myo-inositol cotransporter), 
member 3 (SLC5A3), mRNA.  
0.00052466300 -2.78 
ANKRD1 
Homo sapiens ankyrin repeat domain 1 
(cardiac muscle) (ANKRD1), mRNA. 
0.00006303270 -2.76 
QPCT 
Homo sapiens glutaminyl-peptide 
cyclotransferase (QPCT), mRNA. 
0.00000042933 -2.72 
Appendix 
254 
 
INHBE 
Homo sapiens inhibin, beta E (INHBE), 
mRNA. 
0.00110414000 -2.63 
S1PR3 
Homo sapiens sphingosine-1-phosphate 
receptor 3 (S1PR3), mRNA. 
0.00423431000 -2.62 
TDRD9 
Homo sapiens tudor domain containing 9 
(TDRD9), mRNA. 
0.00098920400 -2.45 
EHF 
Homo sapiens ets homologous factor 
(EHF), mRNA. 
0.00010034600 -2.44 
CYSLTR1 
Homo sapiens cysteinyl leukotriene 
receptor 1 (CYSLTR1), mRNA. 
0.00002905080 -2.34 
FAR2 
Homo sapiens fatty acyl CoA reductase 2 
(FAR2), mRNA. 
0.00028210800 -2.18 
APBB1IP 
Homo sapiens amyloid beta (A4) precursor 
protein-binding, family B, member 1 
interacting protein (APBB1IP), mRNA.  
0.00048978800 -2.14 
FGL2 
Homo sapiens fibrinogen-like 2 (FGL2), 
mRNA. 
0.00201398000 -2.14 
DHRS11 
Homo sapiens dehydrogenase/reductase 
(SDR family) member 11 (DHRS11), 
mRNA. 
0.00131132000 -2.13 
CTNNAL1 
Homo sapiens catenin (cadherin-
associated protein), alpha-like 1 
(CTNNAL1), mRNA. 
0.00000006408 -2.13 
FABP4 
Homo sapiens fatty acid binding protein 4, 
adipocyte (FABP4), mRNA. 
0.03288890000 -2.07 
EPAS1 
Homo sapiens endothelial PAS domain 
protein 1 (EPAS1), mRNA. 
0.00000011244 -2.07 
KAL1 
Homo sapiens Kallmann syndrome 1 
sequence (KAL1), mRNA. 
0.00000035709 -2.02 
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Table S6.2. List of significantly upregulated genes following IFNβ 
stimulation in THP1-derived macrophages 
 
Gene Definition P-value Fold-Change 
CCL8 
Homo sapiens chemokine (C-C motif) 
ligand 8 (CCL8), mRNA. 
0.00012077 -21.67 
RSAD2 
Homo sapiens radical S-adenosyl 
methionine domain containing 2 (RSAD2), 
mRNA. 
0.00002884 -19.45 
ISG20 
Homo sapiens interferon stimulated 
exonuclease gene 20kDa (ISG20), mRNA. 
0.00000171 -17.61 
CXCL10 
Homo sapiens chemokine (C-X-C motif) 
ligand 10 (CXCL10), mRNA. 
0.00350387 -14.95 
ISG15 
Homo sapiens ISG15 ubiquitin-like modifier 
(ISG15), mRNA. 
0.00000197 -10.07 
IFI44L 
Homo sapiens interferon-induced protein 
44-like (IFI44L), mRNA. 
0.00041769 -8.93 
IFI27 
Homo sapiens interferon, alpha-inducible 
protein 27 (IFI27), transcript variant 2, 
mRNA 
0.00003187 -8.84 
HERC5 
Homo sapiens hect domain and RLD 5 
(HERC5), mRNA. 
0.00006691 -8.61 
IFIT1 
Homo sapiens interferon-induced protein 
with tetratricopeptide repeats 1 (IFIT1), 
mRNA. 
0.00007586 -7.62 
IFITM1 
Homo sapiens interferon induced 
transmembrane protein 1 (9-27) (IFITM1), 
mRNA. 
0.00000013 -7.26 
GBP2 
Homo sapiens guanylate binding protein 2, 
interferon-inducible (GBP2), mRNA. 
0.00021958 -6.61 
IFIH1 
Homo sapiens interferon induced with 
helicase C domain 1 (IFIH1), mRNA. 
0.00031432 -6.36 
SAMD9L 
Homo sapiens sterile alpha motif domain 
containing 9-like (SAMD9L), mRNA. 
0.00040086 -6.30 
IFI44 
Homo sapiens interferon-induced protein 
44 (IFI44), mRNA. 
0.00023586 -6.14 
CMPK2 
Homo sapiens cytidine monophosphate 
(UMP-CMP) kinase 2, mitochondrial 
(CMPK2), nuclear gene encoding 
mitochondrial protein, transcript variant 1, 
mRNA.  
0.00044637 -6.08 
NUPR1 
Homo sapiens nuclear protein, 
transcriptional regulator, 1 (NUPR1), 
transcript variant 1, mRNA.  
0.00036527 -5.95 
AIM2 
Homo sapiens absent in melanoma 2 
(AIM2), mRNA. 
0.00043138 -5.87 
CASP1 
Homo sapiens caspase 1, apoptosis-
related cysteine peptidase (interleukin 1, 
beta, convertase) (CASP1), mRNA.  
0.00000125 -5.59 
IFITM3 
Homo sapiens interferon induced 
transmembrane protein 3 (1-8U) (IFITM3), 
mRNA. 
0.00002186 -5.45 
MX1 
Homo sapiens myxovirus (influenza virus) 
resistance 1, interferon-inducible protein 
0.00032693 -5.15 
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p78 (MX1), mRNA.  
EPSTI1 
Homo sapiens epithelial stromal interaction 
1 (breast) (EPSTI1), transcript variant 2, 
mRNA. 
0.00022679 -5.14 
IFI35 
Homo sapiens interferon-induced protein 
35 (IFI35), mRNA. 
0.00001089 -5.11 
UBA7 
Homo sapiens ubiquitin-like modifier 
activating enzyme 7 (UBA7), mRNA. 
0.00000343 -5.01 
IFITM2 
Homo sapiens interferon induced 
transmembrane protein 2 (1-8D) (IFITM2), 
mRNA. 
0.00000119 -4.97 
P8 
Homo sapiens p8 protein (candidate of 
metastasis 1) (P8), mRNA. 
0.00018799 -4.91 
OAS2 
Homo sapiens 2'-5'-oligoadenylate 
synthetase 2, 69/71kDa (OAS2), transcript 
variant 2, mRNA. 
0.00007704 -4.74 
LOC10013304
5 
PREDICTED: Homo sapiens hypothetical 
protein LOC100133045 (LOC100133045), 
mRNA. 
0.00003003 -4.63 
GBP5 
Homo sapiens guanylate binding protein 5 
(GBP5), mRNA. 
0.00048097 -4.63 
SP110 
Homo sapiens SP110 nuclear body protein 
(SP110), transcript variant c, mRNA. 
0.00034483 -4.59 
CARD16 
Homo sapiens caspase recruitment 
domain family, member 16 (CARD16), 
mRNA.  
0.00000488 -4.56 
PARP9 
Homo sapiens poly (ADP-ribose) 
polymerase family, member 9 (PARP9), 
mRNA. 
0.00012118 -4.41 
GBP3 
Homo sapiens guanylate binding protein 3 
(GBP3), mRNA. 
0.00007953 -4.36 
DDX58 
Homo sapiens DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 58 (DDX58), mRNA. 
0.00023865 -4.25 
EIF2AK2 
Homo sapiens eukaryotic translation 
initiation factor 2-alpha kinase 2 
(EIF2AK2), mRNA. 
0.00001114 -4.22 
C3AR1 
Homo sapiens complement component 3a 
receptor 1 (C3AR1), mRNA. 
0.00000705 -4.22 
SAMD9 
Homo sapiens sterile alpha motif domain 
containing 9 (SAMD9), mRNA. 
0.00004147 -4.07 
MMP12 
Homo sapiens matrix metallopeptidase 12 
(macrophage elastase) (MMP12), mRNA. 
0.00047440 -4.03 
HPSE 
Homo sapiens heparanase (HPSE), 
mRNA. 
0.00000541 -4.00 
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Table S6.3. List of significantly upregulated genes following co-treatment 
with IFNβ and IL-4/TNFα compared with IL-4/TNFα alone in THP1-derived 
macrophages 
 
Gene Definition P-value Fold-Change 
CCL8 
Homo sapiens chemokine (C-C motif) 
ligand 8 (CCL8), mRNA. 
0.000185492 -18.72 
ISG15 
Homo sapiens ISG15 ubiquitin-like 
modifier (ISG15), mRNA. 
0.000000453 -14.20 
RSAD2 
Homo sapiens radical S-adenosyl 
methionine domain containing 2 
(RSAD2), mRNA. 
0.000095289 -13.59 
ISG20 
Homo sapiens interferon stimulated 
exonuclease gene 20kDa (ISG20), 
mRNA. 
0.000005159 -13.15 
IFIT1 
Homo sapiens interferon-induced protein 
with tetratricopeptide repeats 1 (IFIT1), 
mRNA. 
0.000015132 -11.11 
HERC5 
Homo sapiens hect domain and RLD 5 
(HERC5), mRNA. 
0.000058755 -8.88 
IFI27 
Homo sapiens interferon, alpha-inducible 
protein 27 (IFI27), transcript variant 2, 
mRNA. 
0.000048877 -8.02 
IFI44 
Homo sapiens interferon-induced protein 
44 (IFI44), mRNA. 
0.000106639 -7.29 
EPSTI1 
Homo sapiens epithelial stromal 
interaction 1 (breast) (EPSTI1), transcript 
variant 2, mRNA. 
0.000050752 -6.93 
CASP1 
Homo sapiens caspase 1, apoptosis-
related cysteine peptidase (interleukin 1, 
beta, convertase) (CASP1), mRNA.  
0.000000446 -6.66 
IFITM1 
Homo sapiens interferon induced 
transmembrane protein 1 (9-27) (IFITM1), 
mRNA. 
0.000000257 -6.47 
IFITM3 
Homo sapiens interferon induced 
transmembrane protein 3 (1-8U) 
(IFITM3), mRNA. 
0.000008469 -6.47 
IFI35 
Homo sapiens interferon-induced protein 
35 (IFI35), mRNA. 
0.000003710 -6.14 
IFITM2 
Homo sapiens interferon induced 
transmembrane protein 2 (1-8D) 
(IFITM2), mRNA. 
0.000000638 -5.47 
OAS2 
Homo sapiens 2'-5'-oligoadenylate 
synthetase 2, 69/71kDa (OAS2), 
transcript variant 2, mRNA. 
0.000057118 -4.99 
UBA7 
Homo sapiens ubiquitin-like modifier 
activating enzyme 7 (UBA7), mRNA. 
0.000004170 -4.85 
C3AR1 
Homo sapiens complement component 
3a receptor 1 (C3AR1), mRNA. 
0.000002808 -4.83 
EIF2AK2 
Homo sapiens eukaryotic translation 
initiation factor 2-alpha kinase 2 
(EIF2AK2), mRNA. 
0.000013176 -4.12 
PARP9 
Homo sapiens poly (ADP-ribose) 
polymerase family, member 9 (PARP9), 
0.000207601 -4.04 
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mRNA. 
BST2 
Homo sapiens bone marrow stromal cell 
antigen 2 (BST2), mRNA. 
0.000002207 -3.65 
GCA 
Homo sapiens grancalcin, EF-hand 
calcium binding protein (GCA), mRNA. 
0.000000281 -3.54 
KIAA1618 
Homo sapiens KIAA1618 (KIAA1618), 
mRNA. 
0.000012718 -3.52 
TAP1 
Homo sapiens transporter 1, ATP-binding 
cassette, sub-family B (MDR/TAP) 
(TAP1), mRNA. 
0.000007239 -3.38 
LOC10012968
1 
PREDICTED: Homo sapiens similar to 
NPC-A-7 (LOC100129681), mRNA. 
0.000000314 -3.36 
C19orf66 
Homo sapiens chromosome 19 open 
reading frame 66 (C19orf66), mRNA. 
0.000109367 -3.34 
TXNIP 
Homo sapiens thioredoxin interacting 
protein (TXNIP), mRNA. 
0.000021028 -3.24 
MICB 
Homo sapiens MHC class I polypeptide-
related sequence B (MICB), mRNA. 
0.000000857 -3.24 
IRF7 
Homo sapiens interferon regulatory factor 
7 (IRF7), transcript variant b, mRNA. 
0.000008902 -3.21 
RGL1 
Homo sapiens ral guanine nucleotide 
dissociation stimulator-like 1 (RGL1), 
mRNA. 
0.000254227 -3.14 
HLA-A29.1 
Homo sapiens major histocompatibility 
complex class I HLA-A29.1 (HLA-A29.1), 
mRNA. 
0.000121552 -3.04 
PRIC285 
Homo sapiens peroxisomal proliferator-
activated receptor A interacting complex 
285 (PRIC285), mRNA.  
0.000179306 -3.03 
SLC15A3 
Homo sapiens solute carrier family 15, 
member 3 (SLC15A3), mRNA. 
0.000002760 -2.99 
CARD16 
Homo sapiens caspase recruitment 
domain family, member 16 (CARD16), 
mRNA.   
0.000111801 -2.99 
PARP10 
Homo sapiens poly (ADP-ribose) 
polymerase family, member 10 
(PARP10), mRNA. 
0.000065927 -2.92 
UBE2L6 
Homo sapiens ubiquitin-conjugating 
enzyme E2L 6 (UBE2L6), transcript 
variant 2, mRNA. 
0.000126345 -2.88 
FBXO32 
Homo sapiens F-box protein 32 
(FBXO32), transcript variant 2, mRNA. 
0.000004180 -2.71 
C1GALT1 
Homo sapiens core 1 synthase, 
glycoprotein-N-acetylgalactosamine 3-
beta-galactosyltransferase (C1GALT1), 
mRNA.  
0.000130793 -2.59 
IFI6 
Homo sapiens interferon, alpha-inducible 
protein 6 (IFI6), transcript variant 3, 
mRNA. 
0.000121699 -2.48 
FTSJD2 
Homo sapiens FtsJ methyltransferase 
domain containing 2 (FTSJD2), mRNA. 
0.000130567 -2.39 
IRF9 
Homo sapiens interferon regulatory factor 
9 (IRF9), mRNA. 
0.000017828 -2.35 
STX11 Homo sapiens syntaxin 11 (STX11), 0.000017470 -2.35 
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mRNA. 
IGFBP4 
Homo sapiens insulin-like growth factor 
binding protein 4 (IGFBP4), mRNA. 
0.000137229 -2.34 
GSDMD 
Homo sapiens gasdermin D (GSDMD), 
mRNA. 
0.000083010 -2.32 
RBCK1 
Homo sapiens RanBP-type and C3HC4-
type zinc finger containing 1 (RBCK1), 
mRNA.  
0.000087255 -2.31 
ACVRL1 
Homo sapiens activin A receptor type II-
like 1 (ACVRL1), transcript variant 1, 
mRNA. 
0.000201017 -2.26 
ADAR 
Homo sapiens adenosine deaminase, 
RNA-specific (ADAR), transcript variant 
1, mRNA. 
0.000007930 -2.23 
IRF1 
Homo sapiens interferon regulatory factor 
1 (IRF1), mRNA. 
0.000178241 -2.20 
HLA-E 
Homo sapiens major histocompatibility 
complex, class I, E (HLA-E), mRNA. 
0.000005959 -2.13 
SP100 
Homo sapiens SP100 nuclear antigen 
(SP100), transcript variant 1, mRNA. 
0.000170003 -2.11 
ACAD11 
Homo sapiens acyl-Coenzyme A 
dehydrogenase family, member 11 
(ACAD11), mRNA. 
0.000046784 -2.07 
CYSLTR1 
Homo sapiens cysteinyl leukotriene 
receptor 1 (CYSLTR1), mRNA. 
0.000138224 -2.05 
GTF2E2 
Homo sapiens general transcription factor 
IIE, polypeptide 2, beta 34kDa (GTF2E2), 
mRNA 
0.000030986 -1.94 
FBXO6 
Homo sapiens F-box protein 6 (FBXO6), 
mRNA. 
0.000005811 -1.90 
SRC 
Homo sapiens v-src sarcoma (Schmidt-
Ruppin A-2) viral oncogene homolog 
(avian) (SRC), mRNA. 
0.000003566 -1.88 
P2RY8 
Homo sapiens purinergic receptor P2Y, 
G-protein coupled, 8 (P2RY8), mRNA. 
0.000141167 -1.87 
ADAMDEC1 
Homo sapiens ADAM-like, decysin 1 
(ADAMDEC1), mRNA. 
0.000052447 -1.87 
RGS2 
Homo sapiens regulator of G-protein 
signalling 2, 24kDa (RGS2), mRNA. 
0.000152043 -1.86 
PSMB8 
Homo sapiens proteasome (prosome, 
macropain) subunit, beta type, 8 (large 
multifunctional peptidase 7) (PSMB8), 
mRNA.  
0.000029865 -1.82 
HCG4 
Homo sapiens HLA complex group 4 
(HCG4), non-coding RNA. 
0.000125208 -1.79 
H1F0 
Homo sapiens H1 histone family, 
member 0 (H1F0), mRNA. 
0.000003773 -1.78 
LOC54103 
Homo sapiens hypothetical protein 
LOC54103 (LOC54103), mRNA. 
0.000181896 -1.77 
TAGAP 
Homo sapiens T-cell activation 
RhoGTPase activating protein (TAGAP), 
mRNA. 
0.000022343 -1.76 
DHX58 
Homo sapiens DEXH (Asp-Glu-X-His) 
box polypeptide 58 (DHX58), mRNA. 
0.000168246 -1.75 
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HIVEP2 
Homo sapiens human immunodeficiency 
virus type I enhancer binding protein 2 
(HIVEP2), mRNA. 
0.000096895 -1.70 
CARD17 
Homo sapiens caspase recruitment 
domain family, member 17 (CARD17), 
mRNA. 
0.000108099 -1.69 
CHMP5 
Homo sapiens chromatin modifying 
protein 5 (CHMP5), mRNA. 
0.000002418 -1.69 
FOSL1 
Homo sapiens FOS-like antigen 1 
(FOSL1), mRNA. 
0.000110290 -1.66 
VAV3 
Homo sapiens vav 3 guanine nucleotide 
exchange factor (VAV3), transcript 
variant 1, mRNA. 
0.000001106 -1.66 
GBA 
Homo sapiens glucosidase, beta; acid 
(includes glucosylceramidase) (GBA), 
mRNA. 
0.000220613 -1.64 
POLR3GL 
Homo sapiens polymerase (RNA) III 
(DNA directed) polypeptide G (32kD)-like 
(POLR3GL), mRNA. 
0.000002657 -1.63 
ANTXR2 
Homo sapiens anthrax toxin receptor 2 
(ANTXR2), mRNA. 
0.000010537 -1.59 
NCAM1 
Homo sapiens neural cell adhesion 
molecule 1 (NCAM1), transcript variant 1, 
mRNA. 
0.000011736 -1.59 
C9orf91 
Homo sapiens chromosome 9 open 
reading frame 91 (C9orf91), mRNA. 
0.000184095 -1.59 
SRBD1 
Homo sapiens S1 RNA binding domain 1 
(SRBD1), mRNA. 
0.000085625 -1.59 
BIRC2 
Homo sapiens baculoviral IAP repeat-
containing 2 (BIRC2), mRNA. 
0.000028880 -1.55 
CBX6 
Homo sapiens chromobox homolog 6 
(CBX6), mRNA. 
0.000130545 -1.53 
GTPBP2 
Homo sapiens GTP binding protein 2 
(GTPBP2), mRNA. 
0.000131960 -1.53 
SAT1 
Homo sapiens spermidine/spermine N1-
acetyltransferase 1 (SAT1), mRNA. 
0.000078953 -1.53 
NDN 
Homo sapiens necdin homolog (mouse) 
(NDN), mRNA. 
0.000190896 -1.51 
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Table S6.4. List of significantly downregulated genes following co-treatment 
with IFNβ and IL-4/TNFα compared with IL-4/TNFα alone in THP1-derived 
macrophages 
  
Gene Definition P-value 
Fold-
Change 
ALDH1A2 
Homo sapiens aldehyde 
dehydrogenase 1 family, member A2 
(ALDH1A2), transcript variant 2, 
mRNA.  
0.000033797 2.88 
TNFRSF10D 
Homo sapiens tumor necrosis factor 
receptor superfamily, member 10d, 
decoy with truncated death domain 
(TNFRSF10D), mRNA. 
0.000002499 2.87 
C5orf13 
Homo sapiens chromosome 5 open 
reading frame 13 (C5orf13), mRNA. 
0.000005072 2.67 
AQP9 
Homo sapiens aquaporin 9 (AQP9), 
mRNA. 
0.000006259 2.65 
MMD 
Homo sapiens monocyte to 
macrophage differentiation-associated 
(MMD), mRNA. 
0.000000514 2.53 
LOC100129667 
PREDICTED: Homo sapiens 
misc_RNA (LOC100129667), 
miscRNA. 
0.000032736 2.43 
LOC100133632 
PREDICTED: Homo sapiens 
hypothetical protein LOC100133632 
(LOC100133632), mRNA. 
0.000012178 2.40 
UBE4B 
Homo sapiens ubiquitination factor 
E4B (UFD2 homolog, yeast) (UBE4B), 
mRNA. 
0.000015071 2.28 
RHOQ 
Homo sapiens ras homolog gene 
family, member Q (RHOQ), mRNA. 
0.000023316 2.18 
PRKCA 
Homo sapiens protein kinase C, alpha 
(PRKCA), mRNA. 
0.000014647 2.10 
NDUFAF2 
Homo sapiens NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex, 
assembly factor 2 (NDUFAF2), mRNA.  
0.000009157 2.09 
TRIB2 
Homo sapiens tribbles homolog 2 
(Drosophila) (TRIB2), mRNA. 
0.000039707 2.09 
EPAS1 
Homo sapiens endothelial PAS domain 
protein 1 (EPAS1), mRNA. 
0.000000101 2.08 
PINK1 
Homo sapiens PTEN induced putative 
kinase 1 (PINK1), nuclear gene 
encoding mitochondrial protein, mRNA.  
0.000208505 1.95 
CTNNAL1 
Homo sapiens catenin (cadherin-
associated protein), alpha-like 1 
(CTNNAL1), mRNA. 
0.000000236 1.95 
TFRC 
Homo sapiens transferrin receptor 
(p90, CD71) (TFRC), mRNA. 
0.000027483 1.88 
QPCT 
Homo sapiens glutaminyl-peptide 
cyclotransferase (QPCT), mRNA. 
0.000070157 1.83 
ADSS 
Homo sapiens adenylosuccinate 
synthase (ADSS), mRNA. 
0.000178024 1.72 
CD300LB Homo sapiens CD300 molecule-like 0.000001470 1.71 
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family member b (CD300LB), mRNA. 
IMPDH2 
Homo sapiens IMP (inosine 
monophosphate) dehydrogenase 2 
(IMPDH2), mRNA. 
0.000092357 1.71 
FAP 
Homo sapiens fibroblast activation 
protein, alpha (FAP), mRNA. 
0.000097885 1.70 
LOC728003 
PREDICTED: Homo sapiens 
misc_RNA (LOC728003), miscRNA. 
0.000007782 1.70 
SYNJ2 
Homo sapiens synaptojanin 2 
(SYNJ2), mRNA. 
0.000134359 1.70 
RPL22 
Homo sapiens ribosomal protein L22 
(RPL22), mRNA. 
0.000042486 1.69 
ROBO1 
Homo sapiens roundabout, axon 
guidance receptor, homolog 1 
(Drosophila) (ROBO1), mRNA.  
0.000022822 1.69 
WDR12 
Homo sapiens WD repeat domain 12 
(WDR12), mRNA. 
0.000011388 1.67 
FAM168B 
Homo sapiens family with sequence 
similarity 168, member B (FAM168B), 
mRNA. 
0.000243086 1.66 
CSDA 
Homo sapiens cold shock domain 
protein A (CSDA), mRNA. 
0.000157102 1.65 
HIBADH 
Homo sapiens 3-hydroxyisobutyrate 
dehydrogenase (HIBADH), mRNA. 
0.000244537 1.65 
KAL1 
Homo sapiens Kallmann syndrome 1 
sequence (KAL1), mRNA. 
0.000012277 1.65 
PRKDC 
Homo sapiens protein kinase, DNA-
activated, catalytic polypeptide 
(PRKDC), mRNA.  
0.000043325 1.63 
GAFA3 
PREDICTED: Homo sapiens FGF-2 
activity-associated protein 3 (GAFA3), 
mRNA. 
0.000218849 1.63 
PKP4 
Homo sapiens plakophilin 4 (PKP4), 
transcript variant 1, mRNA. 
0.000253773 1.62 
CMPK1 
Homo sapiens cytidine 
monophosphate (UMP-CMP) kinase 1, 
cytosolic (CMPK1), mRNA. 
0.000006375 1.62 
C18orf55 
Homo sapiens chromosome 18 open 
reading frame 55 (C18orf55), mRNA. 
0.000042331 1.59 
MRPL24 
Homo sapiens mitochondrial ribosomal 
protein L24 (MRPL24), nuclear gene 
encoding mitochondrial protein, mRNA.  
0.000133401 1.58 
C3orf26 
Homo sapiens chromosome 3 open 
reading frame 26 (C3orf26), mRNA. 
0.000006919 1.57 
C5orf21 
Homo sapiens chromosome 5 open 
reading frame 21 (C5orf21), mRNA. 
0.000117510 1.56 
LOC645236 
PREDICTED: Homo sapiens similar to 
similar to RPL23AP7 protein 
(LOC645236), mRNA. 
0.000078421 1.56 
LOC400027 
PREDICTED: Homo sapiens 
hypothetical gene supported by 
BC047417, transcript variant 2 
(LOC400027)  
0.000229696 1.55 
DKFZp434C1613 Homo sapiens mRNA; cDNA 0.000011393 1.54 
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DKFZp434C1613 (from clone 
DKFZp434C1613) 
RPL23AP53 
Homo sapiens ribosomal protein L23a 
pseudogene 53 (RPL23AP53), non-
coding RNA. 
0.000168442 1.54 
BZW2 
Homo sapiens basic leucine zipper and 
W2 domains 2 (BZW2), mRNA. 
0.000071366 1.53 
C7orf23 
Homo sapiens chromosome 7 open 
reading frame 23 (C7orf23), mRNA. 
0.000008077 1.53 
TBL2 
Homo sapiens transducin (beta)-like 2 
(TBL2), mRNA. 
0.000044398 1.53 
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Table S6.5. List of significantly upregulated genes following pre-treatment 
with IFNβ and IL-4/TNFα compared with IL-4/TNFα alone in THP1-derived 
macrophages 
 
Gene Definition P-value Fold-Change 
IFI27 
Homo sapiens interferon, alpha-
inducible protein 27 (IFI27), transcript 
variant 2, mRNA 
0.000009857 -11.69 
ISG15 
Homo sapiens ISG15 ubiquitin-like 
modifier (ISG15), mRNA. 
0.000002250 -9.78 
IFITM3 
Homo sapiens interferon induced 
transmembrane protein 3 (1-8U) 
(IFITM3), mRNA. 
0.000026218 -5.28 
IFITM1 
Homo sapiens interferon induced 
transmembrane protein 1 (9-27) 
(IFITM1), mRNA. 
0.000002847 -4.43 
IFITM2 
Homo sapiens interferon induced 
transmembrane protein 2 (1-8D) 
(IFITM2), mRNA. 
0.000007622 -3.81 
TXNIP 
Homo sapiens thioredoxin interacting 
protein (TXNIP), mRNA. 
0.000008969 -3.61 
GCA 
Homo sapiens grancalcin, EF-hand 
calcium binding protein (GCA), mRNA. 
0.000004784 -2.62 
IRF9 
Homo sapiens interferon regulatory 
factor 9 (IRF9), mRNA. 
0.000016925 -2.37 
LOC144383 
PREDICTED: Homo sapiens similar to 
Interferon-induced transmembrane 
protein 3 
0.000037699 -2.17 
H1F0 
Homo sapiens H1 histone family, 
member 0 (H1F0), mRNA. 
0.000007698 -1.71 
SRC 
Homo sapiens v-src sarcoma (Schmidt-
Ruppin A-2) viral oncogene homolog 
(avian) (SRC), t 
0.000033432 -1.65 
PTPN6 
Homo sapiens protein tyrosine 
phosphatase, non-receptor type 6 
(PTPN6), transcript vari 
0.000022592 -1.55 
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Table S6.6. List of significantly downregulated genes following pre-
treatment with IFNβ and IL-4/TNFα compared with IL-4/TNFα alone in THP1-
derived macrophages 
  
Gene Definition  P-value Fold-Change 
QPCT 
Homo sapiens glutaminyl-peptide 
cyclotransferase (QPCT), mRNA. 
0.000006416 2.16 
FAP 
Homo sapiens fibroblast activation protein, 
alpha (FAP), mRNA. 
0.000004503 2.08 
MMD 
Homo sapiens monocyte to macrophage 
differentiation-associated (MMD), mRNA. 
0.000009940 2.01 
PRKCA 
Homo sapiens protein kinase C, alpha 
(PRKCA), mRNA. 
0.000041856 1.95 
CPE 
Homo sapiens carboxypeptidase E (CPE), 
mRNA. 
0.000012165 1.93 
DIRAS2 
Homo sapiens DIRAS family, GTP-binding 
RAS-like 2 (DIRAS2), mRNA. 
0.000040028 1.92 
USP53 
Homo sapiens ubiquitin specific peptidase 
53 (USP53), mRNA. 
0.000039938 1.89 
TFRC 
Homo sapiens transferrin receptor (p90, 
CD71) (TFRC), mRNA. 
0.000038310 1.84 
ITGA6 
Homo sapiens integrin, alpha 6 (ITGA6), 
mRNA. 
0.000047755 1.82 
KAL1 
Homo sapiens Kallmann syndrome 1 
sequence (KAL1), mRNA. 
0.000004494 1.73 
LOC644242 
PREDICTED: Homo sapiens hypothetical 
protein LOC644242 (LOC644242), mRNA. 
0.000011555 1.67 
PYGL 
Homo sapiens phosphorylase, glycogen, 
liver (PYGL), mRNA. 
0.000018080 1.51 
CYBRD1 
Homo sapiens cytochrome b reductase 1 
(CYBRD1), mRNA. 
0.000005427 1.50 
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